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Abstract 
In the last decade, a great deal of information has been revealed about chemical 
neurotransmission occurring within the brain. Methods used to monitor brain neurochemicals offer 
an exciting opportunity to enhance quest to understand neurodegenerative disease pathology. In 
addition, these new methods augment the discovery of new and innovative pharmacotherapies used 
for the treatment of neurodegenerative illnesses. Microdialysis has been routinely used to monitor 
the chemical constituents of the brain extracellular fluid in freely moving rats. However, there are 
still analytical challenges such as laborious and time consuming calibration methods associated 
with measurements and monitoring of these neurochemicals using microdialysis. In addition, the 
general complexity of the brain’s chemical activity and the rapid nature some neurochemical 
concentrations change makes brain tissue analysis a challenging task.  
Solid phase microextraction since its introduction has been successfully applied to both 
invasive and non-invasive biological tissue sampling. Advancement in the development of 
calibration methods, introduction of novel biocompatible coatings and the easy coupling to liquid 
chromatography tandem mass spectrometry have contributed to the overall success of the method 
for various in vivo applications. This thesis utilizes the potential of solid phase microextraction 
coupled to liquid chromatography tandem mass spectrometry for in vivo brain tissue analysis of 
freely moving animals.  
Preliminary research in this thesis focused on the investigation of factors that can negatively 
affect post in vivo microextraction of a biological system.  Subsequently, a multi-fiber semi-
automated desorption device was developed on a 96-well plate format and the performance of the 
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device was evaluated. Results presented did not only show very good inter- and intra-well 
variations (% RSD ≤ 15) but also the device, by design, was capable of preventing any possible 
fiber contamination and/or damage. 
The thesis also demonstrates the potential of using new mixed-mode coatings for 
simultaneous extraction of selected multiple endogenous neurochemicals with varying polarities. 
A new robust chromatographic separation method was introduced for the analysis of polar 
neurochemical substances (glutamic acid, gamma amino butyric acid, dopamine and serotonin) 
without the need for derivatization of the analytes.  Chromatographic separation of the selected 
neurochemical substances was achieved on a pentafluorophenyl column with a 5 min total runtime 
with column pre-conditioning. Applying the proposed method to in vitro extractions of 
neurotransmitters from brain tissue samples and cerebrospinal fluid demonstrated the potential of 
in vivo analytical technique. Subsequently, an in vivo technique was developed to simultaneously 
monitor changes in the concentrations of multiple neurochemicals in the brain extracellular fluid. 
The solid phase microextraction method was validated against in vivo microdialysis, a well-known 
sampling tool for brain neurochemical measurements. The proposed solid phase microextraction 
method can be used not only for measurements of basal concentrations of neurochemical, but also 
changes in their concentrations after the application of an external stimulus (intraperitoneal 
administration of fluoxetine drug). Both solid phase microextraction and microdialysis recorded 
an approximately 3- to 4-fold increase in basal concentrations of 5-HT in extracellular fluid after 
the administration of the drug. In addition, solid phase microextraction was used successfully for 
global metabolomics studies; a novel sampling approach with the potential of improving overall 
metabolites coverage. Thus, improving identification of possible disease biomarkers. The new 
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sampling approach combines microdialysis and solid phase microextraction for extracting polar 
and non-polar chemical substances. Thus, for the first time microdialysis and solid phase 
microextraction have been combined in a single platform for untargeted metabolomics studies. In 
addition, as a proof of concept, solid phase microextraction can be used to spatially resolved 
concentration gradient of drugs and/or endogenous compounds within the brain extracellular fluid. 
This was demonstrated using solid phase microextraction to monitor changes in the concentration 
of drugs (carbamazepine and cimetidine) in both frontal cortex and striatum of the brain of rats.  
Finally, but not least, the thesis demonstrates the potential application of in vivo solid phase 
microextraction to clinical studies. In this aspect of the thesis, solid phase microextraction was 
used to study to potential effect of deep brain stimulation on neurotransmitters. Among the four 
analytes monitored, the concentration of serotonin increased by 2 to 3x during deep brain 
simulation and remains constant as long as the stimulation was applied. The method linearity range 
was 0.01 pg/ml to 150 ng/mL for all selected neurotransmitters. A 30-min SPME extraction 
protocol was developed and applied for all in vivo experiments. 
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Chapter 1  
General Introduction 
1.1 Brain Tissue Sampling: Relevance and Challenges 
The brain arguably is the most complex and important organ in animals and with over 
100 billion nerve cells in continuous communication.1 This communication, which occurs 
across the synapse, is known to transmit important neurochemical information that is directly 
link to the function of the central nervous system (CNS), thus controlling our behavior, 
cognition, memory, etc. The interference or alteration of the brain neurotransmission process 
has been linked to various neurological disorders, such as Alzheimer’s Disease (AD),2 
Parkinson’s disease (PD),3 and schizophrenia (SZ)4 among others. The disturbing fact about 
some of these diseases is the predicted increase in the number of cases in the very near future.5 
Thus, it will be vital if further insights can be gained into the fundamental molecular/chemical 
information or mechanisms of the diseases pathogenesis. Successful brain metabolomics or 
chemical profiling using appropriate analytical tools certainly will offer appropriate platform 
for significant advancement in clinical, medical and research studies. In addition, enrich 
chemical information will facilitate the identification of disease biomarkers for clinical 
intervention for early prognosis, diagnosis and even treatment of these neurodegenerative 
disorders. Currently, disease-related changes in local and distributed neural circuits, synaptic, 
and molecular levels are detected through the direct study of the brain tissue. For example, 
through analysis of the brain tissue, it was established that the major cause of PD is due to 
significant reduction in dopamine concentrations in the basal ganglia of the brain,6,7 a condition 
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in which the neurons in the substantia nigra gradually degenerate. Secondly, brain tissue 
analysis provides insights into the potential effects of drugs of abuse in neurological disorders. 
Issues related to drug toxicity can also be well addressed through quantitative brain tissue 
analysis. Direct studies of the brain tumor tissues will provide insight into the existing chemical 
information. Finally, in vitro postmortem studies of the brain tissue can be used to establish 
the mental state of an individual. However, to obtain appropriate and reliable chemical 
information from the brain, very good analytical methods and techniques will be required. In 
addition, the ability to obtain accurate information via effective sample preparation methods 
or tools has always been a challenge and often the method’s effectiveness is debatable. 
Sampling brain tissue for chemical information is fraught with difficulties. The 
heterogeneity of the brain anatomy itself poses difficulties to brain sampling. Typically, for in 
vitro experiments, sample handling, storage, sample pre-treatment, post mortem among others 
and their possible impact on data reliability and interpretation are very critical. The 
conventional homogenization methods like ultra-sonication, acid or base digestions, organic 
solvents, etc, are often faced with the challenge of data interpretation due to the complex 
heterogeneity of the brain structure and also the multiple roles of certain neurotransmitters 
found in the brain. For example, data interpretation can be difficult for in vitro glutamate 
analysis in brain tissue, which plays both metabolic and neurotransmitters functions in the 
brain.8 In a typical in vitro animal postmortem studies, the high oxygen demand of the brain 
often lead to degradation of various substrates and loss of certain key metabolites such as 
glycogen and glucose shortly after death.9 Complications associated with postmortem delays 
can often lead to misinterpretation of detected metabolite changes in the brain during 
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sampling.10 In addition, most of these conventional approaches used for brain tissue analysis 
are often time-consuming and can be labor intensive. Issues of choosing the appropriate 
extraction method in order not to compromise analyte stability and data quality, the amount of 
representative sample required for the tissue sample preparation, effect of matrix especially for 
analytical techniques that require liquid chromatography coupled to mass spectrometric 
detection systems, and the use of appropriate internal standard among others can pose 
significant challenges. In the wake of the difficulties associated with conventional sample 
preparation methods coupled with the demands to obtain faster analysis and to reduce overall 
analytical cost, there is a gradual paradigm shift to in vivo brain tissue analysis. This may be 
due to obvious gains, such as obtaining richer analytical information that is more representative 
of the biological system under study, significant reduction in the number of animals sacrificed 
for studies, improving overall data quality by minimizing inter-animal variability, etc., 
associated with in vivo studies. In addition, there is a gradual shift from bioassays and assays 
of postmortem tissues to the use in vivo extracellular fluid sampling coupled to high 
performance liquid chromatography (HPLC) and other separation analytical systems. 
Generally, the continuous advancements of other technology have significantly improved the 
quest for understanding the dynamics of neurochemicals in the nervous system.  
The role of separation science in tissue bioanalysis in general cannot be 
overemphasized. Separation science literally unlocks detail information of any biological 
sample often in a well-characterized and reproducible fashion, and creates the basis for 
accurate identification and quantitation of the components of the sample. In this regard, it is a 
common phenomenon to have analytical separation systems coupled to sample preparation. 
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Since most of the analytes of interests have relatively negligible volatility, HPLC systems have 
been a common analytical separation tool used in combination with brain tissue analysis. An 
even more powerful approach involves the use of sensitive and selective hyphenated analytical 
techniques, which augment analyte detection and reliable quantitation at ultra-low 
concentrations. In particular, HPLC coupled to mass spectrometry is now a well-accepted 
technique for tissue bioanalysis as well as an analytical technique of choice for both selective 
and sensitive detection of compounds in challenging biological matrices. Although other well 
developed separation and detection methods like capillary electrophoresis coupled with 
fluorescent and electrochemical detection systems have been applied to tissue bioanalysis, 
HPLC coupled to mass spectrometry (MS) continues to appeal to many researchers. 
Application of this hyphenated analytical technique has significantly facilitated studies of the 
chemical dynamics of the central nervous system (CNS) through monitoring of amino acid and 
biogenic monoamine neurotransmitters and neuropeptides among others.11–19 
There is obviously no doubt that the coupling of in vivo analytical sampling tool to the 
appropriate selective and sensitive separation systems will continue to provide the necessary 
platform in overcoming aspects of the challenges associated with brain tissue analysis. 
1.2 In vivo brain sampling methods: focus on neurotransmitters  
1.2.1 Neurotransmitters 
In recent years, measurements of neuronal chemical signals, neurotransmitters, have 
been accepted as a fundamental approach to understanding the chemical dynamics of the CNS. 
Accurate analysis of the brain tissue for neurotransmitters is by no means a trivial issue. This 
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is because the brain nervous tissue is full of nerve endings (neurons), which differ from other 
living tissues, which are in constant communication with each other. However, before 
proceeding to mention in vivo sampling methods for neurotransmitters, it is worthwhile to 
allude to the importance of brain neurotransmitters. Very briefly, neurotransmitters are low 
molecular weight endogenous compounds that play a significant role in brain function and are 
known to affect our behavior, cognition, mood, health, etc. The simplest and commonly used 
classification approach is based on their chemical structure. In terms of their chemical 
structures, neurotransmitters can be grouped as choline ester (acetylcholine), monoamine 
(dopamine, 5-hydroxytryptamine/serotonin, noradrenaline, adrenaline and histamine), amino 
acids (glutamate, gamma amino butyric acid and glycine), peptides (endorphins, enkephalins 
and cholesystokinins) and purines (adenosine and adenosine triphosphate). Most of these 
neurotransmitters are known to play major role in various biological activities.  
Amino acid neurotransmitters are the most abundant in the brain although their 
acceptance as involved in neurotransmission was much later compared to monoamines.1,20  
Glutamic acid (GA) and gamma amino butyric acid (GABA) are respectively fast excitatory 
and inhibitory neurotransmitters with related metabolism. Formation of GABA is through the 
enzyme, glutamate decarboxylase from GA. GA is a known neurotoxin which is converted into 
a nontoxic glutamine within the glial cells. GA is also associated with metabolic regulation in 
the brain and often makes it challenging when studying the role of GA in neurotransmission. 
Neurological disorders such as epilepsy, cerebral ischaemia and hypoxia are associated with 
GA.1 Disruptions in excretions of GABA are observed in pathophysiology of epilepsy, anxiety 
and schizophrenia.  Dopamine (DA) is formed from 3,4-dihydroxyphyneylamine (L-DOPA) 
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with L-amino acid decarboxylase acting as a catalyst.21 Serotonin (5-HT) is formed through 
hydroxylation of tryptophan by tryptophan hydroxylase and subsequently reacting with L-
amino acid decarboxylase.22 A portion of 5-HT is metabolized through aldehyde 
dehydrogenase to form hydroxyindoleacetic acid (5-HIAA) whereas DA forms 
dihydroxyphenylacetic acid (DOPAC) through a monoamine oxidase. Serotonin in the brain is 
associated with various pathological states like migraine, SZ, depression, etc.22 Serotonin is 
also associated with feeding and cognition, sleep, thermoregulation, etc. in animals.22 
Serotonin also mediates in brain development, regulates the growth of serotonergic neurons 
and target tissues, and the likely cause of autism and Down Syndrome (DS) known in 
humans.23 DA is known to be involved in PD3, SZ4, attention deficit hyperactivity disorder, as 
well as influencing cognition,24 focusing,24 and reward.25 Figure 1.1 shows structures of some 
selected neurotransmitters (DA, 5-HT, GA and GABA) used in this project. 
 
Figure 1.1 Structures of the selected amino acid (gamma amino butyric acid and glutamic 
acid) and monoamine (dopamine and serotonin) neurotransmitters studied in this thesis. 
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Some neurotransmitters and their metabolites are generally found in very lower µM 
concentrations in the brain. Thus, sampling and monitoring of these neurochemicals have been 
challenging, as it requires very sensitive, robust and specialized analytical methods and 
techniques. Although, conventional in vitro extraction methods like tissue slicing may be still 
relevant, recently in vivo brain sampling methods have gain significant interest in 
neurosciences and have been used to study neurotransmission within the extracellular fluid of 
the brain. This may be attributed to fact that in vivo methods are able to capture the dynamics 
of neurotransmitters in the ECF, which is a measure of the function of the biological system, 
compared to the static in vitro measurements of in brain tissues. Some of the commonly applied 
analytical methods for in vivo monitoring of neurotransmitters include voltammetry 
(electrochemical), microdialysis, biosensors, etc. 
1.2.2 Voltammetry for monitoring neurotransmitters 
In vivo electrochemical methods have been used for direct monitoring of some 
neurotransmitters within the ECF of brain since chemical neurotransmission is initiated by an 
electrical signal, an action potential. Electrochemical methods, which often involve the use of 
microelectrodes, require that the detected species be electroactive, i.e., voltammetry is based 
on oxidation and reduction reactions of the neurotransmitter(s) at the surface of an electrode. 
In principle, the technique involves the application of a controlled potential between two 
electrodes and the resultant current that flows is indicative of the amount of electroactive 
material in the solution. The unique advantages of the technique are observed with its 
sensitivity, spatial resolution, due to the small size of the carbon electrode (3 μm in diameter) 
and high temporal resolution (fast detection 100 ms or less)26 properties. The technique is 
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commonly used for monitoring monoamines such as 5-HT, DA, noradrenaline (NA), etc. and 
their metabolites because they are readily oxidized at specific potentials on the surface of the 
electrodes within the ECF.  Common electrodes used for direct in vivo electrochemical 
techniques are carbon-fibre27 or chemically modified platinum electrodes.28,29 Other electrodes 
used for voltammetric measurements include the graphite modified with nafion polymer,30 for 
the determination of DA, NE and 5-HT. Electrodes made from nanoparticles31,32 have been 
also explored in in vivo voltammetry applications. 
Normally, for in vivo voltammetric measurements of the changes in concentrations of 
neurotransmitters in the ECF of, say the rat’s brain, microelectrodes are implanted into the 
desired brain region for initial quantitative determination of baseline concentrations. 
Subsequently, the animal is presented with a form of stimulus and the changes in the 
electrochemical potential are correlated with the particular neuronal activity within the ECF. 
Very often the approach used during in vivo voltammetry is dependent on experimental 
objectives such as slow-scanning methods used in monitoring neurochemical behaviour may 
require longer time scale compared to the fast-scanning techniques often used for monitor 
dynamics of transmitters release on a millisecond scale. Most commonly used methods fall 
under three main techniques; cyclic voltammetry, chronoamperometry and differential pulse 
voltammetry. 
Generally, in cyclic voltammetry, the voltage between the working and reference 
electrodes is applied linearly with time and the current is measured. The observed current 
increases with the applied potential until it reach a maximum. At this point, the concentration 
of the analyte at the surface of the working electrode decreases to zero and analyte’s molecules 
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can diffuse to the electrode at the highest rate. The current reaches a steady-state value. The 
process can be repeated in a backward scan by reversing the potential between the electrodes 
to re-oxidize the product formed during the first reduction reaction for reversible reactions. 
Subsequently, a current of reverse polarity is also formed. Features of the voltammogram (plot 
of current versus potential) are used to obtain information concerning the chemical properties 
of the substance detected. For example, the ratio of the peak current during the forward and 
reverse scanning provides information that can be used to identify the chemical substance in 
addition to the measured voltage.33 The detection limits of cyclic voltammetry is dependent on 
the magnitude of the charging and residual currents generated from other components that may 
be present in the ECF other than the current obtained from the electroanalyte of interest. 
Charging current occurs from migration of all other charge chemical species (ions) present at 
the electrode surface but do not form part of the redox reactions. It is important to note that the 
net current measured is always a sum of the current obtained from the redox reactions and the 
charging current, which contributes to the background current and substantively influence the 
method’s detection limit. Due to the fact that the residual current also results from activities at 
the surface of the electrode, often detection limit is improved by employing very slow scan 
rates. This limits the potential of using cyclic voltammetry for monitoring rapid changes in the 
concentrations of neurotransmitters found in the brain.  
In chronoamperometry, the potential of the working electrode is stepped and held 
constant for a period of time, and the resultant current from the faradaic process is measured 
as a function of time at the end of each applied voltage. At the beginning of the applied voltage 
an increase in current is observed, which later reduces as the electroactive species at the surface 
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of the electrodes is depleted. The advantage of chronoamperometry over cyclic voltammetry 
is that the magnitude of the charging current reduces exponentially compared to the faradaic 
current, as the voltage is held constant. In addition, since the measured current is taken at the 
end of the potential step, the interferences observed from the charging current is significantly 
minimal or negligible. In chronoamperometry, the recorded current during the potential step is 
proportional to the electroactive species concentration in the ECF. However, due to the lack of 
selectivity, as other species can be electrolyzed with the applied potential, the main species 
contributing to the observed current is not accurately known. The lack of selectivity therefore 
serves as a major disadvantage of the technique.  
Differential pulse voltammetry may be viewed as a hybrid of cyclic voltammetry and 
chronoamperometry. With this technique the linearly applied voltage is superimposed with 
small amplitude pulses, constant voltage pulses. By this approach, interferences from other 
electroactive species within the potential range are reduced thereby producing minimal 
background noise as charging current. The current measured is the difference between the 
sampled current prior to the change in potential and that observed at the end of the pulse. The 
scan rate is usually low for improved sensitivity (compared to cyclic voltammetry and 
chronoamperometry methods) at the expense of time resolution. Another advantage of the 
technique is that it allows species electrolyzed at each pulse potential to be determined easily.  
The first successful in vivo voltammetry work was reported by Clark, et al. in 1965 as 
cited by Adams, R. N. in his article “Probing brain chemistry with electroanalytical”.34 
Subsequently, the technique has been well explored for in vivo monitoring of monoamine 
neurotransmitters. Marsden, et al. in 1979 in a drug-induced studies, successfully monitored 
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the effect of p-chloroamphetamine and fluoxetine on release of 5-HT in the brain striatum of 
freely moving rat using in vivo voltammetry with graphite working electrodes.35 There are 
various applications of voltammetry for in vivo measurements of neurotransmitters.36–42 The 
technique has evolved over the years with Crespi demonstrating wireless in vivo voltammetric 
monitoring of DA and 5-HT in the rat’s pre-frontal cortex of the brain in drug-induced stimulus 
studies.43 
1.2.2.1 Challenges with in vivo voltammetry methods 
A major challenge encountered with in vivo voltammetry is the effect of other 
electroactive compounds present in the brain tissue, which are oxidized at similar potentials as 
the analyte. Due to the lack of selectivity from the probe, often voltammetry method is unable 
to resolve multi-component signals into separate electrochemical peaks.  For example, ascorbic 
acid and DOPAC oxidize at similar electrode potentials as catecholamines and in addition both 
compounds have much higher basal concentrations in the ECF than catecholamines. Although 
this challenge can be overcome by separating compounds of similar oxidation potentials by 
HPLC, often it is a daunting process. Alternatively, selectivity can be improved by modifying 
the surface of the electrode.44 An electrode coated with the negatively charged nafion polymer 
has increased selectivity for cations such as DA and NE relative to ascorbic acid and DOPAC 
that are negatively charged within the operating electrode potential.30 With this approach the 
tendency of the anions migrating to the surface of the working electrode is minimized. Other 
methods to improve selectivity include the selective sampling of appropriate regions of the 
brain rich in the electroactive compound of interest. For example, monitoring DA in the 
striatum minimizes the potential influence from NE, which is almost negligible in that region.  
 12 
 
It is also important to note that electrochemical measurements in the brain tissue is 
often more difficult than in the cerebrospinal fluid (CSF). Firstly, the size of the probe is very 
critical as the technique has the potential of causing tissue damage. In addition, it is also 
possible to have the surface of the electrode distorted or blocked from deposits of torn out from 
the brain tissue during probe insertion. Also, it is not clear whether electrode surface is exposed 
to the ECF or the brain tissue for that matter. 
In all in vivo voltammetry techniques for monitoring neurotransmitters in the brain, it 
is important that the measured signal is due specifically to the electroactive compound of 
interest. The electroactive analyte when injected in close proximity to the in vivo electrode 
must demonstrate the redox reaction at the same potential as the in vivo electrochemical peak. 
1.2.3 Microdialysis sampling and neurotransmitters 
Microdialysis (MD) is an analytical sampling tool for the extraction of the free-
concentration of small-molecular-weight substances from the interstitial space. This technique 
has gained exponential attention in the neurosciences since its introduction and is a widely 
accepted analytical method available that permits quantification of neurotransmitters. In recent 
times, it has been used for quantification of neurotransmitter release from ECF of the animal 
brain. 
The first developed and implemented dialysis technique used for sampling in the brain 
was introduced in 1966 by Bito et al.44 Small dialysis sacs were filled with 6% dextran in saline 
solution and placed into the brains and subcutaneous neck tissues of dogs and allowed to 
equilibrate with the extracellular surroundings for 10 weeks sampling and the contents were 
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later analyzed for amino acid and electrolyte content. The “dialytrode” was introduced later in 
1972 as an improvement of the “compartment” design of Bito’s work.45 The dialytrode 
included two small stainless steel rods fused to provide a typical push-pull type cannula with 
a seven-electrode contact. This device was capable of providing electrical stimulation and 
recording, together with chemical injection and collection. Based on the dialytrode concept, 
Ungerstedt et al. introduced the thin dialysis tubes or hollow fibers into the brain.45 Deuterated 
dopamine was perfused through the fibers to attain the baseline and subsequently amphetamine 
stimulated release of dopamine was measured. After these initial experiments, the use of 
microdialysis as analytical sampling tool in the neurosciences has expanded. Recent 
neurochemical research using microdialysis has ranged from studies of the effects of traumatic 
brain injuries,46 neurodegenerative disorders47 and the pharmacokinetics and 
pharmacodynamics of drugs.48  
1.2.3.1 Theory of Microdialysis Sampling 
Microdialysis (MD) sampling is a diffusion-based process in which compounds of 
interest migrate through a porous membrane into a gentle flow of perfusion fluid. The perfusion 
fluid, a physiological fluid, deficient in the analyte of interest, is perfused through the 
membrane or is pumped through the MD probe inlet tubing at typical flow rates of 0.5 – 5 
μL/min. As the perfusion fluid (perfusate) traverses the probe, analytes from the surrounding 
fluid, often the ECF for brain sampling, diffuse through the porous membrane and swept along 
by the perfusate. The outflow from the microdialysis probe, termed the dialysate, is collected 
either on-line for real-time analysis or off-line for further analysis. The schematic sampling 
procedure for MD is depicted in Figure 1.2. The diffusion process is as a result of a 
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concentration gradient present between the perfusate and the surrounding ECF.49,50 A typical 
characteristic of MD is the ability to measure only the unbound of free fraction of the analytes 
in the ECF. This is mainly due to the specificity of molecular weight cut-off of the semi-
permeable membrane, which prevents large protein molecules from diffusing through the 
membrane. This implies that in the quantitation of exogenous compounds such as drugs, only 
the pharmacologically active portion of the drug will be measured. MD has therefore been used 
successfully in drug pharmacokinetic and pharmacodynamics studies. 
 
Figure 1.2 A schematic diagram of a typical in vivo microdialysis setup* 
*Printed with permission from “Handbook of neurochemistry and molecular neurobiology; practical 
neurochemistry methods, Eds. Lajtha, A., Baker, G., Dunn, S. Holt, A., Plenum Press, New York , 2007, 219 – 
256.         
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1.2.3.2 Microdialysis Probe Considerations 
As tissue samples may be heterogeneous/homogeneous so selecting the right probe is 
very a critical factor in any MD application. The most common MD probe for monitoring 
neurochemicals is the concentric cannula or rigid probe design.51 Other probe designs include 
the linear, shunt and flexible probes. Often the type of tissue determines the probe type that is 
appropriate for sampling. The linear probe has been used in most applications that involve 
sampling of homogenous soft tissues such as heart, liver and muscles whereas the concentric 
cannula is used for the brain due to the latter’s heterogeneity.   
In addition to the probe design, another critical factor that can affect recovery of the 
analyte is the material used in the fabrication of the semi-permeable membrane and the tubes. 
This is mainly due to the fact that the physicochemical properties of the analyte and its 
interactions with the MD membrane, and thus affecting the analyte’s diffusibility through the 
semipermeable membrane. Generally, the molecular weight cut-off and membrane 
hydrophobicity are among factors that may grossly influence the analyte’s recovery. Some of 
the commercially available probes include polyacrylonitrile, polycarbonate, polyethersulfone, 
and cuprophan.50  
1.2.3.3 Microdialysis Calibration methods 
Microdialysis sampling is a non-equilibrium diffusion-base process. Thus, at any point 
during the sampling process, the analyte concentration in the sample represents a fraction of 
its actual concentration in the immediate vicinity of the probe. In this regard, the extraction 
efficiency of the probe is a vital parameter that relates to the recovery of the analyte. The 
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extraction efficiency in most cases is expressed as the relative recovery (when the analyte 
concentration is higher in the ECF) or relative delivery (when the analyte concentration is 
higher in the dialysate). A mathematical representation of the relative recovery is given as, 
𝑅𝑒𝑙𝑎𝑡𝑖𝑣𝑒 𝑟𝑒𝑐𝑜𝑣𝑒𝑟𝑦 =
𝐶𝑑𝑖𝑎𝑙
𝐶𝑝𝑒𝑟𝑓
                                       (1.1) 
i.e., the ratio of the analyte concentration in the dialysate (Cdial) to the concentration of the 
analyte in the perfusate (Cperf). 
Parameters that influence the relative recovery include the perfusate flow rate, 
temperature, dialysis membrane and analyte properties, probe geometry and typical for in vivo 
applications, physiological processes such as metabolism, uptake, release, transport and 
binding. 51 In MD sampling, the relative recovery is a very critical parameter needed for 
calibration purposes and its determination usually precedes any in vivo sampling. Typically, in 
vitro calibration of the MD probe is carried out by perfusing the probe with artificial 
cerebrospinal fluid (aCSF) devoid of the analyte of interest under well-controlled agitation and 
temperature conditions (typically 37 oC). Dialysate samples are later collected, analyzed, and 
the relative recovery can be calculated using equation 1.1. A major disadvantage of the in vitro 
calibration method is that effect of the matrix such as tissue vascularization, metabolism rate 
and analyte reuptake into cells, all of which may affect the calculated in vitro recovery, are not 
taken into account. Thus, in vitro probe calibration often leads to approximation of the 
analyte’s recovery into the microdialysis probe.52 To provide more accurate data in vivo 
calibration methods have been proposed. 
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The “no net flux” in vivo calibration method involves perfusing the probe with analyte 
concentration estimated to be below or above the expected extracellular concentration in the 
tissue in a random fashion, thus creating conditions in which the analyte molecules are either 
lost to or gained from the tissue.52 In the event that the analyte concentration in the perfusate 
is greater than in the ECF of the brain, the analyte diffuses from the probe through the 
membrane into the brain. The reverse process is observed when the analyte concentration in 
the brain is greater than that in the perfusate. A regression analysis of the relationship between 
the concentration of the analyte in the perfusate and the difference between analyte perfusate 
and dialysate concentrations reveals a linear curve passing through zero. At this point the 
analyte concentration in the perfusate and dialysate is equal, i.e., the point of no net flux (no 
diffusion across the membrane occurs). Despite the reliability of the calibration method, the 
method is very time consuming due to the multiple changes in the perfusate solution and the 
corresponding equilibration time associated with each change. 
An alternative to the no net flux method is calibration by delivery, or retrodialysis.53 In 
this method, once the microdialysis probe has been implanted, a known concentration of the 
analyte is perfused through the probe. The dialysate is collected, analyzed, and compared to 
the perfusate. 
𝑅𝑒𝑙𝑎𝑡𝑖𝑣𝑒 𝑟𝑒𝑐𝑜𝑣𝑒𝑟𝑦 =
(𝐶𝑑𝑖𝑎𝑙 − 𝐶𝑝𝑒𝑟𝑓)
𝐶𝑝𝑒𝑟𝑓
                                       (1.2) 
Equation 1.2 represents the comparison of the two substances. However, this method does not 
consider the dynamic changes in analyte recovery of the microdialysis probe throughout the 
entirety of the experiment. In this method, an internal standard is added to the perfusate during 
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the course of the experiment.54 The diffusion properties of the selected internal standard should 
match that of the analyte to facilitate comparison of the relative recovery of the internal 
standard to the relative recovery of the analyte. The advantage of using an internal standard is 
that probe performance over the course of an experiment does not affect the overall recovery 
results.  
The final but not the least method used for in vivo calibration is the flow rate variation.55 
With this approach, the flow rate of the perfusate is varied throughout the probe calibration 
process. The concentration of the recovered analyte is plotted against the flow rate. An 
extrapolation to zero provides an estimation of the analyte concentration and the relative 
recovery of the probe can be measured. The main disadvantage of this method is that the longer 
sampling times are required for the low flow rates leading to poor temporal resolution. 
1.3 In vivo microdialysis for sampling brain ECF 
Since its introduction many important and successful neurochemical studies have been 
carried out using MD coupled with various analytical systems. MD is currently a well-
established technique for studying physiological, pathological and pharmacological changes 
of a range of low molecular weight compounds within the brain ECF. Major applications 
involve quantitative determination of primarily neurotransmitters, 56–63 and also MD as a tool 
for drug infusions/delivery.64–67In vivo MD in freely moving animals is commonly used to 
study the relationship between changes in neurotransmitters at discrete regions of the brain and 
behavioral changes. In addition to continuously studying extracellular neurotransmitter levels 
in discrete regions of the brain, in vivo MD studies have successfully been used to studies of 
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physiological processes in humans.68 In 2001, MD was used to demonstrate how dopamine 
neurotransmission relates to cognitive processing in humans.69,70 A typical challenge in in vivo 
neurochemical monitoring is the detection of neuropeptides. This is because most of these 
neuropeptides have very low concentrations. However with the combination of tandem MS, 
dialysate fractions were found to contain endogenous met-enkephalin71 and neurotesin,72 and 
other neuropeptides73 from the brain ECF. MD has also been applied in clinical studies to 
determine specific neurotransmitters in patients with traumatic brain lesions.74  
1.3.1 Analysis of dialysates 
MD, unlike voltammetry, requires an additional analytical equipment for the analysis 
of dialysates. Since the dialysates are often in small sizes, contains high concentrations of 
inorganic salts and the fact that neurochemicals are in very low concentrations in the brain 
extracellular fluid, detection and quantitation of brain neurotransmitters still remain an 
analytical challenge. Coupling of MD to chromatography has significantly facilitated 
separation and measurements of individual neurotransmitters in dialysates. Gas 
chromatography (GC) however, has not been a method of choice due to the fact that most 
neurotransmitters are non-volatile. Therefore, further analytical step like chemical 
derivatization of the analytes to improve volatilization must be introduced into GC assays for 
neurotransmitters. For example, analysis of choline and acetylcholine by GC was achieved 
through demethylation of the quaternary nitrogen atom with benzenethiolate.75 Although that 
study was successful, the process of derivatization in itself introduces potential analytical 
errors to the entire technique. Simple, reliable and robust sample preparation methods are 
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always the key elements for any new analytical method. Understandably HPLC systems are 
better alternatives and provide the needed separation stability for the analysis of dialysates.  
Apart from the fact that most of the components captured in dialysates are none volatile, 
HPLC separation is suitable for analyzing dialysates because they are devoid of proteins, which 
reduces fouling. In addition, the development in capillary liquid chromatography (CLC) has 
further enhanced interest in chromatographic separation of dialysates. Despite the advantage 
of HPLC over GC for the analysis of non-volatile compounds, it is important to note that 
neurotransmitters such as, DA, GABA, GA, 5-HT, Ach, NA, etc., are small low molecular 
weight polar compounds. Thus, their retention and separation is not easily attained on a typical 
reverse phase HPLC system. If required, ion-pairing agents are employed in order to achieve 
good retention of neurotransmitters on a standard reverse phase HPLC column. In addition to 
ion pairing, different stationary phases like the pentafluorophenyl (PFP) and chemically 
modified reverse phase stationary phases may be employed to enhance interactions with the 
polar neurotransmitter molecules. Alternatively, hydrophilic interaction chromatography 
(HILIC) can be explored for separation of neurotransmitters.76 
Like any other analytical technique, stable, accurate and reliable detection are 
paramount for attaining excellent data quality. Common methods such as electrochemical 
detection (ECD),56  fluorescence57 and mass spectrometry (MS)73 have been coupled to HPLC 
for routine measurements of neurotransmitters.  
Electrochemical detection (ECD) is primarily used for ionic compounds or compounds 
that are easily oxidized or reduced. Electrochemical detectors are very sensitive with detection 
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limits typically in the nanomolar region and thus very applicable to the analysis of 
neurotransmitters in brain ECF. The selectivity of ECD is derived from the oxidation/reduction 
potential of the neurotransmitters. Despite these advantages, a typical limitation of ECD is 
fouling at the surface of the electrodes, which subsequently masks its overall performance. 
Fluorescence detection is applicable to analytes that contain fluorophoric moieties within its 
core structure and thus able to fluoresce. An advantage of this technique is that very few 
organic compounds are able to fluoresce and therefore enhancing its selectivity. On the 
contrary, this poses analyte detection technique challenge since most neurochemical 
compounds do not have fluorophores. In order to improve detection, fluorophoric groups can 
be introduced to enhance detection. Notable for its specificity and sensitivity, the MS compared 
to the other detection systems, provides further molecular information of the analytes. As a 
result, LC-MS platforms have generally been accepted for bioanalysis. 
For LC-MS applications, the common atmospheric pressure ionization (API) processes 
are electrospray ionization (ESI) and atmospheric-pressure chemical ionization (APCI). In 
ESI, ions are generated in the ionization source, which can affect the sensitivity of the 
analytical signal. Typically, the LC eluent is nebulized in source in the presence of a strong 
electrostatic field and heated drying gas. The electrostatic field enhances dissociation of the 
analyte with the heated drying gas causing solvent evaporation. This leads to reduction in the 
size of droplets containing a cluster of ions. Finally, the generated repulsive forces between 
ions of similar charges surpass the cohesive forces within the droplets leading to ejection of 
ions into the gaseous state. The ions are further attracted to the mass analyzer through an 
orifice. The APCI can be considered as a gas phase chemical ionization (CI) process where the 
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mobile phase solvent acts as the CI to assist in the ionization. In APCI, the LC eluent is sprayed 
through a heated vaporizer, and electrons discharged by a corona needle ionize the resultant 
gas-phase solvent molecules. The formed gas phase ions transfer charge to the analyte and the 
resultant ions passed through an orifice into the mass analyzer. In the mass analyzer the 
generated ions are separated and identified according to their mass-to-charge (m/z) ratios. LC-
MS has extensively been applied to a wide range of thermally labile analytes, typically high 
molecular weight biomolecules. On a LC coupled to tandem mass spectrometry (LC-MS/MS) 
platform, further ion fragmentation is generated in the analyzer for enhanced elucidation of 
analyte molecular information. Commonly applied techniques for MS-MS are the triple 
quadrupole and the ion trap mass spectrometers. The triple quadrupole instruments are very 
rugged and sensitive whereas the ion trap MS systems have the capability of conducting MSn 
experiments to provide clearly define precursor-product ion relationships. In addition, hybrid 
geometries of triple quadrupole and ion trap MS, such as linear quadrupole ion trap systems 
are also available for various bioapplications. The LC-MS/MS is the commonly used method 
for fast and sensitive quantitation of small molecules such as neurotransmitters, peptides and 
drugs from various biological complex matrices including plasma, blood and tissue. This is 
because MS/MS is more sensitive and significantly specific than other LC detectors. In 
addition, the MS/MS can analyze compounds with no suitable chromophore and also 
components in unresolved chromatographic peaks, thus reducing the need for absolutely 
resolved chromatographic peaks. In a triple quadrupole MS, the first quadrupole (Q1) is used 
to select a precursor ion and collision induced dissociation (CID) occurs in the second 
quadrupole (collision cell). For analyte specificity, ion fragmentation is effected through 
collision with neutral molecules. Subsequently, the third quadrupole (Q3) generates a spectrum 
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of the resulting product ions. A major advantage of the LC-MS/MS platform is the ability to 
use Q1 to filter unwanted ions for enhanced sensitivity. The technique has thus been applied 
successfully to targeted analysis of compounds in various biological matrices where the analyte 
concentrations are very low, such as quantitative analysis of neurotransmitters in brain tissue. 
For global untargeted metabolomics studies using LC-MS, where the targeted analytes are 
unknown, reliable confirmatory assays are required. This additional requirement is obtained 
by using mass spectrometers with high accurate mass, i.e., the higher the accurate mass of the 
analyzer; the easier it is to confirm the identity of the chemical substance. The orbitrap is an 
example of a typical mass analyzer with higher resolving power and mass accuracy that has 
been applied for global metabolomics studies.  
Thus, for LC-MS assays, the neurotransmitters will be identified by both retention time 
and molecular weight. Although fluorescence detection is also known for its remarkable 
sensitivity, the LC-MS/MS assay has been reported as the most sensitive.73–78 However, a 
critical concern in LC-MS or LC-MS/MS assays for neurotransmitters is the potential ion 
suppression or enhancement typically observed with the ESI interface. This phenomenon is 
more pronounced in dialysates due to the higher inorganic salt contents (higher ionic strength) 
and therefore generates high background noise and ionization suppression leading to 
considerable loss of sensitivity. It is vital therefore to attain good separation of the analytes 
from co-eluting components in the dialysates in order to minimize ion suppression from the 
sample matrix. Alternatively, the greatly reduced column bore in capillary liquid 
chromatography (CLC) and the lower flow rates can be explored since its introduction has 
augmented the overall effect of mass sensitivity79 and further improved matrix compatibility 
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to MS while reducing also mobile phase consumption. Another advantage of CLC-MS is the 
overall improvement in temporal resolution as noted for ultra-high performance 
chromatography (UPLC). Kennedy et al. reported of 2 – 4 min temporal resolution for 
measurements of acetylcholine in dialysates80 compared to previously reported 20-min 
temporal resolution for LC-MS method.72 Despite these achievements, instrumentation setup 
require specialized parts often due to the associated backpressure, the overall  instrument cost 
and sample introduction can be very challenging and thus require careful manipulation.    
1.4 Comparison of In vivo Microdialysis and Voltammetry 
Since its introduction in the mid-1960s, voltammetry has been primarily used for the 
analysis of biogenic monoamine neurotransmitters and their metabolites in the brain. Despite 
the broad acceptance of voltammetry as a neurochemical technique, in vivo MD has become 
the most widely used sampling tool of the brain ECF, CSF sampling through lumbar puncture 
in humans. The two analytical methods are currently applied to extensive studies of the 
neurochemical composition of the brain. However, due to the differences in their sampling 
principles, voltammetry and MD provide very specific information on the composition of the 
brain ECF. In vivo MD provides further advantage of chemical specificity when coupled to 
HPLC-MS but usually characterized by low temporal resolution in the range of minutes. On 
the contrary, in vivo voltammetry is typically used to measure rapid changes in analyte 
concentration within the ECF and the samples are analyzed over millisecond to a minute 
interval. Thus, by combining these two techniques, simultaneous measurement of slow 
changes in neurotransmitters concentrations, basal levels of neurotransmitters and their 
metabolites, and the dynamic information of neurochemical kinetics can be obtained. Lastly, 
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in vivo voltammetry utilizes extremely small size recording electrodes and thus facilitates 
spatial monitoring of different regions of the brain simultaneously whereas the relatively 
bigger size of MD probe integrates chemical changes from various surrounding tissues. It’s 
worth mentioning that both methods over the years have evolved significantly with the 
introduction of microelectrodes in voltammetric techniques, improvement of its selectivity and 
the attainment of 1s temporal resolution with in vivo MD have been reported.81 
1.5 Electrochemical biosensors for brain neurotransmitters 
Neuronal activities occurring within the mammalian brain typically involve rapid 
changes of some neurotransmitters. As an example L-glutamic acid is known for its fast 
excitatory release during normal neuronal activity. Current analytical techniques used for 
measurements of such rapid changing processes lack the needed fast response to measure 
accurately changes in neurotransmitter concentrations within the rain ECF. For example, MD 
is the primary method for measurements of endogenous neurotransmitters; however it still does 
not have the required temporal resolution for direct measurements of fast changes in the 
concentration of neurotransmitters in the brain ECF. In addition, MD coupled to other detection 
schemes does not always capture the true extracellular concentrations of the analytes. 
Electrochemical techniques, which have been employed extensively, are primarily meant for 
measurements of electroactive neurotransmitters like monoamines and their metabolites within 
the CNS. The technique has shown significant temporal resolution in capturing fast transient 
changes in neurotransmission over most existing conventional methods. However, not all 
endogenous neurotransmitters exhibit electroactive properties for possible ECD 
measurements. A typical example is L-glutamic acid, which does not show electroactivity.82 In 
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order to study the rapid changes in the concentration of neurotransmitters during brain activity, 
there is a growing demand for sensitive, reliable and most importantly rapid analytical 
techniques. In this regard, enzymatic biosensors have also emerged.  
The major motivation for the development of electrochemical biosensors is due to the 
fact that most enzymatic reactions associated with neurotransmission produce, for example, 
hydrogen peroxide as a product, which can be determined via electrochemical measurements.  
Thus, a biosensor can be viewed as any sensor that employs a biological component, such as 
antibody or enzyme, to bind a specific analyte of interest to provide a signal in the form optical 
or amperometric that relates directly to the amount of analyte in a given matrix.83 Among the 
numerous biosensor designs available, enzymatic biosensors form the relatively larger portion 
applied to the brain research study.  The principle of enzymatic biosensors is based on the 
reaction between the analyte and a specific biological substrate to produce a measureable 
product and the amount of the product formed in the biosensor reflects the concentration of the 
analyte. The product formed is usually measured through amperometric detection methods for 
most brain research. 
Common techniques used in the fabrication of biosensors include electropolymers, 
electrodeposition paints, sol-gel and hydrogel methods.83 With electropolymer method, 
monomers such as pyrrole, thiophen or tyramine are used to form a continuous network of 
polymer on a polarized electrode surface. Subsequently, the enzyme(s) can be embedded into 
to the polymer via two possibilities. The first process entails physically entrapping the enzymes 
within the core structure of the polymer. In the second process, the enzymes are cross-linked 
to the previously formed electropolymer that are functionalized for covalent interaction or a 
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non-covalent linkage.83 Due to small size of the electrodes (3 - 25 m), the previous process 
often leads to formation of a highly hydrophobic electrode surface making the entire device 
less sensitive. This is explain the low density of trapped enzyme with a subsequently lower 
enzyme activity. Electrodepostion methods involve the use of long chain polymers with 
charged groups like amines or carboxylic acids. Through careful manipulation of the pH 
surrounding the electrodes, precipitation of the polymer can occur either through protonation 
of the carboxylic or deprotonation of the amine functional groups.  In the process, enzymes 
present in the mixture are also trapped in the insoluble polymer formed on the surface of the 
electrode. Sol-gel methods largely involve the encapsulation of the enzyme into through 
conventional sol-gel production processes. The encapsulation of the enzyme can be done 
during the slow curing procedure for the sol-gel formation. Lastly, redox hydrogels can be 
fabricated by crosslinking water-soluble polymers such as polyvinyl imidazole with other 
polymers resulting in the formation of new high water content polymer in the form of 
hydrogels. The presence of the hydrogels provides the needed excellent aqueous environment 
for most enzymes.83 
1.5.1 In vivo measurements and challenges using electrochemical biosensors 
A major challenge associated with electrochemical biosensors is interference from 
other non-electroactive species that are present in the brain ECF. The interference occurs 
normally when interactions with the non-electroactive species at the surface of the electrode 
often leads to the generation of charging current and thus masking accurate determination of 
the analyte of interest. Another challenge often encountered with amperometric biosensors is 
the loss potential of sensitivity with time during its operation. This may be due to fouling at 
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the surface of the electrode, fouling of the surface of the outer biolayer, which often hinders 
analyte access to the electrode and lastly the loss of enzyme activity due to involvement in 
breakdown of protein.83 Nonetheless, it is worth mentioning that biosensors are very useful 
analytical devices and provide the opportunity for direct measurements of neurotransmitters in 
the brain.  
In 1988, Crespi, et al. successfully developed  a voltammetric biosensor capable of in 
vivo measurements of the basal concentrations of 5-HT stimulations in the brain.84 In a more 
recent publication, Wahono, et al., explored the possibility of using amperometric glutamate 
biosensor for in vivo measurements of glutamate after recording a 35-fold increase in 
extracellular glutamate through in vitro experiemnts.85 In addition to in vivo glutamate 
monitoring in the brain ECF, electrochemical biosensors have be applied to measurements of 
neurotransmitters such as DA, NA, 5-HT, among others,86–88 and even by combining with on-
line MD to monitor dynamic changes in brain metabolism.89 
1.6 In vivo brain tissue sampling: the need for alternative approaches 
It is clear from the foregoing sections that despite the significant success attained in the 
development of in vivo analytical sampling methods to measure changes in the concentrations 
of endogenous compounds within the brain ECF, there are still intrinsic challenges. Although, 
this thesis focused on mainly commonly used in vivo analytical methods for brain tissue 
sampling, there is no doubt that introduction new analytical sampling approaches will augment 
the quest to monitor chemical activity within the brain ECF.  MD to date remains the most 
accepted analytical tool for brain tissue sampling, especially in neuroscience. However, till 
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date issues with probe calibration for accurate quantitation still pose a challenge as most 
calibration methods are carried out through in vitro experiments. These in vitro experiments, 
which provide the relative probe recovery does not take into account factors such as tissue 
tortuosity, possible analyte reuptake and metabolism. Menacherry, et al. reported an in vivo 
calibration method for quantitation of cocaine in the brain. Unfortunately, the approach itself 
was very time-consuming and challenging.90 Other in vivo calibration methods have also been 
reported elsewhere for measurements of other endogenous compounds.52,91,92 However, these 
methods are rarely used because they are also very time consuming and laborious.  
Another important issue is influence of the matrix component on the quality of data. 
From the previous sections, it was obvious that all the in vivo methods like most bioanalytical 
assays were significantly susceptible to matrix effect. This may primarily be due to the poor 
method selectivity, and thus compromise sensitivity especially when coupled to ESI-MS, a 
popular technique used for bioanalysis.  
Given the variety of challenges described above, it is even more paramount that new 
approaches are introduced to boost the efforts made to gain insight in the mammalian brain 
through acquisition of molecular/chemical information within the brain ECF. This can be 
achieved either by the introduction of a new brain tissue sampling approach or by integrating 
new methods with existing systems so as to improve overall data quality. One such method 
worth exploring is solid phase microextraction (SPME).  
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1.7 Introduction to Solid Phase Microextraction Method 
Solid Phase Microextraction (SPME), originally introduced in the early 1990’s93 as a 
non-exhaustive equilibrium extraction method, integrates sampling, sample preparation, 
analyte enrichment and sample introduction in a single step. The general concept was to utilize 
a small extraction phase volume to extract the analytes, typically volatile and semi-volatile 
compounds, from a given matrix. The introduction of the method and subsequent coupling to 
gas chromatography, thus served as an essential analytical technique for the analysis of 
environmental samples.94,95 Extraction phases such as polydimethylsiloxane (PDMS) and 
polyacrylate (PA), to mention a few, were among the first commercially available SPME 
coatings used for analysis of non-polar and polar compounds respectively.96,97 SPME has 
subsequently evolved and has been applied to the analysis of thermally labile compounds 
amenable to liquid chromatography and liquid chromatography hyphenated to other detection 
systems, in various matrices such as food,98–101 urine,102–105 and plasma106–108 to mention a few.  
Figure 1.3 Schematic representation of a typical direct SPME in vivo microextraction 
workflow from a given biological matrix coupled to LC-MC/MS 
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In terms of LC-MS applications, some of the interesting features include the 
development of the open-bed SPME configuration for automated parallel extraction of 
biological samples on a 96-well plate format109–111 and the development and evaluation of new 
“in-house” biocompatible coatings for biological applications.112 The development of 
biocompatible SPME coatings facilitated in vivo SPME bioapplications because the issue with 
fouling was addressed. SPME has therefore been a very useful sample preparation tool for the 
analysis of biological samples113,114 and even in vivo applications.115,116 In addition to 
overcoming issues associated with fouling, SPME also provides efficient sample cleanup due 
to the smaller extraction phase volume, which restricts potential matrix interferences that can 
mask the extraction of the analyte of interest. This important feature about SPME makes it 
very compatible with LC-MS/MS and thus suitable for the analysis of biological samples, 
urine, whole blood, tissue, etc. Figure 1.3 shows a schematic representation of a typical direct 
SPME in vivo microextraction workflow from a biological sample when coupled LC-MS/MS. 
The analyte amount extracted from any given matrix by SPME depends on the exposure time 
between the extraction phase and the sample. For sufficiently long extraction, equilibrium 
between extraction phase and sample is established. Under such conditions, the extracted 
amount is given by the following. 
𝑛𝑒 =
𝐾𝑓𝑠𝑉𝑓𝑉𝑠𝐶0
𝐾𝑓𝑠𝑉𝑓 + 𝑉𝑠
                                                          (1.3)  
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where ne is the amount of analyte extracted at equilibrium, C0 is the initial analyte 
concentration in the sample, and Vf are the volume of sample and fiber coating, respectively, 
and K fs  is the distribution constant between SPME extraction phase and sample matrix.  
The  value is dependent on the nature of analyte and the extraction phase selected 
for the analysis. But is also affected by properties of sample matrix such as temperature, pH, 
ionic strength, etc., and therefore it is paramount to maintain these factors constant during 
sample analysis. It is important to note that at equilibrium, no further extraction of the analyte 
occurs and thus the microextraction process may be deemed as complete unlike MD where the 
extraction process is continues as long as the probe remains in contact with the sample. Thus, 
for SPME the probability for local depletion of the analyte from the matrix is low, making it 
suitable for in vivo applications since it does not disrupt the internal equilibrium of the living 
system. 
From Equation 1.1, under conditions on negligible depletion of the analyte, when VfK fs  
<<< , the amount extracted can be calculated from the Equation 1.4.  
𝑛𝑒 = 𝐶0𝐾𝑓𝑠𝑉𝑓                                                                     (1.4) 
where all factors remain the same as previously defined. 
The microextraction process in SPME may be an absorptive or adsorptive mechanism 
depending on the type extraction phase selected. Absorptive processes are applicable to 
Equation 1.3 where the analyte diffuses within the complete volume of the extraction phase 
during the extraction process. A characteristic extraction phase is the PDMS liquid coating. In 
Vs
K fs
Vs
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the case of adsorptive process, which often occurs for solid porous extraction phases such as 
polypyrrole, the amount of analyte extracted is dependent on the number of surface active sites 
and diffusion within the entire volume of the extraction phase does not occur. For adsorptive 
process, the extracted amount can be obtained using Equation 1.5.117 
𝑛𝑒 =
𝐶0𝐾𝐴𝑓𝑠𝑉𝑓𝑉𝑠(𝐶𝑓𝑚𝑎𝑥 − 𝐶𝑓
∞)
𝑉𝑠+𝐾𝐴𝑓𝑠𝑉𝑓(𝐶𝑓𝑚𝑎𝑥 − 𝐶𝑓
∞)
                                     (1.5)  
where C f max is the maximum concentration of active sites on the extraction phase, KAfs is the 
analyte’s adsorption equilibrium constant and fC is the equilibrium concentration of analyte 
on the fiber. Due to the fact the extracted amount is dependent on the number of active sites, 
at sufficiently high analyte concentrations, surface saturation results, leading to nonlinear 
adsorption isotherms with characteristic shorter linear quantitative range.117 Details of such 
characteristics associated with adsorption processes in SPME are well discussed 
elsewhere.117,118Displacement effects are therefore a common characteristic for solid porous 
extraction phase as analytes compete for the limited active sites. This phenomenon partly 
depends on the values of the analytes, type and concentrations of components within the 
given matrix.  
SPME is largely perceived as an equilibrium microextraction method; however pre-
equilibrium processes can be carried out by terminating the microextraction prior to 
equilibrium being attained. In such cases, the amount extracted is less and if sensitivity is 
critical, often pre-concentration of the analyte in smaller desorption solvent volumes (often < 
100 µL) enhances detection when coupled to LC-MS/MS. It is important to note that for pre-
K fs
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equilibrium extractions, the analyte amount extracted by the extraction phase is based on its 
exposure time to the sample matrix. The amount extracted can therefore be calculated using 
the proposed equation below.119 
𝑛 = (1 − 𝑒−𝑎𝑡)
𝐾𝑓𝑠𝑉𝑓𝑉𝑠𝐶0
𝐾𝑓𝑠𝑉𝑓 + 𝑉𝑠
= 𝑛𝑒 (1 − 𝑒
−𝑎𝑡)                                 (1.6)  
 
where t is the extraction time, a is a factor known as the time constant and its magnitude is 
dependent on the sample volume, volume and extraction phase surface area, mass transfer 
coefficients and the distribution constant. The main advantage of pre-equilibrium 
microextraction is the shorter sampling time and thus increases sample preparation throughput. 
Thus, in certain applications like PK or PD studies where temporal resolution is critical, kinetic 
calibration method can be employed.  
A kinetic calibration method commonly applied for quantitative in vivo studies is the 
on-fiber standardization method.120,121  The approach involves pre-loading the extraction phase 
with a known amount of the calibrant and then using it to calibrate the extraction process 
through simultaneous desorption during extraction process. However, this approach is applied 
only when the extraction and desorption processes are known to be symmetrical, i.e., the 
calibrant has the same time constant as the analyte. This is usually achieved by using the 
deuterated analogue of the analyte122 or by using other compounds with similar diffusion 
properties or kinetics in a given matrix, as shown elsewhere.123 Quantitative determination of 
the amount extracted can be obtained from the equation below. 
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𝑛
𝑛𝑒
+
𝑄
𝑞0
= 1                                                                    (1.7) 
where Q is the amount of calibrant remaining on the fibre at time t, and q0 is the initial amount 
of the calibrant preloaded on the fibre and n and ne are the same as described previously. By 
combining Equations 1.3 and 1.7, the original amount of the analyte in the given matrix can be 
obtained using Equation 1.8. 
𝑛𝑞0
𝑞0 − 𝑄
×
1
𝐾𝑓𝑠𝑉𝑓
= 𝐶0                                                     (1.8) 
From Equation 1.6, knowing the K fsVf  value the initial analyte concentration can be obtained. 
The  value is obtained from equilibrium extractions of known calibration standards using 
the appropriate matrix. An advantage of on-fibre standardization method is that it also 
compensates well for unknown agitation conditions within the living system for in vivo 
applications since that cannot be simulated well using simple in vitro calibration methods. 
From Equations 1.3, 1.4, 1.6 and 1.8, it is obvious that the amount of the analyte 
extracted at equilibrium is directly related to its original amount in the given biological matrix. 
In the case of Equation 1.6 (pre-equilibrium conditions), it is critical that the extraction time 
and agitation conditions remain constant. Equation 1.4 also demonstrates the fact that a defined 
sample volume is not critical for quantitative analysis. Therefore, sampling can be performed 
directly from a living system, like the brain tissue. This feature of SPME makes it suitable for 
in vivo applications while demonstrating the ability to integrate sampling and sample 
preparation in a single extraction process.  
K fsVf
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1.8 In vivo Solid Phase Microextraction and Solid Biological Tissue Sampling: An 
Overview 
In vivo SPME due to its simplicity and suppleness has been applied for sampling of 
various biological tissues. In a human study, using a commercially available fibre (PDMS-
DVB) for extractions, Zhang, et al. investigated volatile emissions from the surface of the skin 
on the arm.124 The fibre was analyzed using GC-MS and over 100 compounds were identified. 
In a similar study, Gallagher et al. combined SPME and solid phase extraction (SPE) in a 
comparative study to demonstrate variability in volatile compounds emitted from the different 
parts of the body by sampling both the fore and upper back arm of various individuals.125  
In vivo SPME has also been applied to the study of emerging contaminants in the 
rainbow trout and greenside darter.126 In this study, authors were able to demonstrate the 
potential of in vivo SPME in determining bioaccumulation of selected pharmaceuticals in the 
fish muscles.  Simon et al. was also able to determine the amount of drugs in the muscle of the 
live fish and in environmental water using in vivo SPME with pre-equilibrium kinetic 
calibration method.127 In addition to quantitation drugs as contaminants in fish, elsewhere, in 
vivo SPME has also be used for the determination of organo-mercury compounds in fish by 
GC-MS128 and also by ICP-MS.129 Lord, et al., were able to quantify triazine herbicides 
(atrazine, simatryn and prometryn) in plants using a in vivo SPME-LC-MS.130 In this 
communication, the authors demonstrated the potential of monitoring in real time the 
movement of the herbicides through the plant and therefore provide a tool for accurate 
assessment of both herbicide mode of action and the plant’s physiological response. In another 
interesting development, space-resolved SPME was used to determine the distribution of 
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chemicals in different parts of a various biological matrices (onion bulb, fish muscle and 
adipose fish tissue).131,132 In this study, segmented PDMS material placed on stainless steel 
wire was separately inserted into the plant (onion) and fish (coating placed in both muscle and 
adipose tissue). Authors were able to demonstrate the potential of in vivo SPME to spatially 
distinguish differences in the accumulation of chemical substance in the muscle and the 
adipose tissue of the fish, and in addition the chemical distribution in the onion.  
1.9 Objectives of the research 
Currently, a lot of effort is directed toward the acquisition of chemical/molecular 
information within the brain ECF in order to gain better understanding of the human brain. 
This has led to development various analytical sampling methods and techniques with a focus 
on sample preparation. As a result, improvements of current analytical methods, especially in 
vivo sampling approaches form a very critical part to reliably determine and/or monitor 
chemicals within the brain extracellular fluid. The main objective of this thesis was to develop 
an in vivo SPME method coupled to LC-MS that can be applied as a sampling tool for 
monitoring endogenous and exogenous chemical substances within the brain ECF. Thus the 
breakdown of the thesis is as follows. 
In Chapter 2, the focus was on optimization of improve post in vivo SPME sampling 
throughput while maintaining sample integrity and stability for further analysis. This led to the 
development and evaluation of a semi-automated desorption device for in vivo SPME probes 
on a 96-well plate format. The evaluation was the carried out using selected benzodiazepines 
(diazepam, oxazepam, lorazepam and nordiazepam). Since most in vivo SPME methods 
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require offsite analysis of the probes, a critical part of the device is maintenance of analyte 
integrity by preventing possible contamination after sampling. Chapter 3 describes initial work 
carried out to identify the appropriate extraction phase/coating that can be used to extract 
chemical substances with wide range of polarities. Since part of the objective is to be able to 
capture small polar endogenous compounds within the brain extracellular fluid, selected 
coatings were evaluated for their ability to extract various neurotransmitters (DA, GA/GLU, 
5-HT and GABA) with wide range polarities. The next chapter (4) describes the development 
of the in vivo SPME sampling method for the monitoring changes in the concentration of the 
selected neurotransmitters (targeted analysis) from the brain ECF. MD is a known sampling 
tool for brain endogenous compounds within the brain ECF that typically extracts more polar 
compounds. In this regard, the results obtained from the newly developed in vivo SPME 
method were compared with that of MD. The chapter also describes the complimentary nature 
of SPME and MD in a typical untargeted metabolites analysis from the brain ECF. Within the 
same chapter, in addition to the analysis of endogenous chemical substances, an in vivo SPME 
method for quantitation of exogenous drugs has been described and the results compared with 
that for in vivo MD, also carried out concurrently. Chapter 5 describes an initial application of 
in vivo SPME in a clinical study on the effect of deep brain stimulation on selected 
neurotransmitters. The study was extended to investigate the possible involvement of other 
compounds affected by deep brain stimulation in a global metabolomics untargeted analysis.  
Conclusions of the research are summarized in Chapter 6 and highlights proposals for future 
directions and challenges associated with this type of studies. 
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Chapter 2  
Optimizing in vivo solid phase microextraction coupled to liquid 
chromatography–mass spectrometry applications 
2.1 Preface and Introduction 
2.1.1 Preface 
This chapter of the thesis is already published as an article under the title “A multi-fiber 
handling device for in vivo solid phase microextraction–liquid chromatography–mass 
spectrometry applications” by Erasmus Cudjoe and Janusz Pawliszyn., J. Chromatogr. A. 
1232. (2012) 77-83. All tables and figures were reprinted from this publication with permission 
from Elsevier Copyright.  
2.1.2 Introduction 
Lately, understanding sample complexity, the quest for improvement of sample 
throughput and data quality has influenced the noticeable paradigm shift in analytical 
procedures. Apart from the conventional factors like high accuracy/precision and 
robustness/reliability, which still remain valid and critical, very often an ideal sample 
preparation method must have high throughput, environmentally safe, simple, and cost-
effective, and in some cases, be amenable to automation. 
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Sample preparation continues to form a critical stage and often the bottleneck in any 
quantitative chemical analysis process especially in when dealing complex matrices like 
biological samples. This is because notwithstanding the sophisticated resource of available 
analytical techniques, it is often literally impossible to obtain every bit of accurate information 
without a well-developed sample preparation step. A very good sample preparation procedure 
often enhances analyte sensitivity by either removing or minimizing matrix/contaminants 
influence, which will hitherto impact negatively on the data quality. As a result, significant 
amount of time and money is often expended for maintaining sample integrity and effective 
preparation procedures. 
Arguably, environmentally safe sample preparation methods like dried blood spot,133 
SPE134 and SPME,135 to mention a few, are replacing the labour intensive conventional 
methods such as Soxhlet extraction136,137 and LLE,138–140 which require the use of large 
volumes of toxic solvents. In addition to the increase in relatively environmentally safe 
methods, automation of analytical procedures has also gained remarkable interest. This could 
be due to the improved precision and accuracy resulting from minimal or no human 
interventions and in certain instances, their cost effectiveness. Developments of hyphenated 
techniques such as gas and liquid chromatography coupled to tandem mass spectrometry have 
also boosted major advancements in quantitative bioanalysis. Although in certain cases, GC 
and LC applications would require analyte derivatization for improved volatility and/or 
chromatographic separation, general chromatography still remains the common analytical 
separation method. For example, the combination of chromatographic separation with the 
sensitivity and specificity of the mass spectrometer have been used in various applications 
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including clinical diagnostics,141–143 environmental application,144–147toxicological studies148–
152and food analysis.98,153–156  
Fully automated sample preparation units coupled to hyphenated techniques (GC-MS, 
LC-MS, etc.) are common now because of the added advantage of reduced analytical labour 
and costs, reduction in probable analytical errors and the improvement of accuracy. In 
quantitative bioanalysis for example, using automated high throughput sample preparation 
(performing parallel extractions and/or dissolutions) units on a 96-well plate format have 
significantly improved overall analysis time.  Jemal et al. in a comparative study of manual 
LLE, automated SPE and LLE for quantitation of determination of carboxylic acid in human 
plasma, demonstrated some clear advantages of automated methods; automation decreased 
sample analysis time by almost 3x more than the comparative manual method.157 
Subsequently, the technique has been used for the determination of insulin, drugs in human 
plasma, 158 and other metabolites in biological matrices.159,160 Similarly, parallel extraction 
methods using the 96-well format has been applied to the analysis of drugs and their 
metabolites in biological matrices.161–164 Recently also, SPME method coupled to LC-MS/MS 
on a 96-well plate format was also introduced for the first time.165 In this particular case, the 
fiber geometry and the effectiveness of the 96-well plate open-bed SPME configuration was 
evaluated with selected benzodiazepines. The method has subsequently been applied to the 
analyses of drugs in urine111 and whole blood without prior sample treatment.110  
SPME being a two-stage (extraction and desorption process) sample preparation 
method was primarily introduced for the analysis of volatile compounds in the environmental 
samples. Subsequently, the method has evolved and successfully been coupled to HPLC and 
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other hyphenated methods for the analysis non-volatiles in various matrices. Various 
bioanalytical applications166–175 available in literature demonstrate the practicality of SPME as 
a sample preparation method. By coupling to LC-MS/MS, the method has been applied to 
chemical analysis of biological matrices in both ex vivo and in vivo applications. For example, 
Zhang et al. developed a quantitative in situ method for ochratoxin A in cheese by direct 
insertion of the SPME probe.123 Recent metabolomics studies, also showed that short-lived 
metabolites could be captured in freely moving rats with an in vivo SPME method.176 Despite 
the fact that in vivo methods and for that matter in vivo SPME, offer enriched information of 
the biological system under study than its in vitro counterpart, most effort focused on 
improving and automating in vitro extraction process. Definitely at the moment, automation of 
the extraction process for in vivo SPME may be impractical, but little or no effort has been 
made to improve its desorption process. An in vivo SPME method till date is characterized by 
conventional/manual desorption process, which is tedious with extended analysis time. Briefly, 
after an in vivo extraction of any biological system, the SPME probes are immediately 
transferred in vials and capped in order to prevent any possible damage or contamination. In 
certain instances, they are placed in vial inserts depending on the volume of desorption solution 
to be used. Depending on the analyte(s) stability, the probes may be stored on dry ice and 
transported to the lab if the sampling location is different from the laboratory for subsequent 
desorption in appropriate solvent system or cannot be analyzed onsite. At the laboratory, the 
vials with the probes are loaded onto a tray, placed on a commercial shaker/agitator for 
desorption and subsequent LC-MS analysis. This post in vivo SPME extraction process, leads 
to low sample throughput often increasing overall analysis time. With the increasing in vivo 
SPME applications, desire for shortened analysis time and to obtain reliable and accurate 
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analytical information, it will therefore be expedient to improve the overall process. In this 
regard, this portion of the thesis shows the design and evaluation of a new tool for handling in 
vivo SPME probes for post extraction sample preparation.   
The new tool, a multi-purpose SPME fiber handling device for in vivo and in vitro LC–
MS was subsequently designed to improve desorption of in vivo SPME probes, prevent any 
possible external contamination during transport, enhance safe handling of probes and also 
improve overall analysis.  
2.1.3 The multi-fiber handling desorption device 
The multiple-fiber handling device was mainly intended as a portable tool for 
simultaneous/parallel desorption of multiple in vivo SPME samplers used for bioapplications 
on a regular 96-deep well plate. In addition, the entire unit was designed to permit easy packing 
and setting of probes to fixed positions inside each individual well of the 96-well plate. Thirdly, 
all loaded probes should be rigid once loaded to prevent damage during transport and agitation. 
In view of the fact that the device will be placed on commercial agitator during desorption, the 
weight of the device should not affect effectiveness of mass transfer inside any of the wells. 
Finally, the design should augment prevention of any external contamination during the 
experiment and/or transportation. 
As a brief description, the device consists of a base, which supports and allows in vivo 
probes to be fitted directly into each well of a 96-deep well-plate immediately following an 
extraction. A flat plate with 96 holes aligned with the wells of the plate is placed on top of the 
base to serve as the guide for the SPME probes. A stopper is in place to ensure each fiber is at 
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the same distance inside the well. Figure 2.1-a shows the guide on the base part of the device 
while Figure 2.1-b is the unit place on a commercially available 96-deep well plate loaded with 
the in vivo SPME fibers. To ensure that the loaded in vivo probes are well protected against 
damage and possible contamination after the extraction process, the entire device is 
subsequently placed in a protective case or cover serving as housing (Figure 2.1-c). The 
protective cover with four clips is used to secure the device with the well-plate together for 
easier transportation to the laboratory for further analysis as shown in Figure 2.1-d. 
To establish that the device works as expected, it was evaluated using commercially 
available SPME in vivo blood probes, which comprised a hypodermic needle and a medical 
grade stainless steel wire as a plunger with one end coated with the extraction phase. The other 
end of the plunger is fitted into a cylindrical rubber-like material. Depressing the plunger 
exposes the extraction phase for subsequent extraction and desorption processes in a given 
matrix.  
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Figure 2.1 Prototype multiple SPME probe desorption device: (a) in vivo SPME sampler 
guide placed on the base part of the device, (b) device holding in vivo SPME samplers fitted 
on a regular 96-deep well plate, (c) protective casing with 4 clips as lockers, (d) entire unit is 
placed on a 96-deep well plate with clips locking the various parts as a single unit. 
2.2 Experimental Section 
2.2.1 Reagents and materials 
HPLC grade solvents were used for chromatographic separation. Acetonitrile solvent 
were obtained from EMD Chemicals Inc. (Darmstadt, Germany) and HPLC grade acetic acid 
was obtained from Supelco (Bellefonte, PA, U.S.A.). Benzodiazepines (diazepam; 
nordiazepam; oxazepam; and lorazepam) were obtained from Radian International (Austin, 
TX, U.S.A.) as 1 mg/mL standard in methanol with the exception of lorazepam, which was in 
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acetonitrile. The drugs were stored at 4 0C in a refrigerator. A mixed standard (100 ng/mL) of 
the drugs was prepared in 1:1 (v/v) acetonitrile-water mixture and always stored in the fridge. 
The mixed standard was used as the stock solution for all subsequent experiments. Phosphate 
buffer solutions (PBS) were prepared in the laboratory using analytical grade chemicals by 
mixing 8.0 g of NaCl, 0.2 g of KCl, 144 g of Na2HPO4, and 0.24 g of KH2PO4 in deionized 
water and the pH adjusted to 7.4. In vivo SPME probes with 5 µm C18 particles as extraction 
phase used in this study were obtained from Supelco (Bellefonte, PA, U.S.A.). Deionized water 
used in part for dilution of stock solutions was from a Barnstead/Thermolyne NANO-pure 
water system (Dubuque, IA, U.S.A.). The VWR DVX-2500 Multi-tube vortexer was used for 
vial agitations for all extractions while the PAS Concept 96 was used during desorption 
experiments. Figure 2.2 shows the structures of the benzodiazepines. 
 
Figure 2.2 Molecular structures of selected benzodiazepines used in the evaluation of the 
multi-probe desorption device. 
             
Diazepam      Lorazepam 
 
 
 
       
     Oxazepam       Nordiazepam 
 
Figure 1 Molecular structure of the selected benzodiazepines 
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2.2.2 LC and mass spectrometry conditions 
LC analyses were performed on the Accela instrument from Thermo Scientific® 
equipped with a binary pump. Chromatographic separation of analytes was achieved with a 
Waters® reverse phase C18 column (Symmetry Shield; 5 µm, 2.1 x 50 mm) in 5 min using 
gradient elution at a flow rate of 0.5 mL/min. Mobile phase A consisted of 90% aqueous and 
10% acetonitrile and mobile phase B was 90% acetonitrile and 10% aqueous. Both mobile 
phases contained 0.1% acetic acid to enhance ionization in the ion source. The LC method 
started with 100% of mobile phase A, which was held for 0.5 min. Mobile phase B was 
increased gradually to 3.0 min and held constant for half a minute. The initial column condition 
was subsequently restored for column re-conditioning till 5 min. The Accela autosampler 
from Thermo Scientific was used for sample introduction into the HPLC system. A sample 
volume of 10 L was injected and analyzed by a triple quadrupole mass spectrometer (TSQ 
Vantage). 
The TSQ Vantage had the HESI probe installed for nebulization and ionization. All 
ions were monitored in the positive ionization mode. The mass ion transitions monitored were 
271.1140.1, 285.1193.1, 287.1241.1 and 321.0275.1 for nordiazepam, diazepam, 
oxazepam and lorazepam respectively. The source voltage, vapourizer and capillary 
temperature were 2000 V, 350 0C and 350 0C respectively. The optimized sheath and auxiliary 
gases were set at 55 and 25 (arbitrary units) respectively. All data analyses were performed 
with the Xcalibur software version 2.0.7.  
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2.2.3 Optimization of SPME procedure 
Prior to evaluation of the multiple in vivo probe desorption device, optimization of the 
extraction and desorption processes were completed. The extraction process was optimized by 
generating an extraction time profile for each analyte and from the plots their equilibration 
times were determined. The equilibration times for all the analytes during the extraction 
process were determined with the VWR DVX-2500 multi-tube vortexer using preset agitation 
speed of 1200 rpm. For the extraction process, selected probes were placed in a 2.0 mL amber 
vial containing 100 ng/mL working solution of the drugs dissolved in PBS. The working 
solutions were prepared freshly in PBS while maintaining the same organic content. 
Extractions were carried out at different preset times (5, 10, 15, 30, 45 and 60 min) under the 
same agitation conditions. After the extraction process, the analytes were desorbed from the 
probes using 70% acetonitrile-water solution. 
In SPME method development for liquid chromatographic applications, optimization 
of the desorption process involves selecting an appropriate solvent system for which the 
analytes have better affinity and also requires the least time to effectively remove almost all or 
all of the analytes from the probe. The purpose is to decrease the amount of carryover to 
negligible limits for accurate quantitation of analytes in the sample. Desorption of analytes 
from the SPME probe was achieved by placing the probes in a 1000 µL desorption solvent 
inside the well of a 96-well plate. The 1000 µL desorption volume was selected because it 
maximum solvent that could be contained in each well without any spilling at during agitation. 
Lower desorption volumes can be used also in cases where sensitivity is paramount. However, 
it is critical to ensure that all probes remain fully immersed in the desorption solution during 
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agitation to prevent any variability. The Concept 96® was used to provide effective agitation 
for enhanced desorption kinetics. The amount of carryover was determined to be less than 
0.4% for all four analytes. Details of the optimized parameters are presented in Table 2.1. 
Subsequent experiments were all carried out using the optimized experimental conditions. 
Table 2.1 Optimized SPME conditions for analysis of benzodiazepines 
Parameter Condition 
Agitation speed 1200 rpm 
Desorption solvent 70% acetonitrile solution 
Equilibration time 25 min 
Desorption time 25 min 
 
The evaluation was carried out focusing on factors likely to affect data reproducibility 
during parallel desorption of the probes on a 96-well format. The results were also compared 
with data obtained for conventional desorption approach. All extractions were carried out with 
C18 coated surface probes. Prior to the extraction process, probes were pre-conditioning in 50% 
methanol-water solution and subsequently washed PBS solution briefly to reduce the organic 
content. Each probe was placed in a 1.8 mL sample volume in a vial through the septum screw 
cap. All extractions were done using the optimized method conditions described in Table 2.1. 
After the extraction process, all the probes were loaded into the desorption device and placed 
directly unto a 96-deep well plate containing 1000 µL desorption solution. The SPME probe 
guide was subsequently removed while the base part with the deep-well plate was later 
transferred to a commercial agitator (Figure 2.3) for simultaneous desorption of the analytes 
from all the fibers using the optimized desorption conditions. 
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Figure 2.3 Prototype multi-fiber device used for desorption of SPME fibers on a regular 
commercial agitator for a 96-deep well plate 
2.3 Results and discussion 
In vivo sampling though is often challenging and complicated as the biosystem under 
study undergoes continual dynamic chemical changes, data acquired provide better indication 
of the biosystem. Therefore, any in vivo sampling that requires off-line sample treatment 
should preserve sample integrity especially in cases when the samples could not be analyzed 
immediately and must be transported to the lab. This will ensure that the data provide accurate 
information about the biosystem. SPME as a portable sampling technique that integrates 
sampling and sample preparation has seen remarkable application to various in vivo studies in 
recent times. However, all in vivo SPME-LC-MS applications require off-line probe analysis 
and in most cases off-site analysis. Thus, critical measures are required to prevent probe 
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contamination and protection from damage after sampling and during transport. Typically, 
these probes are kept in small vials and trays, which sometimes present handling challenges to 
the researcher. This part of the thesis focuses on a handling device, which not only provides a 
solution to possible probe contamination and damage, but also provides an alternative high 
throughput approach for parallel desorption of all in vivo SPME probes without compromising 
data integrity. For desorption processes, the handling device houses a maximum of 96 probes, 
directly fits into a deep well plate and can be placed on a commercial agitator for enhanced 
analyte desorption. To confirm its sturdiness, efficacy and reliability of the device for parallel 
desorption of multiple SPME probes, evaluation was carried out, by investigating the agitation 
uniformity during desorption process.  Intra- and inter-well variations, effect of device weight 
on the agitation process and comparison of performance with conventional desorption 
approach were among the parameters considered. 
2.3.1 Investigating effect of the device on the uniformity of agitation during fiber 
desorption  
The device was designed to be placed on a commercial agitator after the probe-loading 
process for agitation. Thus, it was paramount that each probe was kept in steady position during 
agitation to prevent movements resulting in the change of the original positions. Typically, for 
open-bed configuration of SPME-LC-MS applications on a multi-well plate, probes were kept 
steady inside each well, which ensures effective desorption and data reproducibility. This is 
because probes movements inside the well result exposure of the coating out of the desorption 
solution and thus leading to poor data reproducibility. In addition, in this study it is possible 
that the weight of the device could also impact overall agitation and mass transport properties 
 52 
 
in each well, because the entire device weight would be brought to bear on the agitator. The 
weight in this case included a regular 96-deep well plate containing the desorption solution, 
the total number of in vivo SPME probes, and part of the device holding the probes in place 
during the agitation process (Figure 2.3). The overall force exerted on the agitator during 
desorption could therefore be significant and affect the uniformity of the agitation inside each 
well. If the agitation and therefore mass transport properties within the wells were not uniform, 
this leads to errors in the amount of analyte desorbed in each well, and affected overall data 
precision/reproducibility. The effect of the device weight was consequently evaluated by 
comparing the amount of each drug extracted/desorbed in each of the selected well positions 
for 5 independent desorption processes with/without the device. To accomplish this, 100 ppb 
of benzodiazepines was prepared in PBS buffer and then extracted using 20 selected probes 
using the optimized extraction conditions. The selected probes were placed in various positions 
in the 96-well plate. After the extraction process, desorption of the analytes was carried out on 
multi-tube vortexer by placing the probes in 1 mL solution for an hour. Similar experiment 
was carried out using the same probes. However, in this case desorption was carried out using 
the multi-probe desorption device, which was placed directly on the agitator (Figure 2.3). The 
amount of analyte extracted by each probe was determined from an extraction calibration curve 
generated from standards prepared in PBS. 
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Figure 2.4 Comparison of the amount of diazepam extracted/desorbed from the fibers at 
selected well positions with/without the desorption device (n = 5). The results are expressed 
as the mean ± standard errors for 5 extractions. 
For desorption of SPME probes in a 96 well-plate format, inter-well agitation 
differences could lead to non-uniformity in analyte mass transfer from each probe into the 
desorption solution, thus leading to poor data reproducibility. On the contrary, results shown 
in (Figure 2.4), suggest that the amount of analyte extracted from each well were not 
significantly different for both experiments. Thus, it could be concluded that the weight of the 
multi-probe desorption device does not affect the efficiency of well agitation for the individual 
wells. In addition, it can be inferred from the results that any relative movement of the probes 
during the agitation process does not affect the amount of the analyte extracted from the well. 
Another important factor for parallel desorption of multiple probes in 96-well plate 
format is the agitation speed. As a proof of concept, lower agitation speeds are characterized 
by agitation non-uniformity and slow mass transfer from the probes into the solution. As a 
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result, the variation in the amount desorbed from each probe as a function of the agitation speed 
was monitored. This was achieved by determining the amount desorbed at two different 
agitation speeds, 500 rpm and 1200 rpm respectively, for five successive experiments. The 
percent relative standard deviations (RSD%) at higher agitation speed were lower (RSD% ≤ 
7.0; n=5) compared to that obtained (RSD% ≥ 15; n=5) for lower speed for the selected wells. 
Thus, for excellent precision, reproducible and reliable data higher agitation speed (~1200 rpm) 
of the 96-well plate was necessary provided it does not lead to a possible cross-well 
contamination. The relatively higher RSD% observed at lower agitation could be attributed to 
incomplete desorption of analytes from all the wells. This phenomenon could be corrected 
though with longer desorption times. From the results obtained using the optimized 
experimental conditions, any differences in the amount extracted from the selected wells result 
from factors other than the probe positions, weight of the device and speed of agitation. 
2.3.2 Investigating well variations during multiple probe desorption process 
In addition to inter-probe variations, a critical factor in SPME-LC-MS applications 
with open-bed configurations that could affect data reproducibility is the inconsistencies in the 
bulk well conditions during agitation of the well-plate. Irreproducible well agitation conditions 
affect the extraction/desorption rate and thus change the amount of analyte extracted by or 
desorbed from the probe in different wells for same batch experiments. This leads to poor data 
reproducibility, and often inaccuracies in the data among batches. So for a 96-well plate where 
individual well conditions could vary from well to well, it is worthwhile to maintain same bulk 
movement of desorption solution. Thus, the overall inter- and intra-well variations for selected 
wells were investigated. This was carried out using a 100 ng/mL solution of benzodiazepines 
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in a physiological fluid (PBS) as sample. One mL of sample was placed in each selected well, 
and extraction and desorption processes were carried out from the same well positions for 5 
independent experiments. The amount extracted/desorbed from each of the selected wells was 
determined and variations among and within wells were determined from a standard calibration 
curve using a neat solution of benzodiazepines.  
The calculated inter-well variation (RSD%) for 20 selected wells (n = 20) for all 
benzodiazepines ranged from 8 – 12% with oxazepam and nordiazepam being the least and 
highest respectively. It is important to indicate that although variability from the probes may 
also contribute to the overall well variations, the reproducibility in general was very good. 
Intra-well variations were investigated by considering reproducibility of the amount extracted 
from the same well using the same set of probes for five successive experiments, while pre-
conditioning each probe in 1:1 v/v methanol-water solution prior to the experiments. The pre-
conditioning step was necessary for accurate quantitation of the amount extracted, as carryover 
effect will be negligible. The contributions to the variations obtained from the same well for 
each probe at specific well locations were each ≤ 10% RSD. This implies that any possible 
significant variations could be attributed to the differences in probe coatings and not the bulk 
sample movement within the wells. 
To investigate contributions from differences in the coatings, a single probe was 
initially placed at different well positions for five independent extractions and desorptions for 
the same concentration of benzodiazepines in PBS. The experiment was also repeated using a 
single probe for 5 extractions and desorptions from the same well. As shown in Figure 2.5, 
results obtained were not significantly different for extractions from different well positions 
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and at the same well position for all the analytes. The RSD% calculated for all benzodiazepines 
was ≤ 9% in both cases. Thus, in a typical in vivo SPME-LC-MS/MS bioanalytical application 
using the 96-well format, poor data reproducibility may be due to other factors other than the 
multi-probe desorption device.  
 
Figure 2.5 Comparison of variations obtained from same well using same fiber with same 
fiber at different well positions (n=5). The results are expressed as the mean ± standard errors 
for 5 extractions. 
2.3.3 Investigating inter-probe variations for parallel desorptions on 96-well plate 
After establishing the performance of the device on 96-well plate format during 
agitation, it was important to assess the variation associated with the use of different probes. 
This is because during in vivo SPME experiments, different probes are employed and therefore 
it will be important to establish at least the extent variability introduced. To investigate this, 
extractions and desorptions of 100 ng/mL benzodiazepines were carried out from the same 
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well using 5 different probes. The experiments were carried out in this manner so as to avoid 
any variability from the use of different wells. The RSD% for 5 independent experiments for 
each analyte was then calculated. The calculated RSD% for the benzodiazepines ranged from 
10 – 15% with oxazepam and nordiazepam having the highest and least variations respectively.  
Comparing results obtained from inter-well and inter-probe variations, reproducibility 
of the data was largely influenced by the variability in the extraction phase and not from the 
well. This implies that the handling device does not in any way significantly affect the data 
precision, reproducibility and reliability.  
 
Figure 2.6 Monitoring inter fiber variability for multiple desorptions of benzodiazepines from 
different numbers of fibers (n = 7). The results are expressed as the mean ± standard errors 
for 7 extractions. 
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2.3.4 Comparison of device with conventional in vivo SPME probe desorption method 
After careful evaluation of the device, the performance of the device was compared 
against the conventional desorption method for in vivo SPME applications. This was carried 
out to demonstrate the efficiency and advantage of the device as a tool for parallel desorption 
of multiple in vivo SPME probes in comparison with already existing method. Similar 
experiments using the optimized conditions as indicated in the previous were thus carried out 
with 50 ng/mL benzodiazepines. To facilitate good comparison, same optimized conditions 
were used for both approaches and the total analyses time in addition to the overall method 
reproducibility were determined after extraction of the drugs from PBS solution. In these 
experiments, a different set of 20 SPME probes were used. 
Table 2.2 Comparison of the performance of the multiple fiber desorption device with 
conventional SPME desorption process 
Parameter 
Multi-probe handling 
desorption device 
method 
Conventional fiber 
desorption method 
Total analysis time after 
sampling (min) 
30 min 65 min 
Reproducibility (CV%);  
n = 20 
6 – 9% 11 – 14% 
 
Table 2.2 shows an overall analysis time of 30 min for the multiple probe desorption 
device while the conventional SPME desorption approach took 65 min. Thus, providing an 
improved sample throughput with the multi-probe desorption device. In addition, lower RSD% 
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(6 – 9%) compared to the conventional SPME approach was observed. The significant 
difference in time between the two methods was due to the time taken for handling and 
preparing probes prior to desorption process. The new approach reduces human contact time 
of physically handling the probes and thus minimizes any possible contamination during 
preparation. In addition, results obtained were similar to previous work reported elsewhere165 
using the automated robotic autosamplers for parallel desorption of SPME blades on a 96-well 
plate format.  
2.4 Summary 
In this section, a multi-probe desorption device tailored for in vivo SPME applications 
using the LC-MS/MS platform for analysis has been described. The device, which fits into a 
96-well plate, offers fast alternative approach to handling, preparing and desorption of in vivo 
SPME probes after extraction process. The results outlined the advantage of using the multi-
probe device and its potential to enhance desorption process in SPME applications to 
bioanalysis, especially for in vivo analysis. From the evaluation, data recorded from all 
experiments had ≤ 15% RSD. Generally, successful in vivo SPME experiments require a lot of 
careful planning and effort to obtain meaningful and reliable, thus the need for prevention and 
protection of the probes cannot be overemphasized. The new device from the design effectively 
minimizes any possible external contamination of SPME in vivo probes during post sampling 
processes as there is no need for direct contact with the probes. Although the device was 
primarily introduced for in vivo SPME-LC-MS bioanalytical applications, it can also be 
applied effectively for batch analyses of contaminants in environmental water samples and 
biological matrices such as urine, plasma and whole blood for situations where the automated 
 60 
 
robotic systems are not available for parallel analyses on a 96-well plate format. It is important 
to indicate that no direct bioanalytical application was considered during the evaluation process 
as this may introduce its own errors and thus prevent accurate assessment of the performance 
of the device. 
With the completion of a device for handling and desorption of in vivo SPME probes 
primarily for bioanalytical applications, the thesis was further advanced into development of 
extraction phase to be applied for in vivo sampling of neurotransmitters from the rat brain for 
LC-MS/MS analysis.  
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Chapter 3  
Development of new solid phase microextraction coatings for sampling of 
polar neurotransmitters 
3.1 Preface and Introduction 
3.1.1 Preface 
This chapter of the thesis is already published online (In Press) as an article under the 
title “Optimization of Solid Phase Microextraction Coatings for Liquid Chromatography Mass 
Spectrometry Determination of Neurotransmitters” by Erasmus Cudjoe and Janusz Pawliszyn., 
J. Chromatogr. A. (http://dx.doi.org/10.1016/j.chroma.2014.03.035). All tables and figures 
were reprinted from this publication with permission from Elsevier Copyright.  
3.1.2 Introduction 
Neurotransmitters as used in this chapter of the thesis refer to small endogenous polar 
molecules or chemical substances found in the brain, which are used to communicate 
information throughout the brain and body. Information about their classification, functionality 
and involvement in various neurological diseases had been mentioned in the preceding chapter. 
DA, a monoamine, is an important neurotransmitter with changes in its function linked to, for 
example, Parkinson’s disease and schizophrenia.177 Amino acid transmitters unlike 
monoamines are the most abundant transmitters in the brain and the CNS. Their acceptance as 
neurotransmitters in the mammalian brain came much later than the monoamines probably 
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because they were involved in intermediate metabolism and constitute important building 
blocks for proteins.178 Currently, GABA and GA are putative major neurotransmitters for 
inhibitory and fast excitatory synaptic transmission respectively. Due to their large abundance 
and utilization, GA and GABA are usually involved in many functions of the CNS as well as 
associated with various neurological diseases. Many clinical conditions including psychiatric 
disorders appear to involve an imbalance in excitation and inhibition.179 Basically, abnormal 
neurotransmission has been linked to a wide range of conditions, including depression, drug 
dependence and degenerative diseases among many others. Consequently, over the years 
numerous analytical methods like MD, voltammetry, biosensors, etc., to mention a few, have 
been developed for measurements of brain neurotransmitters. Measurements of these 
compounds have undeniably improved understanding of the relationship between the 
chemistry in the CNS and the behavioral, cognitive and emotional state of an organism.180 
However, being endogenous polar compounds coupled with the dynamics of 
neurotransmission in the extracellular space, development of quantitative sample preparation 
methods is a challenge.  
Developing analytical methods for quantitation of very polar compounds is critical for 
pharmaceuticals as most of these drugs have polar characteristics. Polar compounds are also 
often intermediates of various biological processes, and thus can provide insight into some of 
the mechanisms of these processes. In addition, they form also the metabolites or end products 
of certain biological reactions. In clinical applications, there can be more than one polar 
compound that may assist in disease diagnoses or as biomarkers. Last but not least, polar 
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compounds, for example melamine181,182 and folic acid183,184 can also be used as indicators in 
food safety and nutrition. 
Microdialysis is an analytical tool used for sampling of drugs and metabolites, and 
other endogenous substances from various body fluids or the interstitial cell fluid of selected 
tissues. The technique is known for its selectivity towards polar hydrophilic compounds 
notwithstanding the challenge with very complicated calibration methods, especially for in 
vivo bioanalysis of endogenous compounds. Despite its effectiveness in sampling small polar 
substances, MD is often characterized by low recoveries at higher perfusion rate, the challenge 
handling efficiently smaller dialysate volumes when the probe is perfused at lower flow rates, 
and the potential matrix influence when coupled to ESI-LC-MS/MS technique.   
Often analysis of highly hydrophilic molecules in biological matrices is challenging 
due to low extraction recovery. For most in vitro applications, protein precipitation (PPT), 
liquid-liquid extraction (LLE) and solid phase extraction (SPE) are typically used sampling 
tools. For higher throughput, PPT has been the commonly used sample preparation method. 
Nonetheless, matrix contributions due to the large presence of extracted phospholipids and the 
competition between aqueous and organic phases may result in lower recoveries. With LLE, 
apart from not being environmentally safe due to the larger solvent volumes involved, the 
analyst is often confronted with the challenge of choosing the appropriate organic solvent for 
the extraction of the polar hydrophilic compounds. Sorptive methods like SPE have been often 
applied to the extraction of polar analytes in various matrices including in vitro bio-
applications. The primary interest in sorptive methods is due to the ability to modify the 
characteristics of the sorbent material to enhance selectivity for target compounds.185 
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Conventional polymeric sorbents can be modified to improve their hydrophilicity by 
incorporating polar substrates into their structure. Various hydrophilic sorbents with affinity 
for polar analytes have been prepared either by copolymerization of appropriate functional 
monomers or by chemically modifying the hydrophobic polymer with a polar moiety.185 The 
Oasis HLB for example; a divinylbenzene-based copolymer used in SPE method has been 
shown for its potential to extract highly polar compounds. An online SPE method coupled to 
liquid chromatography and tandem mass spectrometry (LC-MS/MS) was used for the 
extraction of antibiotics in aqueous matrix.186 Also off-line SPE-LC-MS methods have been 
developed for the analysis of herbicides187 and endocrine disrupting compounds (EDCs)188 
with the Oasis HLB sorbents. Smith et al. used commercially available sorbent (Porapak RDX) 
from Waters for the determination of polar nitroaromatic compounds in aqueous matrix.189 
Despite the vast availability for sorbents, SPE techniques are characterized with clogging of 
the cartridge complex matrices, especially biological samples. This limitation invariably 
requires additional step(s) of sample pre-treatment prior to SPE extraction, which not only 
makes the method time consuming but may also lead to loss of some chemical information 
resulting from matrix modifications. 
Another sorptive method that has gain considerable success for the analysis of polar 
hydrophilic compounds in various matrices is SPME. Unlike the column-like packing for SPE 
cartridges, where wider range of sorbents can be easily applied, SPME coatings are usually 
immobilized on a rigid support. This limits SPME applicability to sorbents having appropriate 
morphology, which allow direct deposition unto a rigid support. Despite this challenge various 
types of commercially available SPME coatings such as polydimethylsiloxane (PDMS), 
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polyacrylate (PA), polypyrrole (PPY), divinylbenzene (DVB), etc, to mention a few, and in-
house silica-based octadecyl (C18) and reverse phase amide (RPA) have been used for the 
extraction of analytes from complex matrices. For example PPY, a fiber fabricated through 
electro-deposition has been used for the determination of -blockers,190,191 phenols,192 and 
aliphatic alcohols.193 Since SPME was initially introduced for gas chromatography 
applications, analysis of polar analytes required derivatization. Derivatization can be 
performed either during or post analyte extraction for enhanced efficiency and to prevent 
destruction of thermally labile compounds in the GC injector. Online in-tube SPME-LC, 194–
196 which involved the use of the stationary phase of GC capillary columns as extraction 
material provided the platform for the analysis of thermally labile polar and apolar analytes in 
various matrices using LC for separation. This on-line method can be performed without the 
need for derivatization, provided good retention and was achieved on the LC separation 
column. Subsequently, recently developed “in-house” coating methods pioneered the 
fabrication of new SPME extraction phases for LC-MS applications to both in vitro and in vivo 
complex systems.197,198 
Another form of challenge encountered by researchers during the analyses of small 
polar organic molecules is effective retention in LC separation without the need for 
derivatization. The C8 and C18 stationary phases are the most commonly used for reverse 
phase LC and by using the appropriate solvent composition, temperature, pH, etc, separation 
has been attained for many analytes. However, chromatographers sometimes encounter 
challenging separations for which selectivity, ruggedness or reproducibility is not easily 
obtained using traditional C8 and C18 phases. Generally, conventional reverse phase 
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chromatography does not have good retention for polar compounds and thus make it unreliable 
for quantitative analysis. Thus, the use of reverse phase columns often require ion-pairing 
agents as one of the approaches to improve retention factor for polar compounds.199 
Derivatization agents like ortho-phthalaldehyde (OPA),200 naphthalene-2,3-dicarboxaldehyde 
(NDA),201 and 1-dimethylaminonaphthalenesulfonyl (DANSYL),202 to mention a few, have 
been used for the analysis of neurotransmitter molecules. Understandably, apart from being 
time consuming, derivatization introduces another analytical step to the entire procedure, 
which makes the method more susceptible to errors. The hydrophilic interaction 
chromatography (HILIC) column revolutionized separation of various polar analytes without 
the need for derivatization. HILIC since its introduction has established itself as the separation 
mode of choice for uncharged highly hydrophilic compounds that are too polar to be well 
retained in reverse phase chromatography. HILIC separation still continues to attract a lot of 
interest because it solves various hitherto difficult separation problems, such as the separation 
of small organic acids, basic drugs, and many other neutral and charged substances.27 However, 
the characteristics of the stationary phase may affect and in some cases limit the choices of 
mobile phase composition, ion strength or buffer pH value available.203 The technique often 
requires careful manipulation of the mobile phase pH and buffer salt concentration. The 
resultant effect is often signal or ion suppression depending on the analyte type when 
hyphenated to mass spectrometry. Alternatively the pentafluorophenyl (PFP) bonded to silica 
stationary phase can be used for retention of polar compounds. PFP stationary phases have 
demonstrated unique retention for small polar analytes. PFP stationary phase separate 
compounds based upon selective interactions such as steric recognition, charge transfer or by 
- interactions. By using a novel selective phase, like PFP, it is often possible to improve 
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separation and elution of difficult polar compounds in LC for easier quantitation.  The PFP 
stationary phases also offer the flexibility of using simpler mobile phases thus avoiding ion-
pairing reagents, concentrated buffer systems, strong pH conditions and complex mobile phase 
preparations. Since most of the mobile phases used with PFP stationary phase do not require 
strong buffers as observed in the case of HILIC column, enhanced MS signals with improved 
sensitivities can be observed.  
This study therefore investigates the potential of using silica- or polymer-based mixed-
mode as new sorbents for quantitative SPME-LC-MS/MS analysis of selected polar 
neurotransmitters with wide range of polarities without the need for derivatization. The 
selected neurotransmitters encompass polar organic molecules of varying polarities.  In order 
to improve extraction efficiency, coatings with higher surface to volume ratio were prepared 
using the flat blade/thin film configuration. The study compares the extraction efficiencies of 
various “in-house” mixed-mode SPME coatings for the analysis of neurotransmitters. The 
mixed mode sorbents where chosen due to their ability to offer multiple modes of interaction. 
In addition to exploring the new mixed-mode SPME coatings, this chapter demonstrates LC 
separation of polar neurotransmitters without the need for analyte derivatization or use of 
buffers. The approach offers a robust LC separation using very simple chromatographic 
solvents compatible with the mass spectrometer. Chromatographic optimization and retention 
of the polar neurotransmitters were performed using the HILIC and PFP stationary phases. The 
PFP stationary phase was finally chosen for retention and separation of both amino acid 
(glutamic acid and -aminobutyric acid) and monoamine (dopamine and serotonin) 
neurotransmitters due to higher signal-to-noise ratio.    
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3.2 Experimental section 
3.2.1 Materials and reagents 
HPLC grade acetonitrile (ACN) was purchased from EMD Chemicals Inc., Ontario. 
All mixed-mode sorbent particles were obtained through the assistance of Chromatographic 
Specialties®, Ontario as research samples. The Loctite 349 impruv™ (R. S. Hughes Company, 
Plymouth, MI) and Kasil 1®, (PQ Corporation, Valley Forge, PA) were used as adhesives. 
Medical grade stainless steel tubes used for making flat surface blades with the assistance of 
University of Waterloo science machine shop were purchased from Small Parts® Inc., Miami, 
FL.  Glutamic acid (GA), -aminobutyric acid (GABA), dopamine (DA) and serotonin (5-HT) 
were purchased from Supelco®, Oakville, Ontario. Artificial cerebrospinal fluid (aCSF) used 
for preparing samples and method development was obtained from Harvard Apparatus 
(Holliston, MA). HPLC grade formic acid was also purchased from Supelco®, Oakville, 
Ontario. Whole rat brain samples were obtained from a certified and qualified animal facility, 
NoAb BioDiscoveries, Mississauga, ON. Deionized water for preparation of standards and LC 
mobile phases were from Barnstead/Thermolyne NANO-pure water system (Dubuque, IA, 
U.S.A.) and the Thermolyne® Maxi mix plus vortexer was also from Barnstead/Thermolyne 
(Dubuque, IA, U.S.A.). The HPLC columns for chromatographic separation were obtained 
from Phenomenex (Torrance, CA). Sprague Dawley rat cerebrospinal fluid (CSF) was 
purchased from Bioreclamation, Hicksville, NY.  
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3.2.2 Preparation of standards 
The selected neurotransmitters represent polar organic compounds with wide range of 
pKa values: 2.13, 4.03, 8.9 and 9.8 for GA, GABA, DA and 5-HT respectively. Individual 
stock standard solutions (1 mg/mL) were all prepared in a final solution of 
acetonitrile/water/formic acid in amber vials and kept refrigerated for a maximum of four 
weeks until discarded. With the exception of GA, which was initially dissolved in acidified 
water (0.1% formic acid), all other standards were directly prepared in acetonitrile/water 2:3 
(v/v) mixture with 0.1% formic acid. Instrument calibration standard solutions were freshly 
prepared by serial dilution of 1 g/mL solution prepared from the stock to cover a 
concentration range of 0.006 – 200 ng/mL. All samples and working calibration standards were 
prepared in physiological fluid (aCSF) while maintaining an organic content of less than 1%.  
3.2.3 Chromatographic procedure and mass spectrometry conditions 
Three main types of LC columns (reverse phase C18, HILIC and PFP) were examined 
for their effectiveness in separating the polar neurotransmitters (GABA, GLU, DA and 5-HT) 
as reported in this chapter. Other polar-embedded alkyl phases did not yield any better results 
in providing good retention and separation of the neurotransmitters. A 25-ng/mL standard 
containing all the analytes was used for the chromatographic method optimization. As part of 
the objectives, chromatographic separation of the compounds was attained in their non-
derivatized form in order to reduce the number of analytical steps and subsequently improve 
throughput. Various mobile phase compositions appropriate for a specific column 
type/stationary phase were used to determine the efficiency in retaining and separating the 
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analytes. Initially, separate isocratic runs (reverse and normal phase method) using mobile 
phases A (95 % water, 5 % acetonitrile and 0.1 % formic acid) and B (5 % water, 95 % 
acetonitrile and 0.1 % formic acid) at 300 L/min flow rate were used for the C18 column (100 
mm x 4.6 mm x 5 m). The Accela autosampler (Thermo Scientific, USA) equipped with 
temperature controlled tray chamber was used to introduce 10 L sample for chromatographic 
separation using the Accela HPLC Pump with a dual piston pump. In addition to evaluating 
the C18 column, the PFP and HILIC columns were also assessed using acetonitrile/water 
mobile phase systems with 0.1 % formic acid and acetonitrile/ammonium formate buffer 
respectively. 
The TSQ Vantage triple quadrupole mass spectrometer (Thermo Scientific, USA) in 
a positive mode was used to identify and quantify all analytes. The source voltage was 
optimized and set at 1000 V, while the capillary and vapourizer temperatures were 250 0C 
each. Optimized sheath and auxiliary gases were respectively, 55 and 15 arbitrary units. The 
parent and daughter ions monitored for each compound were as follows: GABA (104.1; 69.1), 
GA (148.1; 84.1), DA (154.1; 91.2) and 5-HT (177.1; 115.1). All data analyses were performed 
with the Xcalibur software version 2.0.7. 
3.2.4 Preparation of SPME coatings 
Two different coating preparation methods were firstly evaluated in this project. The 
first coating method involved the use of Loctite 349 impruv™ glue as an adhesive to support 
particles unto a stainless steel metal blade. With the second coating approach, Kasil 1® was 
used as adhesive to immobilize a thin film of extraction phase on the flat stainless steel blade. 
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Prior to the coating process, the metal blades were pre-treated in concentrated nitric acid for 
about an hour to etch the surface. Subsequently, the blades were washed thoroughly with tap 
water followed by deionized water. After drying the surface of the metal for few minutes the 
metal blades were then placed into acetone in a beaker and then agitated for 30 min to remove 
any possible organic contaminants introduced during the washing process. Later, the blades 
were thoroughly dried under a gentle stream of nitrogen gas.  
Using the Loctite 349 impruv™, the first set of metal blades were dipped into the 
adhesive inside a 2 mL vial covered with a cap and a pre-cut septum. To ensure that each blade 
was exposed to the same length of adhesive inside the vial, a small piece of Teflon material 
was placed underneath the adhesive. Thus, the metal blade will be pushed through the pre-cut 
septum and into the adhesive until it touches the top of the Teflon material. The blade was then 
withdrawn from the vial with the septum ensuring that a fine layer of the adhesive was 
deposited on the surface of the metal. After covering surface of the metal with the adhesive, 
the blade was subsequently rotated several times in a pile of particles on a clean paper. The 
prepared coating was then placed under a UV lamp for an hour while rotating the blade every 
10 min. In the case of the Kasil 1™, the treated metal blade was dipped into the adhesive for 
about 15 sec followed by rotating the adhesive coated blade in the pile of particles. The 
particle-coated blade was subsequently passed over fumes of concentrated nitric acid for a few 
seconds. Later the particles were kept inside a desiccator overnight. 
Sorbents used for this study were categorized into two main groups: silica- and 
polymer-based support (Table 3.1). For the purpose of evaluation, 3 replicates of each coating 
were selected, initially evaluated and later assessed for their extraction efficiency prior to use 
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for further extractions. This was done to minimize variations between coatings. Prior to SPME 
extractions, all coatings were pre-conditioned overnight in 1:1 (v/v) methanol/water with 
agitation on at 150 rpm on a SK-300 mechanical shaker (JEIO TECH, Korea). Subsequently, 
the coatings were placed in aCSF, diluted 10x with deionized water, for less than 2 minutes to 
reduce the organic content prior to extraction. As part of the objective, the reusability of each 
coating type was also monitored to ascertain its robustness. 
Table 3.1 Types of SPE sorbents used for SPME coatings 
Sorbent Support Type of interaction 
Chromabond SA Silica strong ion exchange 
DPA-6S n/a polyamide resin 
C18 particles Silica reverse phase 
Clean screen DAU Silica reverse phase and strong ion exchange 
Clean screen GHB Silica n/a 
SSBCX Silica strong ion exchange 
C18+B Silica reverse phase with mixed-mode strong ion exchange 
C8+B Silica reverse phase with mixed-mode strong ion exchange 
MCX Polymer reverse phase with strong mixed-mode ion exchange 
MAX Polymer reverse phase with strong mixed-mode ion exchange 
WCX Polymer reverse phase with weak mixed-mode ion exchange 
WAX Polymer reverse phase with weak mixed-mode ion exchange 
 
3.2.5 SPME extraction procedure 
All extractions and desorptions were carried out in aCSF and water/acetonitrile 3:2 
(v/v) with 0.1 % formic acid respectively. An hour extraction of 50 ng/mL solution of the 
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analytes was carried out under static conditions with each sorbent type and subsequently the 
neurotransmitters were desorbed in 180 L desorption solution in a 300 L amber vial. During 
the one-hour desorption process, the blades were agitated at 800 rpm on the SK-300 
mechanical shaker. After the desorption process, the samples were further subjected to liquid 
chromatographic separation and tandem MS analysis using the conditions stipulated in the 
previous section. Details on chromatographic method are presented in the following section. 
3.2.6 Extraction of neurotransmitters from CSF and rat brain samples 
Approximately 2.0 g of brain samples were weighed into previously cleaned 20 mL 
vials and subjected to high speed vortex for about 3 – 5 min at approximately 30 sec intervals 
to avoid heating of the samples beyond laboratory room temperature. All the brain samples 
were later pooled into a laboratory petri-dish, covered and vortexed again. After this process, 
approximately 1.0 g of the macerated brain tissue sample was transferred into 3 separate vials 
and distinctly spiked at different concentration levels (50 ng/mL and 500 ng/mL) and then 6 
vials spiked at 5 ng/mL and vortexed for about 2 min. Each of the spiked samples was prepared 
in 3 replicates and extracted with the C18+B SPME blade coating for 30 min with agitation at 
750 rpm. In addition, unspiked macerated brain tissue samples were also extracted and treated 
as blank correction. After the extraction process, the SPME blades were wiped with 
Kimwipes to physically remove the deposits of brain tissue from the surface of the coatings, 
dipped into a deionized water for about 2 sec and then desorbed in 300 µL of desorption 
solution containing 5 ng/mL diazepam as an internal standard. The same set of SPME blades 
were used for all extractions at a particular concentration level. Prior to the extraction process, 
preliminary extractions from aCSF under steady state conditions revealed that all the analytes 
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reach equilibrium within 20 min. A relatively longer extraction time was chosen, despite the 
agitation, to ensure that all analytes reaches equilibrium due to the tortuosity of the brain tissue 
samples. The average area response of each analyte for the blank samples (unspiked samples) 
was subtracted from their respective responses at each concentration level. A 6-point 
calibration curve was prepared by extracting spiked samples of aCSF with neurotransmitters 
at concentrations ranging from 1 ng/mL to 200 ng/mL. A plot of the area ratio of each analyte 
to the internal standard (diazepam) versus the nominal concentration of the standard was used 
for the quantification.  
Extractions were also carried out using the rat CSF obtained from Bioreclamation. 
The sample and desorption solution volumes used in this experiment were 750 L and 150 L 
respectively. However, all CSF experiments were carried out without agitation and spiking, 
and the experiments were carried out in triplicate.  
3.3 Results and discussions 
3.3.1 Chromatographic method optimization 
A major challenge that most chromatographers encounter during separation of small 
polar compounds, in their non-derivatized form, is the ability to develop a robust bioanalytical 
method with good retention. This is because these small polar compounds, and in this case 
neurotransmitters, elute in the void volume of a conventional reverse phase separation on alkyl 
hydrophobic chains on silica. In order to improve their retention, the analytes are usually 
derivatized and in certain cases improve analytical signal when coupled to MS. The 
derivatization process not only introduces additional step(s) to the analytical process, but also 
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makes it susceptible to more analytical errors. Ion-paring agents have also been employed for 
chromatographic analysis of very polar organic compounds. However, the major limitation of 
this technique is the lack of method specificity and therefore cannot be applied to the analysis 
of group of compounds with widely different functionalities. In addition, some of the ion-
pairing agents are not compatible with MS detection systems. To avoid the difficulties and the 
laborious characteristics of a derivatization procedure and use of ion-pairing agents, in this 
thesis, a robust chromatographic separation method coupled to the MS for the analysis of the 
non-derivatized neurotransmitters with wide range of polarities has been demonstrated.  
As a proof of concept, a 300 L/min flow rate with the C18 column (150 mm × 2.1 mm 
× 3 m) did not provide any retention of the analytes for isocratic reverse phase separation 
method with an acetonitrile/water mixture spiked with 0.1 % formic acid. As shown in Figure 
3.1, the non-derivatized polar analytes were not retained on the hydrophobic reverse phase C18 
column. This was because the polar neurotransmitters did not have strong interactions with the 
relatively hydrophobic C18 stationary phase. 
Subsequently, two types (Supelco Discovery® HS F5; 100 mm x 2.1 mm x 3 m and 
Phenomenex Kinetex core shell; 100 mm x 2.1 mm x 2.6 m) of PFP stationary phase 
columns were also evaluated for their effectiveness in separating and retaining the polar 
molecules using mobile phases previously indicated. A maximum flow rate of 300 L/min in 
a reverse phase chromatographic separation was used for the Supelco Discovery HS F5. 
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Figure 3.1 Chromatograms of polar neurotransmitters eluting on a C18 column. (A) 
Unretained polar neurotransmitter peaks eluting within a minute of chromatographic runtime 
under high aqueous content. (B). GABA and GA peaks (1) eluted under a minute at the same 
retention time and DA (2) eluted at 1.7 min under high organic content mobile phase. 
The chosen flow rate resulted from the huge backpressure experienced with this column 
at higher flow rates. This resulted in a longer run time of 15 min. DA, which eluted at about 
11.5 min, had a characteristic broader peak. In order to improve the observed broad peak for 
DA at lower flow rate, the Kinetex® core shell PFP column (100 mm × 2.1 mm × 2.6 m) was 
used. This column had relatively smaller particle sizes and with the core shell technology it 
was able to accommodate higher flow rates with relatively low backpressure. The overall effect 
was narrower peak shapes with an improvement in the signal-to-noise ratio for each analyte.  
Mobile phase used for the Kinetex column consisted of A (90 % water, 5 % methanol, 
5 % acetonitrile and 0.1 % formic acid) and B (10 % water, 90 % acetonitrile and 0.1 % formic 
acid) at 450 L/min flow rate for both normal and reverse phase methods.  In the typical reverse 
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phase gradient separation mode, most of the analytes were tailing and eluted with the void 
volume as shown in Figure 3.2.  
 
Figure 3.2 Separation of underivatized polar neurotransmitters in a reverse phase 
chromatography mode using the PFP column. GABA and Glutamic acid eluted under a 
minute. 
Alternatively, the chromatographic separation was started with 100 % mobile phase B 
phase followed by gradual increase in the aqueous content. Retention and separation was 
achieved within a 5-min runtime starting with 0 % mobile phase A, held for one minute and 
then gradually increased to 100 % A by 3.5 min. Mobile phase A (100 %) was maintained for 
half a minute before re-conditioning of the column for another minute. Diazepam used as an 
internal standard for correction of any potential injection errors eluted earlier due to its 
characteristic higher hydrophobicity compared to the neurotransmitters. 
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Figure 3.3 Robust chromatographic separation of underivatized polar neurotransmitters in a 
typical normal phase chromatography without the need for buffers 
 In the case of the HILIC column, (Phenomenex Kinetex® HILIC; 50 mm × 2.1 mm × 
5 m) mobile phase A consisted of 1:1 (v/v) water and ammonium formate buffer and B 
contained 95 % acetonitrile and 5 % ammonium formate with pH adjusted to 3.5. The 
chromatographic method started with 0 % mobile phase A, held for one minute, gradually 
increased to 95 % A by 4 min and then the column was re-conditioned for the next minute. 
Although retention and separation of all the neurotransmitters was attained within the 5 min 
runtime on the HILIC column, there was about 50-fold decrease in sensitivity compared to the 
response observed with the PFP column. The reduction in sensitivity most likely resulted from 
signal suppression at the MS ion source due to the presence of the high concentration of buffer 
ions in the mobile phase, which might have affected effective ionization of the 
neurotransmitters in their non-derivatized forms.  
 79 
 
3.3.2 SPME coatings evaluation 
Evaluation of SPME coatings was based on the overall extraction efficiency for the 
analyte from aCSF solution by each coating type. The pH of the aCSF was maintained at 
physiological conditions to mimic a typical biological system. The aCSF pH was maintained 
so that the optimized method can be applied to in vivo biological systems where the 
physiological pH cannot be adjusted. With the exception of the Chromabond, Clean Screen 
sorbents, DPA-6S and C18
 particles, the rest were all mixed-mode sorbents on either a silica- 
or polymer-based support (Table 3.1). The mixed-mode sorbents were chosen because of their 
characteristic multi-interactions of hydrophobic and hydrophilic mechanisms.  All the analytes 
were typically polar with pKa ranging from 2.13 for GLU to 9.8 for 5-HT in aqueous media. 
3.3.3 Evaluation of coating procedures 
To compare the two coating procedures, the extraction efficiencies, robustness, inter- 
and intra-coating reproducibility of the selected fibers were compared. Each coating was 
prepared in triplicate and was used for 5 extractions of GA, DA and GABA from aCSF. Figure 
3.4 shows percentage of GA that was extracted by each sorbent for the two different coating 
approaches. However, of the two methods, coatings made from the Kasil 1™ adhesive extracted 
higher amount of GA. The difference in the amount extracted could be attributed to the 
difference in the particle sizes. Smaller particle sizes (≤ 10 m) were used with Kasil 1™ 
adhesive method, while larger particle sizes (30 m ≤ particle size ≤ 60 m) were used with 
the Loctite adhesive method. It is important to note that with the smaller particle sizes, a larger 
surface area of the coating would be obtained and thus improve the extraction efficiency. The 
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smaller error bars may also be due to the uniformity of the particle sizes used with the Kasil 
1 adhesive compared to the greater variation in the particle sizes used with the Loctite 349 
impruv™ adhesive. The %RSD for 3 replicates of coatings were respectively 15% and 9% for 
the Loctite 349 impruv™ and the Kasil 1™ adhesive. Subsequently, all analyses were performed 
using the Kasil 1™ adhesive coating procedure.  
 
Figure 3.4 Comparison of the efficiencies of SPME coating methods for the extraction of 
glutamic acid from artificial cerebrospinal fluid for selected sorbents (n=5). The results are 
expressed as the mean ± standard errors for 5 extractions. 
3.3.4 Evaluation of sorbent extraction efficiency 
The initial criterion used in the evaluation process involved the selection of sorbent(s) 
that is/are able to extract quantitative amounts of all four neurotransmitters, i.e., the ability of 
the developed SPME coating to extract analytes with wide range of pKa values. Thus, the 
sorbents were screened for their ability to extract all 4 neurotransmitters using spiked samples 
of aCSF containing 50 ng/mL of each analyte. Table 3.2 shows that most of the mixed-mode 
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sorbents were able to extract all 4 neurotransmitters. Chromabond SA, Clean screen GHB, 
SSBCX, DPA-6S and C18 sorbents extracted ≤ 3 analytes with DPA-6S and C18 sorbent 
extracting only glutamic acid and dopamine, respectively. This observation may be due to the 
fact that DPS-6S and the C18 do not exhibit multiple interaction modes (hydrophobic and 
hydrophilic interactions) with the analytes and therefore the observed low extraction 
efficiency. The remaining sorbents extracted quantitative amounts of all 4 neurotransmitters.  
Table 3.2 Screening of sorbents used for SPME coatings for their ability to extract  
Neurotransmitters 
 
Sorbent type Neurotransmitter 
 GA GABA DA 5HT 
Chromabond SA + + ˗ n/a 
DPA-6S + ˗ ˗ n/a 
Clean screen DAU + + + n/a 
Clean screen GHB + + + ˗ 
SSBCX + + + ˗ 
C18+B + + + + 
C8 + B + + + + 
MCX + + + + 
MAX + + + + 
WCX + + + + 
WAX + + + + 
C18 particles ˗ ˗ + n/a 
n/a: not available at the time of experiment  
(+): quantitative amount extracted  
(˗): analyte detected but cannot be quantified 
 
Subsequent to the initial sorbent screening process, the amounts extracted by each of 
the selected mixed-mode SPME coatings (C18+B; C8 + B; MCX; MAX; WCX; WAX) were 
determined and compared in a separate set of extractions. The comparison process entailed 
triplicate one hour SPME extractions of 50 ng/mL neurotransmitters in aCSF samples with 
subsequent desorption for another hour. A second desorption of the same SPME coating was 
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carried out to ascertain any carryover amounts after the initial desorption. The percent amount 
of each extracted analyte was determined for the selected coatings. Results showed that C18 
with benzenesulphonic acid group (C18+B) extracted equal amounts of GABA, DA and 5-HT 
with GA being the highest. Among the analytes, GA was extracted the most by all the sorbents 
with DA being the least extracted. With the exception of C18+B, there were no significant 
differences in the amounts of GABA and GA extracted by the MAX, C18+B and C8+B sorbents. 
MCX sorbent showed higher extraction efficiency for 5-HT however, there was no significant 
difference in the amount when compared to that of C18+B sorbent. Whereas WCX sorbent did 
not show any significant difference in its extraction efficiency for all the analytes, WAX 
showed higher extraction efficiency for GABA and GA only. Finally, in terms of base support 
(silica- or polymer-based sorbents), there were no observable patterns in the extraction 
efficiencies of the sorbents for these analytes. This implies that the extraction efficiency of the 
sorbent was not necessarily dependent on the base support. In addition, the strength of the ion 
exchange properties of the sorbents did not show any remarkable influence on the extraction 
efficiencies.  
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Figure 3.5 Comparison of the extraction efficiency of selected mixed-mode sorbents as 
SPME coatings for neurotransmitters spiked in artificial cerebrospinal fluid (n=5). The 
results are expressed as the mean ± standard errors for 5 extractions. 
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3.3.5 Extraction of neurotransmitters from CSF and rat brain samples 
Results obtained for the extraction of neurotransmitters from CSF and rat brain samples 
are shown in Table 3.3 
Table 3.3 Results obtained for the extraction of spiked rat brain tissue sample and CSF 
  Neurotransmitter (ng/mL) 
  GA GABA DA 5-HT 
Spiked brain 
samples 
50 ng/mL (n=3) 48.0 (4) 45.0 (6) 52.0 (5) 43.0 (4) 
500 ng/mL 
(n=3) 
510 (11) 493 (9) 505 (8) 496 (10) 
5 ng/mL (n=6) 
5.50 
(1.2) 
4.80 (1.0) 
5.10 
(0.7) 
4.50 
(1.0) 
      
  GA GABA DA 5-HT 
CSF Sample 
0.92 
(0.1) 
0.53 
(0.06) 
nd nd 
nd: not detected 
The precision (%RSD) for each analyte at each concentration level determined was less 
than 12%. The analytical figures of merit determined were the limit of detection and 
quantitation, and the linear range using neat solutions of standards prepared in desorption 
solution and method robustness. The RDS% obtained for 6 replicates of lowest concentration 
(5 ng/mL) spiked brain sample was used to measure method robustness. The linear range was 
determined from to be between 0.01 – 150 ng/mL for all the analytes except for GABA, which 
was from 0.1 – 100 ng/mL. The limit of detection range from 6 pg/mL to 10 pg/mL for all the 
neurotransmitters and the limit of quantitation were in the range of 20 pg/mL to 35 pg/mL.  
 85 
 
3.4 Summary  
This chapter demonstrated the use of simple solid phase microextraction method 
coupled to liquid chromatography mass spectrometry for the analysis of four neurotransmitters 
with a wide range of aties in physiological fluid. A chromatographic method was developed 
without pre-column derivatization of analytes by considering the retention capacity of various 
types of liquid chromatography columns. Among three column types investigated, the 
pentafluorophenyl core shell and hydrophilic interaction chromatographic columns showed 
significant retention of the polar compounds. A normal phase chromatography method on the 
pentafluorophenyl column was optimized to separate the neurotransmitters with wide range of 
acidities on a triple quadrupole mass spectrometer: glutamic acid (pKa 2.13), gamma 
aminobutyric acid (pKa 4.03), dopamine (pKa 8.9) and serotonin (pKa 9.8). New solid phase 
microextraction method using “in house” coatings were prepared for extraction and pre-
concentration of the analytes using Loctite 349 impruv and Kasil 1 as adhesives. The 
performance of both coating procedures was evaluated and the latter was adopted for this study. 
Coating(s) selection was based on the ability of the commercially available sorbent(s) to extract 
quantitative amount of all the analytes. Among the silica-base sorbents, reverse phase with 
mixed-mode strong ion-exchange properties proved superior for the extraction of all analytes 
within the range of polarities investigated. Clean screen DAU showed the highest efficiency, 
followed by C18 and C8 with benzenesulphonic ion exchange and SSBCX sorbents, which were 
of comparable extraction efficiencies. The polymer-based reverse phase mixed-mode sorbents 
with strong ion exchange properties also had higher extraction efficiencies compared to similar 
sorbents but with weak ion exchange properties. Generally, there were no significant 
differences in the extraction efficiencies of the silica-base mixed-mode reverse phase coatings 
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and their polymer-based counter parts. Clean screen gamma hydroxy butyric acid showed good 
affinity for compounds with lower pKa. The method limit of quantitation was 20 pg/mL. Inter-
coating variation was ≤ 15 % and repeatability was ≤ 10 %. 
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Chapter 4  
  In vivo solid phase microextraction method for monitoring endogenous 
and exogenous chemical substances in the brain of freely moving rats  
4.1 Preface and Introduction 
4.1.1 Preface 
Major portions of this chapter of the thesis is already published as an article under the 
title “Solid phase microextraction: A complementary in vivo sampling method to 
microdialysis” by Erasmus Cudjoe, Barbara Bojko, Inés Delannoy, Victor Saldivia & Janusz 
Pawliszyn. J., Angwandte Chemie. Vol. 52, 46, 12124 - 12126.  Some of the tables and figures 
were reprinted from this publication with permission from Wiley VCH.  
In this chapter of the thesis, the contributions from the author, Erasmus Cudjoe, are 
indicated as follows: 
 Author developed and optimized SPME method for in vivo extractions of 
neurotransmitters and drugs from the rat brain 
 Authored performed in vivo SPME and MD extraction experiments, which were 
carried out at NoAb BioDiscoveries® animal facility 
 With the exception of a portion of MD samples, which were analyzed for 5-HT 
and DA at NoAb BioDiscoveries®, author carried out all LC-MS/MS analysis of 
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SPME and MD samples for neurotransmitters and drugs using the HPLC and TSQ 
Vantage® instruments. Subsequently analyzed all data. 
 Author carried out LC-MS analysis of SPME and MD samples in a global 
metabolomics studies using the HPLC and (Orbitrap) Exactive® instruments. 
Subsequently participated in the statistical evaluation of metabolomics data. 
4.2 Introduction 
Effective brain tissue sampling is critical for clinical diagnosis and therapeutic 
treatment of neurological diseases. In vivo analysis of brain tissue compartments facilitates 
brain disposition studies aimed at understanding drug uptake in specific brain regions and also 
obtains evidence on the concentration of physiologically important endogenous compounds 
and their metabolites. Conventional brain tissue sampling methods, such as brain excisions, 
are labour intensive, and often result in the loss of vital chemical information.1 Often the 
approach also requires the sacrifice of a large number of animals.204 The advantages of 
continuous in vivo measurements in the same animal over time, therefore, cannot be 
overemphasized. Apart from providing a more comprehensive view of the dynamic biological 
system under study, in vivo measurements also avoid the complications associated with data 
interpretation typical of brain isolation studies and reduce variations resulting from the use of 
multiple animals. In view of this, analytical methods that offer an opportunity for in vivo 
measurements have been very much embraced for brain studies.  
Microdialysis, since its early application in the early 1970s, has continued to receive 
extensive use for in vivo analysis, especially for the analysis of neurotransmitters in the 
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brain.205 Although in vivo MD has had relatively poor temporal resolution compared to 
electrochemical methods due to lower flow rates for improved recoveries, it is still applied 
considerably for measurements of brain neurotransmitters. This may be due to that fact that 
sampling occurs over a continuum and it is possible to measure multiple neurotransmitters in 
a sample, and thus facilitates studies of potential neurotransmitter interactions.204 Coupling of 
the method to other hyphenated analytical techniques such as liquid chromatography tandem 
mass spectrometry (LC-MS/MS) has significantly improved its applications to bioanalysis. In 
vivo MD is a microextraction sampling process, which is able to extract small amounts of the 
bulk analyte at any given time via a concentration gradient created between the biological 
matrix and the MD probe. This characteristic can be critical for in vivo sampling of brain 
neurotransmitters, as the issue with local depletion of the analyte(s) at any given time during 
sampling may be avoided. MD generally has been applied extensively to animal studies of 
brain neurotransmitters206–215 and also in other forms of applications.77,216–222 Details on the 
principles underlying in vivo MD method, calibration methods and technical considerations 
have previously been discussed in Chapter 1. 
Another emerging in vivo microextraction method that has successfully been applied 
to drug bioanalysis in dogs,223,224 rats,172,225 mice and fish226–228 is SPME. SPME coupled to 
LC-MS/MS has been successfully used in various pharmacokinetic (PK) studies in conscious 
animals.225,229,230 Like MD, the SPME sampling process is driven by the concentration gradient 
of the analyte in the extraction phase and in the bulk matrix system. However, unlike MD that 
depends on the molecular weight cut-off of the pores in the dialysis membrane to screen 
analytes, the selectivity of SPME extraction is primarily dependent on the type of extraction 
phase used for the analyte enrichment process. Recent use of commercially available solid 
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phase extraction particles (mixed-mode phases) as new in vivo SPME biocompatible coatings 
has facilitated the ability to extract analytes of a wide range of chemical properties, giving 
improved compound coverage.231 This may be attributed to the multiple interactions of the 
mixed-mode particles with various analytes. Thus, by utilizing the right mixed-mode coating, 
multiple endogenous neurotransmitters in a targeted analysis may be monitored by exposing 
an SPME fiber to the brain ECF of a specific region of interest. The new biocompatible SPME 
fiber for in vivo extractions also prevents extraction of proteins and other bio-interferences 
due to the coatings small pores and subsequently minimizes matrix effect significantly. 
Thus, in vivo SPME has the potential to provide enriched chemical information for tissue 
analysis when coupled to analytical techniques such as LC-MS/MS. 
As mentioned earlier, SPME derives its selectivity from the type of extraction phase 
selected for the analysis. This allows the analyst the flexibility to skew the investigations to 
particular biologically hydrophilic/hydrophobic compounds. However, for global untargeted 
analysis of the metabolome the extraction phase must have relatively lower selectivity so as to 
extract simultaneously hydrophilic and hydrophobic endogenous compounds.  
Herein, an in vivo SPME and MD coupled to LC-MS/MS have been used to study the 
chemical components of the brain extracellular fluid in freely moving rat. Owing to their 
characteristic ability to interact with both hydrophobic and hydrophilic compounds, the mixed-
mode in vivo fibers was used. The present study aims to provide an alternative in vivo 
microextraction method capitalizing on the selectivity and sensitivity of LC-MS for a targeted 
and untargeted analysis of the brain extracellular fluid, and also in a demonstrate the ability to 
use SPME to monitor exogenous drug concentration profile in the brain. 
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 The targeted analysis focused on monitoring multiple neurotransmitters (GABA, GA, 
DA and 5-HT) with varying polarities in the rat brain ECF. Basal concentrations of these 
neurotransmitters were measured in the striatum and compared to concentrations measured 
following a single intra-peritoneal (i.p.) injection of vehicle (fluoxetine drug).  The results 
obtained for 5-HT and DA were compared to those obtained from a microdialysis probe 
implanted in the striatum in the opposite brain hemisphere, sampling concurrently.  
The untargeted chemical analysis focused using simultaneously SPME and MD for 
improved metabolites coverage. SPME and MD typically have stronger affinity for 
hydrophobic and hydrophilic chemical substances respectively. Thus, by combining these two 
methods, it is expected that compounds with wider range of polarities will be extracted and 
thus improve metabolites coverage for potential biomarker discovery. 
Finally, till date no true quantitative measurements of drugs in the brain ECF have been 
carried out using SPME. Therefore, as part of the objectives, in vivo SPME method was used 
to determine the unbound concentration of exogenous drugs (carbamazepine and cimetidine) 
in discrete regions of brain. In vivo MD was used concurrently to validate the results obtained 
by SPME.  
4.3 Experimental section 
4.3.1 Reagents and Materials 
Chromatographic solvents (Optima® grade acetonitrile, water and formic acid) were 
obtained from Fisher Scientific, (Ontario, Canada). GA, dopamine hydrogen chloride, GABA, 
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5-HT, carbamazepine (CBZ), carbamazepine-d10, and cimetidine were obtained from Supelco 
(Bellefonte, PA. U.S.A.). Stock standard solutions were all prepared in a final solution of 
acetonitrile/water/formic acid in amber vials and kept refrigerated for a maximum of two 
weeks and then discarded. Artificial cerebrospinal fluid (aCSF) was purchased from Harvard 
Apparatus, (Holliston, MA, U.S.A.). Diazepam and lorazepam standards for SPME 
experiments was obtained in the form of 1 mg/mL methanolic solution and purchased from 
Cerilliant (Round Rock, TX, U.S.A). Prototype biocompatible in vivo SPME mixed-mode 
fibers (C18 with benzenesulphonic acid group) and C18 fibers were obtained from Supelco 
(Bellefonte, PA, U.S.A.). The biocompatible fiber coating thickness was 45 µm and the length 
was 7 mm. For the targeted analysis study, the coating length was reduced to 4 mm using a 
special precision tool manufactured at the machine shop at the University of Waterloo. This 
was necessary to minimize variability in coating length. Ultra-pure deionized water was 
obtained from a Barnstead/Thermolyne NANO-pure water system (Dubuque, IA, U.S.A.). 
Guide cannulae and microdialysis probes (CMA-12; 4 mm) were obtained from CMA 
Microdialysis® (Stockholm, Sweden). 
4.3.2 Targeted Analysis 
4.3.2.1 HPLC and mass spectrometry conditions for SPME sample analysis 
HPLC and mass spectrometry analyses were performed using Thermo Scientific 
Accela and TSQ Vantage instruments, respectively. Chromatographic separation of the 
neurotransmitters (GABA, GA, DA and 5-HT) was possible using a Phenomenex® 
pentafluorophenyl (PFP) kinetex core shell column (2.6 µm, 2.1 x 150 mm) within a 5 min 
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run-time. The mobile phase flow rate was maintained at 450 µL/min using gradient elution 
program. Mobile phase A contained 90% water and 10% acetonitrile while mobile phase B 
consisted of 90% acetonitrile and 10% water. Both mobile phases contained 0.1% formic acid 
to enhance ionization in the ion source. The Accela autosampler from Thermo Scientific was 
used to introduce a 10 µL-sample into the HPLC system coupled to the TSQ Vantage triple 
quadrupole mass spectrometer. MS conditions were as follows: sheath and auxiliary gases were 
55 and 15 psi, respectively. The spray voltage was set at 1000 V, while the capillary and 
vapourizer temperatures were set at 250 0C. All ions were monitored in the positive ionization 
mode. The mass ion transitions monitored were 104.169.1, 148.184.1, 154.191.2 and 
177.1115.1 for GABA, GA, DA and 5-HT, respectively. The mass ion transition for 
diazepam used as an internal standard 285.1193.1   All data analyses were performed with 
the Xcalibur software version 2.0.7.  
4.3.2.2 HPLC-electrochemical detection conditions for microdialysis samples 
DA and 5-HT in dialysate samples were analyzed using a high-performance liquid 
chromatography method with an electrochemical detector system (EiCOM HTEC-700). DA 
and 5-HT were separated using an EiCOM PP-ODS column (4.6 x 30 mm) at 25°C with a 
mobile phase containing 0.1 M sodium phosphate buffer (pH 6.0), 500 mg/L of sodium 
decanesulfonate, 50 mg/L of EDTA disodium salt and 1% methanol at a flow rate of 0.5 
mL/min.  A graphite electrode maintained at +450 mV relative to the Ag/AgCl reference 
electrode was used for the detection.  The retention time for DA and 5-HT was 2.0 min and 5.0 
min respectively, and the total run time was 5.5 min per injection.  Calibration standards 
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ranging from 10 to 1000 pg/mL were used for quantitative determination of DA and 5-HT in 
each dialysate sample.  The calibration curve for each analyte based on peak height was 
generated using GraphPad Prism™ software and utilized for calculating the concentration of 
DA and 5-HT in dialysate sample.  
4.3.3 Non-Targeted Analysis 
4.3.3.1 HPLC and mass spectrometry conditions for in vivo sample analysis 
The Accela autosampler, HPLC system and Orbitrap mass spectrometer (Exactive) 
were obtained from Thermo Fisher Scientific and used for the analysis. A typical reverse phase 
chromatographic separation was carried out in positive mode only using a PFP (Discovery HS 
F5; 2.1 mm × 100 mm; 3 μm) from Supelco. The total run time was 40 min at a constant flow 
rate of 300 µL/min. Mobile phase A consisted of water/formic acid (99.9/0.1, v/v) and mobile 
phase B was acetonitrile/formic acid (99.9/0.1, v/v). Due to the fact that the PFP column could 
handle 100 % aqueous conditions, the initial condition of 100 % A was held for 3 min followed 
by a linear gradient to 90 % B to 25 min. An isocratic condition maintained for further 9 min 
and then finally the column was re-equilibrated for the next 6 min. The volume of sample 
injected was 10 µL. Mass spectrometer conditions: The AGC was maintained at 100000 ions 
and the injection time into the C-trap was 100 ms. Sheath gas and auxiliary gas were set at 40 
and 25 (arbitrary units) respectively. The ionization voltage, capillary voltage, tube lens 
voltage and capillary temperature were respectively 4.0 kV, 27.5 V, 100 V and 275 0C. 
Data processing was performed with the SIEVE® software version 1.2.0 (Thermo 
Scientific). A total of 20,000 features were generated with a 0.005 mass window and the 
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minimum signal intensity was set at 5,000. The first minute of the chromatographic run time 
was considered as the void volume of the column while the last 5.0 min was for re-equilibration 
purposes, and therefore were omitted in the data processing. All the 20,000 frames generated 
were manually and singly evaluated to exclude all frames that were not true chromatographic 
peaks. In addition, also peaks found at the same level in the blank samples were exempted. In 
terms of compound identification, putative identification is based on accurate mass (5 ppm 
mass window). Subsequent to the determination of the accurate mass, data was compared with 
an open access database (Human Metabolomics Database). Generally, the data generated 
(accurate masses), is compared with a list of accurate masses of various compounds and 
adducts are provided from the database with particular attention to the possible adducts that 
can form based on the LC mobile phase.  
4.3.4 Measurements of unbound drug concentrations in extracellular fluid of the rat 
brain 
4.3.4.1  HPLC and mass spectrometry conditions 
Two types of drugs (carbamazepine and cimetidine) were considered for this project. 
Chromatographic separation of carbamazepine was achieved on the Symmetry Shield reverse 
phase C18 column from Waters Corporation. Mobile phase A consists of 90% deionized water 
and 10% acetonitrile and mobile phase B had 10% deionized water with 90% acetonitrile. Both 
mobile phases contained 0.1% formic acid for enhanced ionization in the ESI ionization source. 
The chromatographic separation was attained in 5 min at a constant flow rate of 500 µL/min. 
The separation started with 100% of mobile phase A, held for 0.5 min and the gradually 
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decreased to 10%. This was maintained for another 0.5 min and then immediately increased to 
the initial conditions till 5 min. The Thermo Scientific® autosampler, HPLC system and tandem 
MS were used for the analysis. The parent/daughter ion masses monitored for lorazepam, CBZ 
and CBZ-d10 were respectively 321.0/275.1, 237.1/194.1 and 247.1/204.2. The MS conditions 
were as follows: sheath and auxiliary gases were 50 and 25 arbitrary units, respectively. The 
spray voltage was set at 2200 V, while the capillary and vapourizer temperatures were both set 
at 300 0C. All ions were monitored in the positive mode. CBZ-d10 was used as an internal 
standard whereas lorazepam was used to monitor any injections errors. 
In the case of cimetidine, the Kinetex PFP column (50 mm  2.1 mm; 2.6 m) from 
Phenomenex was used for chromatographic separation.  Mobile phase A consisted of 90 % 
aqueous and 10 % acetonitrile while mobile phase B contained 60 % acetonitrile, 30 % 
methanol and 10 % aqueous. Both mobile phases were spiked with formic acid to make a final 
concentration of 0.1 %. The chromatographic separation was attained within 5 min at a flow 
rate of 500 L/min in a gradient elution. The chromatographic separation method started with 
90 % of mobile phase A and was held constant for 1 min. Mobile phase B was gradually 
increased to 100 % by 3 min, held for 0.5 min and immediately decreased to the starting 
condition for column equilibration. The mass ion transition for cimetidine was 253.2 to 159.1 
in a positive ionization mode. The MS conditions were as follows: sheath and auxilliary gases 
were 55 and 25 arbitrary units, respectively. The spray voltage was set at 2500 V, while the 
capillary and vapourizer temperatures were 320 0C and 300 0C, respectively. Lorazepam was 
used as an internal standard. 
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Figure 4.1 Chemical structures of lorazepam, carbamazepine and cimetidine 
4.3.5 Sampling Procedure 
4.3.5.1 In vivo brain sampling for targeted and non-targeted analysis of endogenous 
chemical substances 
In these experiments MD and SPME were used to sample the brain tissue 
simultaneously. Their respective probes were placed in the opposing striatum of the two 
hemispheres of the brain. Male Sprague Dawley rats (Charles River Labs, St. Constant, QC) 
weighing 250 – 300 g were used. The rats were kept in the vivarium at a certified and qualified 
animal facility, NoAb BioDiscoveries, maintained on a 12 h light-dark cycle with free access 
to food and water, and allowed to acclimatize for at least 5 days prior to surgery. Two guide 
cannulae were surgically implanted into the striatum (co-ordinates were AP (0.20 mm), DL (± 
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2.8 mm) and DV (-3.6 mm)) of the left and right hemispheres of the brain at least 2 days prior 
to the in vivo experiments. 
4.3.5.2 In vivo microdialysis sampling from the striatum of rat brain 
A 4 mm microdialysis probe with a molecular weight cut-off of 6 kDa was inserted 
into one hemisphere of the rat brain a day prior to the experiment. Immediately the probe was 
perfused overnight at a flow rate of 0.2 µL/min with aCSF, which was supplemented with 
freshly prepared 250 µM ascorbic acid.  At least 1.5 hours prior to sampling, the flow rate was 
adjusted to 1 µL/min and the system was allowed to equilibrate. The rats were kept in a Raturn 
(BASi®), an automated sampling system where they were allowed to freely move throughout 
the study having access to food and water, except for SPME sampling times points when the 
probes were inserted and replaced. After the MD system has equilibrated, the dialysate was 
collected at 30 min intervals for a 3-hour period to determine baseline concentrations 5-HT 
and DA. Subsequently, a single dose of 10 mg/kg fluoxetine, which was prepared by dissolving 
fluoxetine in saline with the pH adjusted to 3.5 using 0.1 N HCl or a vehicle control was 
administered i.p. Dialysate samples were collected at 30 min intervals over another 3-hour 
period. In order to prevent any possible degradation of the neurotransmitters through oxidation 
reactions, samples were collected into vials already containing a 30-µL solution of 20 mM 
phosphate buffer (pH 3.5) and 25 mM disodium ethylenediamminetetraacetic acid (EDTA-
Na). The MD samples were divided into two portions and a portion was analyzed by liquid 
chromatography coupled with electrochemical detection for 5-HT and DA at NoAb 
BioDiscoveries Inc. The second portion of the MD samples was analyzed at the University 
of Waterloo for GA and GABA. MD samples transported to the university laboratory were 
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each diluted 6-fold using the desorption solution. Samples were vortexed for about 30 sec and 
then later analyzed by LC-MS/MS. 
4.3.5.3 In vivo solid phase microextraction from the striatum of rat brain 
With respect to the in vivo SPME sampling experiments, mixed-mode particles 
immobilized on a stainless steel fine wire by means of a biocompatible adhesive material was 
used as the extraction phase. The extraction phase (4 mm) was selected after initial thorough 
assessment of its applicability to measuring multiple neurotransmitters. The SPME probes 
were designed such that after insertion, only the extraction phase/coating was exposed at the 
end of the guide cannula similar to the MD probe. The same sampling time was used for both 
MD and SPME, except that a new probe was inserted into the opposing hemisphere at the 
beginning of each 30 min sampling. During the insertion and removal of each SPME probe, 
the rat was physically restricted from moving. After the extraction, the probe was removed 
from the brain, wiped clean with a tissue, briefly (~ 2 sec) exposed to deionized water and 
immediately placed inside an insert containing 60 µL desorption solution (3:2 water-
acetonitrile mixture with 0.1 % formic acid) at an approximate pH of 3.5. Each insert was 
stored in a 2 mL amber vial, capped and immediately placed on dry ice inside a cooler until 
further LC-MS/MS analysis. All samples were transported to the laboratory and the in vivo 
probes were later desorbed for 60 min on a vortexer at 750 rpm. After the desorption process, 
the extracted samples were analyzed for 5-HT, DA, GA and GABA. 
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4.3.5.3.1 In vivo brain sampling for non-targeted analysis of endogenous compounds 
For the non-targeted (global) analysis, all the in vivo MD and SPME samples were 
diluted a 100-fold in 3:2 deionized water/acetonitrile with 0.1% formic acid and then vortexed 
for about a minute. A quality control sample was generated for SPME and MD respectively by 
taking 30 µL of each individual fraction of all the in vivo samples collected. In this analysis, 
desorption solution transferred into 300 µL inserts was used as blank samples. Figure 4.2 
shows a typical in vivo sampling of the rat brain using both MD and SPME probes. 
 
Figure 4.2 Simultaneous in vivo sampling of the left and right brain extracellular fluids of a 
Sprague Dawley rat using SPME and MD. The in vivo biocompatible SPME probe is to the 
right in the picture without any connecting tubes whereas MD tube is to the left showing 
connecting tubes to an external pumping device delivering constant flow perfusate. 
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4.3.5.4 Extraction of unbound exogenous drugs from the rat brain 
Two CMA-12 guide cannulae were surgically implanted into the right and left striatum 
and frontal cortex of the rat brain hemisphere (coordinates: 0.2 mm anteroposterior, ±3.0 mm 
lateral and 1.0 mm dorsoventral relative to the bregma) respectively. The femoral vein and 
artery were catheterized. The rats were allowed to recover for at least two days after surgery. 
A day prior to the study, a microdialysis probe (2 mm) was placed into the frontal cortex and 
perfused with aCSF at 0.2l/min overnight. The flow rate of the perfusate was later adjusted 
to 0.5 l/min and allowed to equilibrate for at least an hour. The rat was then given an i.v. bolus 
(1.5 mg/kg for Carbamazepine or 13 mg/kg for Cimetidine) and subsequently an i.v. infusion 
(1 mg/kg/hr for Carbamazepine or 24 mg/kg/hr Cimetidine) for 5.5 hr (steady state). The i.v. 
infusion was later discontinued (dynamic state) and samples were collected for another 1.5 
hours. Blood samples (150 µL) were withdrawn from the femoral artery cannula also collected 
at 30 min. The collected blood samples were centrifuged immediately and the resultant plasma 
was stored in the freezer at -80 °C. All the samples were stored at -80 °C until being assayed. 
MD dialysates were collected every 30 min in both steady and dynamic states. For the plasma 
samples, 15 L of the plasma samples were carefully pipetted in a small centrifuge tube. 
Approximately, 85 L of acetonitrile were added, centrifuged for 5 min and then finally 5 L 
of the supernatant was pipetted and 55 L of the desorption solution (80 % acetonitrile and 20 
% deionized water containing 10 ng/mL lorazepam) was added. In the case of MD, 5 L of the 
dialysate were pipetted and later diluted 10x with the desorption solution. 
In the case of SPME sampling, the extraction phase was prepared from C18 particles 
and was obtained from Supelco®. The length of the extraction phase was 7 mm. However, this 
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was later modified by carefully removing the middle portion (3 mm) of the extraction phase to 
obtain a segmented fiber. The final length of each segmented coating was 2 mm. In vivo SPME 
sampling was carried out by strategically inserting the probes in the frontal cortex and striatum 
of the rat brain. Each probe was exposed to the brain tissue for 10 min, carefully removed, 
wiped with Kimwipe® and then placed in a 100 L desorption solution (80 % acetonitrile and 
20 % deionized water containing 10 ng/mL lorazepam).  A new SPME probe was introduced 
at 30 min interval into the brain few minutes prior to the collection of the MD dialysates.  
4.3.6 SPME Calibration Procedure 
4.3.6.1 Calibration procedure for targeted endogenous compounds 
Working stock solutions were prepared in the desorption solution in 2 mL amber vials 
and kept refrigerated for a maximum of two weeks. Calibration standards for the instrument 
were freshly prepared by serial dilution of the 1 g/mL stock solution to cover a concentration 
range of 0.006 – 200 ng/mL.  
For the neurotransmitters, external calibration standards were prepared by extracting 
known concentrations (0.01 – 200 ng/mL) of the analytes spiked in aCSF while maintaining 
the total amount of organic content in each standard to be ≤ 0.5 %. Each calibration standard 
in aCSF was prepared in triplicate and extraction was carried out under static conditions to 
mimic as closely as possible the in vivo sampling procedure. A 1.8 mL volume of each 
calibration standard was extracted for 30 min in 2 mL amber vials and the analytes were later 
desorbed from the fibers in 60 L desorption solution for 1 hour at 250 rpm. Calibration curves 
of the amount extracted versus nominal concentration were used to quantify each analyte. 
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Thus, an external equilibrium method was used for quantitative analysis of the 
neurotransmitters. 
However, for quantitative analysis of CBZ and cimetidine, a pre-equilibrium kinetic 
calibration method was used. The fiber was pre-loaded with a known concentration of the 
deuterated analogue before the sampling commenced. Therefore, during sampling the 
deuterated desorbed while the analytes are extracted simultaneously from the brain 
extracellular fluid. 
Prior to in vivo sampling, in vitro experiments utilizing spiked aCSF solutions were 
performed to pre-screen the fibers by comparing and grouping those with similar extraction 
efficiencies for DA and 5-HT. 
4.3.6.2 Developing an in vitro SPME external calibration method  
Two of the most commonly used SPME calibration methods are pre-equilibrium on-
fiber kinetic and external equilibrium calibration methods. Briefly, pre-equilibrium calibration 
requires a calibrant for the analyte to be previously loaded onto the fiber. By means of a 
concentration gradient, the calibrant will be simultaneously desorbed from the coating into the 
matrix during extraction process while the opposite process occurs for the analyte. Details of 
calibration method have been mentioned in previous chapter. The major concern for the pre-
equilibrium calibration method is that smaller amounts of the analyte will be extracted and 
therefore further detection can be very challenging depending on the type of coating and 
analyte used. The technique, however, has been applied successfully for other studies 
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elsewhere.227 To improve sensitivity and detection, the external equilibrium calibration method 
was used.  
For the external equilibrium calibration method, the initial concentration of each 
analyte is directly related to the amount extracted at equilibrium. Equation 4.1 shows the 
relationship between the original concentration (C0) of the analyte that will be in the brain 
ECF, volume of extracellular fluid (Vs), fiber constant (fc) and amount extracted at equilibrium 
(ne) of the extracted analyte. 
𝐶0 = (
𝑉𝑠 + 𝑓𝑐
𝑉𝑠𝑓𝑐
) 𝑛𝑒                                                (4.1)   
Under conditions of negligible depletion of the analytes from the matrix, in which case 
the fiber constant is far lower than the volume of brain ECF, the equation can be simplified as 
follows:  
𝐶0 = 𝑓𝑐𝑛𝑒                                                               (4.2)   
From equation 4.2, the amount extracted at equilibrium (ne) will be directly dependent 
on the original concentration of the analyte within the brain ECF. By using the appropriate 
matrix for external calibration standards the original concentration can be easily determined 
from the slope of the regression line, which will be equal to the fiber constant. In this study, 
all calibration standards were generated by extracting, under static conditions, known 
concentrations of the neurotransmitters spiked in aCSF.  
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Prior to obtaining the calibration standards, the effect of tortuosity of the brain tissue 
on the diffusive property of each analyte was investigated using an aCSF-agar gel matrix. This 
is because the diffusion-based extraction process conforms to Fick’s diffusion law and, 
therefore, the path length for diffusion of the analytes in the brain tissue to the coating may 
significantly influence the equilibrium time as a result of the tortuosity, among other factors. 
Subsequently, the equilibration time for each analyte in aCSF under static conditions with 1% 
aCSF-agar gel matrices was determined and compared. Results obtained from the extractions 
show that the equilibrium times where similar and ≤ 20 min for all of the analytes in both 
matrices.  
The mathematical representation of the extraction process is controlled by Equation 
4.3: 
𝑛
𝑛𝑒
= 1 − 𝑒−𝑎𝑡                                                         (4.3)   
where n is the amount of neurotransmitter extracted by the coating at a specific time t 
and a is the time constant, which is a measure of the rate of diffusion of the analyte in the 
coating. Therefore, similar time constants for each analyte in the brain tissue, aCSF and 1 % 
aCSF-agar gel matrices, implies that the extraction rate will not be significantly influenced by 
the tortuosity of the brain tissue. To determine the time constant, 100 ng/mL samples were 
separately prepared in aCSF and 1 % aCSF-agar gel and the analytes were extracted for 10 min 
from 3 replicate samples without agitation (static condition) under controlled temperatures (35 
– 37 0C). In order to avoid any possible inter-fiber variability a single fiber was used for each 
replicate, while ensuring that the fiber was appropriately pre-conditioned in a 1:1 (v/v) 
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methanol-water solution and then in water, before each extraction. Although, the current 
approach does not take into consideration the influence of other matrix components such as 
analyte re-uptake in a living system, it is a very good alternative approach to measurements of 
neurotransmitters in the brain. 
4.3.6.3 Developing an in vitro SPME pre-equilibrium on-fiber kinetic calibration method 
As previously indicated, a pre-equilibrium on-fiber calibration method was used for 
quantitation of the exogenous drugs in the brain ECF. Prior to the in vivo sampling, kinetics of 
the diffusion of the drugs in an agar gel was determined as shown in Figure 4.3 3 replicate 
extractions. The experiment was carried out at about 37 0C on a hotplate. From the extraction 
profile, even at 180 min CBZ has not reached equilibrium yet, as a result the pre-equilibrium 
approach was adopted. The 10 min extraction time was chosen because quantitative amounts 
of the analyte could be extracted and analyzed by LC-MS/MS. 
Thus, each SPME fiber was pre-loaded with CBZ-d10 from a spiked solution of aCSF 
containing 100 ng/mL of the deuterated analogue. An overnight extraction with agitation was 
carried out on a mechanical shaker set at 250 rpm. 
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Figure 4.3 Extraction time profile for carbamazepine in a 1 % aCSF gel matrix (n=3). The 
results are expressed as the mean ± standard errors for 3 rats. 
4.3.7 Results and Discussions 
4.3.7.1 Quantitative measurements of targeted endogenous compounds 
4.3.7.1.1 In vitro external equilibrium SPME method for targeted analysis 
An external equilibrium calibration method requires that the in vitro conditions 
replicate to a greater extent the in vivo conditions within the living system. To this effect, the 
equilibrium times of each analyte in aCSF and 1 % aCSF-gel mixture were determined. Both 
experiments were carried out on a hotplate at a preset temperature (37 0C) and the extractions 
from aCSF were carried out under static conditions. The observed equilibration times for the 
analytes in both systems were similar (≤ 20 min). This indicated that the kinetics of diffusion 
under both conditions was similar and thus the volume of brain ECF may not a rate limiting 
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step for the amount of analytes extracted. In order to ascertain the above observation, the time 
constant or rate constant (a), as shown in Equation 4.3 was determined for each of the analyte 
in both systems. Separate 10 min extractions in triplicates were carried out using spiked 
samples of aCSF only and aCSF-gel mixtures containing 100 ng/mL of each analyte. Results 
are shown in Table 4.1.  
Table 4.1 Extraction rate constant of selected neurotransmitters in aCSF and aCSF-gel 
mixture 
Compounds 
Time constant (a) 
min-1 
Standard error 
(n=3) 
 aCSF aCSF-gel aCSF aCSF-gel 
Serotonin 0.0014 0.0012 0.0003 0.0004 
Dopamine 0.0011 0.0099 0.0002 0.0003 
Glutamic acid 0.0021 0.0018 0.0002 0.0004 
-amino butyric acid 0.0009 0.0085 0.0003 0.0004 
 
The calculated time constants for each analyte from the aCSF and the aCSF-gel matrix 
were not statistically different. In this regard, it would be logical to conclude that the rate-
limiting step of the absorption process will not be dependent on the tortuosity of the brain 
tissue in the absence of all other matrix influence. Rather the amount of analyte extracted onto 
the fiber will be dependent on the analyte’s concentration in the brain ECF within the 
immediate vicinity of the fiber. This implies that calibration standards obtained from aCSF in 
a static mode could be used for quantitative measurements of the concentration of 
neurotransmitters in the brain ECF. It is worthwhile mentioning that possible matrix 
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interactions with the analytes within the brain ECF were not accounted for in the in vitro gel 
experiments.  
4.3.7.1.2 Effect of matrix on the amount extracted 
The influence of the matrix on the analytical method is very critical to obtaining reliable 
results when quantifying target analytes in complex biological matrices. Most analytical 
methods thus use internal standardization or a standard addition method to compensate for the 
effect of the matrix for quantification. For in vivo SPME involving analysis of exogenous 
molecules, using an appropriate internal standard, such as a deuterated analogue of the analyte, 
pre-loaded onto the fiber often compensates for the effect of the matrix. However, the use of 
an internal standard is not always possible for measuring endogenous compounds due to the 
non-availability of an appropriate deuterated analog or due to the significant expense. An 
alternative external approach would be to evaluate the effect of the matrix on the amount 
extracted using the same sample matrix, if possible. This would make it possible to determine 
the relative recovery in order to compensate for the influence of the matrix on analyte 
extraction. In this study, no internal standard was used for quantitation of neurotransmitters in 
the brain ECF. Therefore, the effect of the matrix was evaluated using homogenized brains, 
obtained from naive rats.  
Five replicate extractions of the analytes from brain homogenate samples were 
performed using the optimized SPME method conditions determined above and then the 
analytes were subsequently desorbed from the fibers for LC-MS/MS analysis. Similar 
experiments were performed with blank solutions of aCSF. Both desorption solutions from the 
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brain tissue homogenate and aCSF extracts were later spiked with 50 ng/mL 5-HT and the 
samples were analyzed by LC-MS/MS. The peak area ratio (analyte/diazepam) obtained for 
each extract was compared to that obtained from a 50 ng/mL neat standard solution. By this 
approach, it is possible to ascertain the effect of the matrix and fiber coating on the recovery 
of the analytes.  
The area ratio obtained for all brain homogenates and aCSF extracts were comparable 
as there were no statistically significant differences in the percent relative standard deviation 
(RSD %), which ranged from 4 - 12 % for 5 replicate extractions (Figure 4.4). 
 
Figure 4.4 Evaluation of the effect of brain tissue matrix on the SPME extraction method 
(n=5 replicate determinations.). The results are expressed as the mean ± standard errors for 5 
rats. 
Since the analytes are endogenous and, therefore, it is impossible to obtain blank brain 
tissue samples, the basal concentration of the serotonin already present will contribute to the 
0.00
0.50
1.00
1.50
brain extract aCSF extract neat solution
P
ea
k 
ar
ea
 r
at
io
Matrix Component
 111 
 
analytical signal determined for the brain tissue sample. However, the concentrations of 5-HT 
typically found present in the homogenized rat brain were very low (pg/mL), therefore, the 
latter contribution to the overall analytical signal compared to the 50 ng/mL 5-HT added were 
negligible. 
4.3.7.1.3 In vivo monitoring of dopamine and serotonin by SPME and MD 
To facilitate the comparison of data obtained by SPME and MD, the concentrations of 
the neurotransmitters following fluoxetine or vehicle control administration were expressed as 
percentages of the average basal (pre-dose) concentration in the brain ECF. This was, in part, 
necessary as the dialysate samples were analyzed at NoAb BioDiscoveries, whereas the SPME 
samples were analyzed at the University of Waterloo. 
4.3.7.1.4 Monitoring serotonin and dopamine in both brain hemispheres 
Concentrations of 5-HT and DA were measured over a 2 hour period to determine the 
mean basal concentrations. Subsequently, a single i.p. injection of vehicle control or 10 mg/kg 
fluoxetine was administered and the neurotransmitter concentrations were measured over 4 
hours by MD and SPME. 
The average results, as shown in Figure 4.5, indicate a sustained increase in the 
concentration of 5-HT, which may be attributed to the inhibition of the serotonin re-uptake 
transporter in both brain hemispheres over the 4-hour period post-fluoxetine administration. 
The increase in the concentration of 5-HT was consistent with results obtained in the 
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literature,232 which demonstrate that systemic administration of fluoxetine elevates 
extracellular 5-HT concentrations significantly by selectively inhibiting its re-uptake. 
 
Figure 4.5 Percent changes in serotonin concentrations (relative to the mean basal 
concentration) in the rat brain extracellular fluid determined by SPME and microdialysis 
(MD) methods following an i.p. injection of fluoxetine (10 mg/kg) at time t = 0. The results 
are expressed as the mean ± standard errors for 12 rats. 
Both SPME and MD exhibited similar increases in 5-HT concentrations following 
fluoxetine administration. Statistical analysis (paired t-test at 95% CI assuming unequal 
variance) of data obtained by both methods, showed no significant difference in the data for 
the average of each time point. The concentrations of 5-HT determined by SPME appeared to 
be less variable than those measured by MD. The increase in 5-HT corroborates results 
obtained in a fluoxetine-induced studies reported elsewhere in literature.24 
As expected, DA concentrations (Figure 4.6) did not exhibit any significant changes in 
the ECF after a single i.p. injection of fluoxetine, when determined by MD and the SPME 
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methods. These results confirm that fluoxetine inhibits the re-uptake of 5-HT and not of DA. 
In addition, the effectiveness of SPME as a method for the in vivo monitoring of 
neurotransmitters is demonstrated relative to that of MD.  
 
Figure 4.6 Percent changes in dopamine concentrations (relative to the mean basal 
concentration) in the rat brain extracellular fluid determined by SPME and microdialysis 
(MD) methods following an i.p. injection of fluoxetine (10 mg/kg) at time t = 0. The results 
are expressed as the mean ± standard errors for 12 rats. 
Results obtained for monitoring 5-HT and DA in the ECF of the rat brain for the various 
sets of experiments are presented in Figure 4.7. With the exception of Figure 4.7 (a), which 
showed relatively higher concentrations of 5-HT after the administration of fluoxetine drug, 
results obtained for the other plots showed very similar concentration patterns for both DA and 
5-HT. However, a paired t-test analysis of the results by MD and SPME revealed that there 
were no significant differences for the mean concentrations of 5-HT at any particular time 
point as recorded by both methods.   
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Figure 4.7 Results for in vivo SPME and MD study of the effect of single dose fluoxetine on 
selected neurotransmitters. Changes in serotonin (a - c) and dopamine (d - e) concentrations 
(relative to the mean basal concentration) in the rat brain extracellular fluid determined by 
SPME and MD methods following an i.p. injection of fluoxetine (10 mg/kg) at time t = 0. 
The results are expressed as the mean ± standard error for 3 rats (Figure 4.7a – f). 
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As depicted in Figure 4.8, a sharp increase (~ 4x increase relative to % basal) in the 
concentration of 5-HT in rat SPME-R04 as recorded by SPME compared to MD, which 
showed a gradual increasing response. This observation was attributed to a severe pain inflicted 
on the tail of the animal at the 30 min point sampling. Evidence of monoamine 
neurotransmitters, serotonin and norepinephrine, associated with pain has been reported 
elsewhere in literature.233,234 This observation supports the notion that SPME is able to capture 
rapid changes in analyte concentration that can occur within the brain extracellular fluid. 
Similar observation was reported elsewhere by using SPME coating coupled to LC tandem 
mass spectrometry to capture elusive metabolites in metabolomics studies.116 Microdialysis on 
the other showed a gradual increase in 5-HT with time. The relative gradual increase in 5-HT 
may be due to the slower response time of MD, which may be due to interference from 
hydrophobic components that often bind to the surface of the MD probe; a phenomenon of MD 
known to slow down diffusion of analytes through the membrane into the dialysate. It is 
important however to note that the sharp increase in 5-HT observed with SPME data 
phenomenon was not be fully substantiated due to the lack of adequate data to support the 
phenomenon irrespective of its corroboration with other reported cases in literature. In this 
regard, the result was treated as an outlier and was not used in determination of the average 
concentration of each analyte. 
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Figure 4.8 Effective and rapid response of SPME probe to capture sudden changes in 
concentration of 5-HT in rat R04 while MD showed an overall gradual increase in 
concentration 
4.3.7.1.5 Control Experiments 
In view of the fact that SPME method involved introduction of a new fiber at each 
sampling time point, possible tissue damage that may result from the multiple physical 
insertions and withdrawals of the fiber on the brain ECF on neurotransmissions was of primary 
concern. In addition, this experiment will confirm the fact that any change in the basal 
concentrations of the neurotransmitters was due to the fluoxetine drug and not from the 
mechanical insertions of the SPME fiber. Control experiments were therefore performed using 
2 rats administering only the dosing vehicle. Figure 4.9 shows results obtained from control 
experiments carried out using SPME and MD.  
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Figure 4.9 Comparison of SPME and MD methods for monitoring changes in serotonin (5-
HT) concentration in the rat brain extracellular fluid following administration of the dosing 
vehicle for fluoxetine. 
The data in Figure 4.9 indicate that relative to the single insertion of a MD probe and 
multiple insertions of the SPME fibers via a guide cannula into the same location in the brain 
do not have any effect on the concentrations of 5-HT and DA in the ECF space over the 4 hour 
sampling period. Therefore, the previously recorded increase in 5-HT was very likely caused 
by the fluoxetine drug.  
4.3.7.1.6 Monitoring GABA and Glutamic acid by SPME 
A major challenge associated with monitoring of neurotransmitters is the use of a single 
sample to measure analytes of varying physicochemical properties. Although MD facilitates 
the detection of multiple analytes and thus could be used to study interactions between 
neurotransmitters, the approach is often faced with critical methodological challenges. A 
notable disadvantage of MD is the low recovery for some analytes, which often poses serious 
challenge to the sensitivity of the analytical method.  Apart from being time consuming and 
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often tedious due to the difficulty in the handling of very small dialysate volumes, issues with 
matrix influence due to the presence of salts in the dialysate tend to affect the general 
effectiveness of the method when coupled to LC-MS/MS. On the other hand, SPME is an 
analyte enrichment sample preparation method with its selectivity primarily dependent on the 
type of coating employed. This part of the study seeks to demonstrate the use of a single mixed-
mode SPME fiber to extract multiple neurotransmitters, including GABA and glutamic acid 
in, addition to 5-HT and DA, in a single sample.  
As depicted in Figure 4.10, the single dose injection of the fluoxetine drug did not 
significantly change the basal concentrations of GABA and GA in the brain ECF. 
 
Figure 4.10 Percent changes in GABA and GA concentrations (relative to the mean basal 
concentration) in the rat brain extracellular fluid determined by SPME method following an 
i.p. injection of fluoxetine (10 mg/kg) at time t = 0. The results are expressed as the mean ± 
standard errors for 9 rats. 
0
40
80
120
160
200
-150 -100 -50 0 50 100 150 200 250
G
A
B
A
 a
n
d
 G
L
U
 (
%
 o
f 
B
as
al
)
Time (mini)
GABA
GLU
 119 
 
4.3.7.2 Non-targeted chemical profiling of the striatum of rat brain 
As a result of their respective tendencies to extract hydrophilic and hydrophobic 
compounds, a combination of MD and SPME methodologies in global non-targeted 
metabolomics studies will significantly enhance the chance to identify any disease biomarkers. 
Subsequently, all MD and SPME samples were analyzed in a positive mode only on an LC-
MS analysis platform. 
This was in agreement with the results obtained by Wibom et al.235 and Hrydziuszko et 
al.236 who used MD for a metabolomics study in Glioblastoma and liver transplants, 
respectively. However, the SPME data was biased generally to less polar/hydrophobic 
compounds. Some of the metabolites detected by SPME included arachdonyl carnitine, 
gangliosides, fatty acids and lysophospholipids including lysophosphatidic acid and 
lysophosphatidylethanolamine, etc. Carnitines have been reported for multifactorial functions 
in brain metabolism. Their neuroprotective, neurotropic and neuromodulatory properties have 
various medical implications.237 For example, a malfunction of biochemical pathways 
involving carnitines was found in Alzheimer’s, Parkinson’s, Huntington’s disease and 
attention deficit hyperactivity disorder (ADHD), as well as other neuropathies.237 Thus, 
detection of these compounds also expresses the suitability of in vivo SPME for reliable 
analysis of brain lipids, especially when current in vitro methods such as brain tissue slicing, 
homogenization and extraction with organic solvents could be very challenging and 
laborious.238 A lipid mediator, lysophosphatidic acid, involved in brain development was 
recently also cited as been likely involved in changing blood-brain barrier permeability.239 The 
fatty acids and polyunsaturated fatty acids (PUFA) are main components of cellular membrane 
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and precursors for eicosanoid biosynthesis. Recently, reports have linked neurodegenerative 
diseases to changes in the profile of the PUFA membrane with subsequent change in fluidity. 
Additionally, modifications of arachidonic acid, eicosapentaenoic (EPA) and docosahexaenoic 
acid (DHA) could affect intra- and extra-cellular signal transduction.238,240 Lastly but not least, 
impaired metabolism of gangliosides may result in pathological states.241,242 These results thus 
create the opportunity to extend in vivo SPME to lipidomics studies and other clinical 
applications. 
Table 4.2 Tentatively identified endogenous compounds present in SPME extract but 
absent in dialysate after sampling of the striatum of live Sprague Dawley rats 
Name# m/z LogP 
Triglyceride 529.41022 9.34 
Arachidonyl carnitine 546.43671 3.47 
Ganglioside NeuAcalpha-2-3-Galbeta-Cer 
(d18:1/24:1(15Z)) 
551.39227 9.77 
Glycerophosphocholines 530.41370 n/a 
Ganglioside GD3 (d18:0/23:0) 530.41370 2.99 
Lysophosphatidyl ethanolamine (LysoPE (0:0/18:1(11Z)) 
or (0:0/18:1(9Z)) or (18:1(11Z)/0:0) or (18:1(9Z)/0:0)) 
480.30848 4.64 
Lysophosphatidic acid LPA(0:0/18:0) or LPA(18:0/0:0) 480.30848 4.91 
Triglyceride 311.29465 10.71 
Fatty acids/Fatty Acyls 329.30530 n/a 
diglyceride DG(15:0/14:1(9Z)/0:0) or 
DG(14:1(9Z)/15:0/0:0) 
547.44000 9.25 
18Z,21Z,24Z,27Z,30Z,33Z-hexatriacontahexaenoic acid 547.44000 10.57 
1,2-ditetradecyl-sn-glycero-3-phosphate 547.44000 n/a 
trans-retinyl linolate 547.44000 10.80 
# identification based on the comparison of the experimental data against Human metabolome 
database 
(Originally published in and printed with permission from Angewandte Chemie) 
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Table 4.3 Provisionally identified endogenous compounds present in dialysate samples but 
not in SPME extracts after sampling of the striatum of live Sprague Dawley rats 
Name# m/z LogP 
Dihydrouracil 132.07671 -1.28 
Creatine 132.07671 -1.59 
β-Guanidinopropionic acid (β-GPA) 132.07671 -1.7 
Glutamyl valine 132.07671 -2.49 
Valyl glutamate 132.07671 -2.6 
Norsalsolinol 166.08627 -0.13 
D-Aspartic acid 178.00870 -3.52 
Iminodiacetic acid (IDA) 178.00870 -2.5 
# identification based on the comparison of the experimental data against Human metabolome and 
Metlin databases 
(Originally published in and printed with permission from Angewandte Chemie)  
 
In addition to the above, principal component analysis of the data, clearly distinguished 
components obtained by in vivo MD from SPME. Figure 4.11 demonstrates that the results 
obtained by SPME complement the MD data and vice versa and thus supports the hypothesis 
that a combination of the two sampling methods will enhance the discovery of potential 
biomarkers with the larger metabolite coverage. 
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Figure 4.11 A principal component analysis (PCA) of data showed the complementary 
aspects of MD and SPME data in a global non-targeted chemical profiling of the brain 
extracellular fluid; (a) A 3-D PCA plot of data without any outliers (b) A 3-D PCA plot of 
data with outliers 
4.3.7.3 Quantitation of exogenous unbound drugs concentrations in brain extracellular 
fluid 
A typical characteristic of both MD and SPME methodologies is that they both measure 
the free/unbound concentration of the drug, which is pharmacologically active concentration, 
in the living system. For this reason, it is easier to compare data obtained from both methods. 
Carbamazepine is generally an anticonvulsant, which is used for the treatment of 
epileptic seizures and other types of neurological disorders.243 Although, there are various PK 
studies of the drug and its main metabolite in the rat brain, for the first time SPME is used to 
quantitatively measure the amounts of the free drug concentration in the brain. By using the 
on-fiber calibration method, issues with matrix match, which is typically observed in external 
 123 
 
SPME equilibrium calibration method is avoided completely since both calibrant and analyte 
are treated in the same manner during sample preparation.  
Prior to the simultaneous monitoring of CBZ in the brain ECF using SPME and MD, 
the concentration of CBZ was closely observed by taking dialysates at 30 min intervals for 
over 3.5 hours. Figure 4.12 shows concentration of CBZ in the brain ECF in the dialysates 
during i.v. infusion to attain a steady state. Subsequently, both SPME and MD samples were 
collected for another two hours in the steady state and later when the drug infusion was 
discontinued for 1.5 hr (dynamic state).  
 
Figure 4.12 Monitoring steady state concentration of CBZ in the brain using microdialysis 
(n=6). The results are expressed as the mean ± standard errors for 6 extractions. 
Figure 4.13 shows results obtained for SPME and MD samples both steady and 
dynamic states concentrations of CBZ in the frontal cortex of the brain. The comparable results 
indicate that SPME can be used for quantitative measurements of exogenous unbound drug 
concentrations in specific regions of the brain. 
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Figure 4.13 Measurements of free concentration of CBZ in the frontal cortex of the rat brain 
using in vivo microdialysis and solid phase microextraction (n=6). The results are expressed 
as the mean ± standard errors for 6 rats. 
 
Figure 4.14 Measurements of the concentration of CBZ in the rat plasma samples.  
The concentrations of CBZ found in the plasma samples were higher than the calculated 
concentrations in the frontal cortex of the rat brain. The difference in concentration may be 
attributed to the fact that the protein precipitation sample treatment method provides 
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information on the total drug concentration rather than the unbound or free concentration. 
Similar results were obtained for cimetidine concentrations in plasma samples compared to 
MD dialysates and SPME. 
 
Figure 4.15 Measurements of free concentration of Cimetidine in the frontal cortex of the rat 
brain using in vivo microdialysis and solid phase microextraction (n=3). The results are 
expressed as the mean ± standard errors for 3 rats. 
Cimetidine is a histamine H2-receptor antagonist usually used for the treatment of 
peptic ulcers and heartburn. It is known for its low permeability across the blood-brain barrier 
into the brain. Owing to the fact that in vivo MD and SPME are relatively invasive sampling 
methods and that cimetidine has low permeability into the brain, assessing the concentration 
of cimetidine in the brain can be used as to gain insight into the disruption of the blood-brain 
barrier during sampling. From Figure 4.15, it can be observed that both SPME and MD 
detected cimetidine in the brain ECF. By comparing with the calculated concentrations of 
cimetidine in the plasma samples, a higher concentration of the drug was detected from the 
brain by both methods. The plasma samples were found to be about 40 % higher in 
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concentration than in the MD and SPME samples. However, a comparable ratio of CBZ 
concentration in the plasma and MD/SPME samples could not be obtained. This observation 
suggests that there are other factors contributing to the permeability of the drug through the 
blood-brain barrier to the brain. 
Finally, results obtained for space-resolved concentration analysis of the cortex and 
striatum suggest no differences in the drug concentrations within this region. Table 4.4 shows 
the amount of CBZ determined by each method from the specific regions of the brain. 
Table 4.4 Free concentration of carbamazepine from brain specific regions by MD and 
SPME 
 
Concentration of Carbamazepine  
(ng/mL) 
R01 R02 R03 
Cortex Striatum Cortex Striatum Cortex Striatum 
MD 208 nd 308 nd 219 nd 
Mean  
(n=3) 
245 (55) 
SPME 215 212 250 271 221 240 
Mean 
 (n=3) 
Cortex: 229 (19) Striatum: 241 (30) 
 
From the results there was no significant difference between the free drug concentration 
of CBZ in the frontal cortex by both MD and SPME. This confirms the fact that SPME is a 
potential in vivo tool that can be used for quantitative measurements of exogenous drugs in 
specific brain regions. Carbamazepine concentrations obtained by SPME in both the frontal 
cortex and striatum also showed no significant difference. This can be attributed to the fact that 
there is no concentration gradient in the distribution of the drug with these two regions. 
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4.3.7.4 Histology studies 
4.3.7.4.1 Protocol for histology study 
The Harris’ hematoxylin and eosin staining protocol was used for this study. In brief, 
staining was achieved with Harris hematoxylin solution for 8 min and then rinsed following 
initial tissue preparation. Blue staining was carried out with 0.2 % ammonia solution for about 
30 sec and a contrasting counterstaining procedure was performed in eosin-phloxine solution 
for about a min. Figure 4.16 shows results obtained for histological studies performed on some 
selected rat brain tissue. 
 
Figure 4.16 Results of histology studies of rat brain tissues; images (a & b) reflect tissue 
damage caused by SPME probes (magnification x1000) after multiple sampling from the 
same site using a probe for each sampling point for two different rat brain tissue; images (c & 
d) reflect tissue damage caused by single microdialysis probe (magnification x500) after 
sampling for two different rat brain tissue. 
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In general, data obtained from SPME method showed variations or inconsistencies in 
the extent of damage caused by the probe, and in some cases, less damage was observed 
compared to MD (Figure 4.16). This implies that reducing the size of the probe could further 
decrease the extent of tissue damage caused by SPME significantly. These results thus provide 
an avenue for introducing SPME microprobes using submicron/nano particle sizes 
immobilized on relatively smaller diameter wires for in vivo tissue bioanalysis. The approach 
will further augment overall extraction efficiency due to the increase in the effective surface 
area of the extraction phase.  
4.4 Summary 
An in vivo SPME method coupled with liquid chromatography tandem mass 
spectrometry was developed for monitoring changes in the concentrations of multiple 
neurotransmitters (5-HT, DA, GABA and GA) in the rat brain extracellular fluid (ECF). A 
SPME mixed-mode biocompatible coating was utilized. Intracerebral MD was performed to 
validate the method for the quantitation of 5-HT and DA. SPME and microdialysis probes 
(both 4 mm) were placed in the striatum of opposing brain hemispheres through implanted 
guide cannulae for simultaneous monitoring of the neurotransmitters after intraperitoneal 
administration of 10 mg/kg of the 5-HT reuptake inhibitor, fluoxetine. Dialysate was collected 
over 30 min intervals from the microdialysis probe, whereas a new SPME probe was 
introduced at successive 30 min extraction intervals.  As expected, brain ECF 5-HT 
concentrations increased rapidly (~3 – 4-fold) relative to basal concentrations, whereas DA 
concentrations remained unchanged when quantified by both methods.  GABA and GA 
concentrations, quantified by the SPME method, were also not affected by fluoxetine 
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administration. Control experiments carried out using dosing vehicle only did not show any 
change relative to the basal concentrations of the neurotransmitters. Statistical evaluation (one-
tail paired t-test at 95% confidence interval) of the 5-HT and DA data confirmed there were no 
significant differences between the microdialysis and SPME methods.  
An untargeted global chemical profiling of the rat brain striatum was successfully 
carried out using the MD and SPME coupled to LC-MS system. Overall data analysis of PCA 
plots of identified compounds revealed that both method produce complementary results. It 
can therefore be inferred that the combination of MD and SPME methodologies in global 
untargeted metabolomics studies will certainly augment the chances of discovery new disease 
biomarkers. 
In addition to quantitatively measuring endogenous compounds, in vivo SPME can also 
be used to determine free concentrations of exogenous drugs in the brain tissue. Histological 
studies also showed disruption of the brain tissue as a result of the invasiveness of the methods. 
In a nutshell, the results demonstrate that in vivo SPME method can be effectively 
utilized as a brain sampling tool to monitor multiple endogenous neurotransmitters, has the 
potential to efficiently distinguish rapid changes neurotransmitters and also applied to 
measurements of exogenous drug concentrations in the brain. 
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Chapter 5  
Application of solid phase microextraction for monitoring 
neurotransmitters during deep brain stimulation in freely moving rats 
5.1 Introduction 
Tissue sampling is very critical in bioanalysis owing to its significant contribution to 
the pharmaceutical industry, forensics, and determination of drug/chemical toxicity, food 
science and molecular biology.244 As an example, proper quantitative methods assist in 
obtaining drug and/or metabolite concentrations at their active sites in an animal tissue (brain, 
liver, lungs, etc.) and also improve data on research toxicity. In this regard, it is paramount that 
appropriate sample preparation methods are developed to obtain actual chemical information 
in a particular tissue. However, bioanalysis of solid biological tissues, pose significant often 
pose significant analytical challenges. Conventional analysis of tissues, typically tissue 
homogenization, introduces additional step(s) to the already often complex and tedious 
analytical procedure.244,245 Issues with obtaining a representative biological control sample 
cannot be avoided. In addition, traditional on ex-vivo sample preparation methods for tissues 
are appropriate for situations where real monitoring of actual changes in the concentrations of 
drug/chemical and endogenous substances in the tissue are required.  
MD is a sampling technique that has successfully been used to monitor concentration 
changes of molecules in biological matrices. Although primarily applied to research direct 
brain tissue analysis for neuroscience, microdialysis probes have been used for studies 
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involving various tissues/organs including the stomach,246,247 skin,248 liver,249,250 and the ear,251 
to mention a few. Microdialysis despite its invasive characteristics is continually used sampling 
in the brain. This may be due to the fact that microdialysis offers high degree of selectivity and 
also facilitates the detection of multiple analytes in one sample, where other devices such as 
microsensors have largely failed to demonstrate high selectivity252. Zhang and Beyer, observed 
that microdialysis shows significant advantage in its ability to measure neurochemicals in 
discrete regions of the brain by employing multiple probes.253 Despite the advantages offered 
by microdialysis for in vivo measurements of neurochemicals, the method is characterized with 
some major challenges. Some of these shortfalls include limited sample volume due to required 
low perfusion rates (0.2 – 3 µL), which often poses significant sensitivity challenges in cases 
where further dilution is needed to reduce the impact of matrix effect. In addition, the very 
small sizes of the dialysates make sample handling very difficult and often results in losses due 
to sample evaporation from longer sampling times. Issues related to adsorption of hydrophobic 
components to the membrane always pose greater challenge. The technique is relatively 
expensive and the use of tubing occasionally restricts the free movement of animals in cases 
where real-time monitoring of neurochemical changes is required.  
In addition to microdialysis, microelectrodes and biosensors have been used not just 
for sampling, but also as integrated analysis device to measure directly the dynamics of 
neurochemicals.254,255 Although these methods often exhibit high temporal and spatial 
resolution, detection of analytes is based on direct redox activity at the electrode, for which 
most neurotransmitters do not have such properties.254 Other major setbacks characterized with 
microelectrodes or biosensors are the lack of selectivity (inability of electrode to detect more 
than one ion at a time) and gross interferences from relatively high concentration of other 
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electroactive neurochemicals. Solid phase microextraction, an equilibrium-based sampling 
method has in recent times also, gained significant attraction for in vivo measurements of 
chemicals from biological matrices. 
SPME, which combines sampling and analyte-enrichment method, has been applied 
successfully for in vivo quantitative pharmacokinetic studies in dogs223 and very small animals 
like mice,229 measurement of real-time drug concentrations in a dynamic system,256 
determination of pharmaceuticals in fish,257 and the space-resolving capability of solid phase 
microextraction was applied to the determination of pharmaceuticals using a segmented-
sorbent fiber.258 One of the unique advantages of solid phase microextraction that has 
contributed to its successful application to the measurements of chemicals in vivo biological 
systems is that a single experiment can be used to determine both free- and total-analyte 
concentrations. This is achieved, as stated in a review by Vuckovic et al., by using appropriate 
external calibration curves in which, (a) one curve is obtained from physiological buffer or 
artificial cerebrospinal fluid devoid of any binding component and used to calculate free 
analyte concentration, and (b) another curve obtained using suitable matrix matching sample 
which includes the binding components of the biological system under study is used to 
determine total concentration.259 Another advantage offered by solid phase microextraction is 
that selectivity is dependent on the analyte-fiber partition coefficient. This implies that 
depending on the type of extraction phase, analytes of varying degrees of polarities can be 
selectively extracted from a given biological system. Finally, the method offers an efficient 
sample clean-up with minimal or no matrix interferences, making it easy to be coupled to liquid 
chromatography mass spectrometry. 
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In this section of the thesis, the potential of equilibrium-based solid phase 
microextraction as a sampling and analyte-enrichment method for simultaneous monitoring of 
neurotransmitters (GABA, GA, DA and 5-HT) in freely moving rats. This simple and relatively 
inexpensive approach employed a mixed-mode extraction phase fiber, which is capable of 
extracting compounds with a wide range of polarities. The fibre, supplied by Supelco®, also 
was made from biocompatible material and thus prevented fouling or adverse tissue reaction. 
To demonstrate that solid phase microextraction can successfully monitor changes in 
neurochemical concentrations in the brain, the animals were subjected to deep brain 
stimulation of the pre-frontal cortex. Deep brain stimulation (DBS), when used as a surgical 
treatment technique has been shown to provide major therapeutic advantages for neurological 
disorders like Parkinson’s disease260,261 and epilepsy.262 Despite these achievements, the 
fundamental neural and chemical mechanisms associated with deep brain stimulation are still 
very much unclear. A recent report by Hamani et al. using MD demonstrated that DBS in the 
ventromedial prefrontal cortex (vmPFC) induces a significant increase in serotonin 
hippocampal levels.263 
In the present study, for the first time, solid phase microextraction probes were 
implanted in the hippocampus of freely moving animals to assess the potential of the method 
to detect the neurotransmitter changes that occur after vmPFC DBS. 
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5.2 Experimental section 
5.2.1 Reagents and materials 
All chromatographic solvents were HPLC grade. Optima® grade acetonitrile solvents 
were obtained from Fisher Scientific (Ontario, Canada) and HPLC grade formic acid was 
obtained from Supelco (Bellefonte, PA, U.S.A.).  Glutamic acid, -aminobutyric acid, 
dopamine hydrogenchloride and 5-hydroxytryptamine (Serotonin) were also obtained from 
Supelco (Bellefonte, PA, U.S.A.). The serotonin stock was stored at 4 0C in a refrigerator. 
Diazepam was purchased from Cerilliant (Round Rock, TX) as a 1 mg/mL methanolic solution. 
Artificial cerebrospinal fluid (aCSF) was obtained from Harvard Apparatus, Holliston, MA. 
U.S.A. Solid phase microextraction fibers, which had mixed mode particles (C18-
benzenesulphonic acid group) as extraction phase, used for this study, were obtained from 
Supelco (Bellefonte, PA, U.S.A.). Deionized water used for the preparation of standards was 
from a Barnstead/Thermolyne NANO-pure water system (Dubuque, IA, U.S.A.). Guide 
cannulae were obtained from CMA Microdialysis®, Stockholm, Sweden.  
5.2.2 Liquid chromatography and mass spectrometry conditions 
All liquid chromatographic separations were performed on a Thermo Scientific 
Accela instrument equipped with a binary pump. Chromatographic separation of analytes was 
achieved with a Phenomenex® kinetex core shell pentafluorophenyl column (2.6 µm, 2.1 mm 
x 150 mm) in 5 min using gradient elution at a flow rate of 0.45 mL/min. Mobile phase A 
consisted 90% aqueous, 10% acetonitrile and mobile phase B was 90% acetonitrile and 10% 
aqueous. Both mobile phases contained 0.1% formic acid to enhance ionization in the ion 
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source. An Accela autosampler from Thermo Scientific was used for sample introduction into 
the HPLC system. A sample volume of 10 L was injected and analyzed by a triple quadrupole 
mass spectrometer. 
The TSQ Vantage triple quadrupole mass spectrometer from Thermo Scientific had 
the heated electrospray ionization (HESI) probe installed for effective nebulization and 
ionization. All ions were monitored in the positive ionization mode. The mass ion transitions 
monitored were 104.169.1, 148.184.1, 154.191.2 and 177.1115.1 for -aminobutyric 
acid (GABA), glutamic acid (GA), dopamine (DA) and serotonin (5-HT) respectively. The 
source voltage, vapourizer and capillary temperatures were 1000 V, 250 oC and 250 oC 
respectively. The lower source voltage (1000 V) was due to the fact that higher voltage settings 
may result in arcing at the tip of the nebulizer needle. This occurred mainly because the 
nebulizer needle was placed relatively close to the orifice of the metal ion transfer tube for 
improved sensitivity. Although higher voltages could be used with the nebulizer tip withdrawn 
farther away from the orifice, the sensitivities for all the analytes were lower compared to the 
optimized conditions used for this study. The optimized sheath and auxiliary gases were set at 
55 and 15 respectively. All data analyses were performed with the Xcalibur software version 
2.0.7.  
5.2.3 SPME brain probe for brain tissue sampling 
In order to perform in vivo sampling from the brain tissue, the SPME sampler was 
designed such that the extraction phase can be exposed through a CMA guide cannula. The 
sampler consists of an approximately 200 µm diameter wire coated on one end with a 4 mm 
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length of mixed mode extraction phase and a thickness of 45 µm. The non-coated end of the 
wire was supported by a small piece of rubber septum material, cut appropriately to fit directly 
into the CMA guide cannula. Figure 5.1shows a schematic representation of the SPME brain 
sampler. 
 
Figure 5.1 Schematic representation of SPME brain tissue sampler 
5.2.4 Surgical Procedures 
All protocols were approved by the Animal Care committee of the Centre for Addiction 
and Mental Health, Toronto. The surgical procedure was similar to that previously described.22 
Briefly, male Sprague-Dawley rats (250 to 300 g) were anesthetized with ketamine/xylazine 
(100/7.5 mg/kg intraperitoneal) and had bilateral cathode electrodes implanted in the vmPFC 
at the following stereotaxic coordinates: anteroposterior (AP) _ 3.0, lateral (L) _0.4, and depth 
(D) 5.6 mm. Stainless steel electrodes implanted over the somatosensory cortex were used as 
anodes.  During the same procedure, guide cannulae were bilaterally implanted the dorsal 
hippocampus (AP 3.7, L 2.4, D 5.1). A total of eight hemispheres were studied after the surgical 
procedures of 4 rats.  
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5.2.5 In vivo brain SPME 
After surgery, the animals, separated from each other were left a week for recovery 
before SPME sampling and were allowed to move freely in a plastic cage with access to food 
and water supply. Figure 5.2 shows the in vivo SPME extraction with the electrical probe 
connected to the frontal cortex. 
 
Figure 5.2 In vivo SPME sampling of neurotransmitters from the pre-frontal cortex of a 
freely moving rat 
SPME sampling was performed by exposing the 4 mm mixed-mode coating (extraction 
phase) to the pre-frontal cortex of the brain through each microdialysis guide cannula. The 
extraction was carried out for a period of 30 min. The 30 min extraction time was chosen based 
on in vitro experiments carried out in both aCSF and agar gel matrices to establish the 
equilibration time for each analyte. Details have been discussed in Chapter 4. The basal levels 
of the neurotransmitters were obtained over a 2-hr period simultaneously from both right and 
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left brain hemispheres and defined as the average of 4 samples for each brain hemisphere. 
SPME sampling was then stopped and the animals received electrical stimulation for a one-
hour period. Afterward, SPME sampling was re-started for another 2-hr period during deep 
brain stimulation. All fibers were immediately placed into a 100 µL insert containing 60 µL 
desorption solution of water - acetonitrile mixture with 0.1 % formic acid (pH approximately 
3.5). The inserts were subsequently placed in sealed amber vials and stored immediately on 
dry ice for later analysis.  
5.3 Results and discussions 
5.3.1 HPLC Analysis 
Optimization of chromatographic separation has been widely illustrated in Chapter 3 
(Paragraph 3.3.1). Owing to the advantage of the pentaflurophenyl column discussed in the 
paragraph mentioned above, the retention and separation was achieved in this study by a 
gradient elution, which starts with a high organic content while gradually increasing the 
aqueous content. Diazepam which has less hydrophilic properties eluted first at 1 min followed 
by separation of the neurotransmitters with 5-HT having the greatest retention factor under 
these conditions. The active particle size of 1.7 µm of the core shell column used for this study 
enhanced signal-noise ratios to ensure separation of both amino acid and monoamine 
neurotransmitters without the need for derivatization. This offers greater potential for sample 
preparation methods like SPME capable of selectively extracting these compounds without the 
need for multiple derivatization methods for the different classes of neurotransmitters. 
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5.3.2 Determination of SPME equilibration time 
Equilibrium calibration method was used for this study as longer extraction time 
enhances the analyte-enrichment in the extraction phase. Therefore various in vitro 
experiments were carried out in artificial cerebrospinal fluid (aCSF), a physiological fluid and 
agar gel-aCSF matrices to establish the time within which all analytes would be expected to 
have reached equilibrium with the fiber.  
To estimate the equilibration time, aCSF experiments were performed under static 
conditions as this will provide the slowest diffusion of the molecules similar to the molecular 
movement within the extracellular fluidic space in the biological matrix. The gel-aCSF 
experiments were carried out to investigate any possible effect of tortuosity on the diffusion of 
analytes to the fiber and thus affect the equilibration time. In addition, the effect of the sample 
volume was also investigated to establish whether the extracted amount will be independent of 
the sample volume as a proof of concept. If this deduction is true, then it is possible that the 
amount of analyte extracted from the brain extracellular space will not be significantly 
dependent on the fluid volume provided there is no analyte depletion from multiple extractions 
at the same sampling site. 
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Figure 5.3 Equilibrium-time profiles for neurotransmitters in aCSF under static conditions. 
The results are expressed as the mean ± standard errors for 3 extractions. 
The equilibration time for all the analytes in aCSF was determined using a 100 ng/mL 
solution. In these experiments, extractions were carried out using the 4 mm mixed mode fiber 
for different time points (5, 10, 20, 30, 45, 60 min) in a 2 mL vial. Volume of sample was 1.8 
mL of the aCSF. After the extraction process, the fibers were desorbed in 60 µL desorption 
solution containing 3:2 ratio of water to acetonitrile with a 0.1% formic acid in 150 µL inserts. 
To enhance desorption of the analytes from the fiber, the vials were agitated at 1000 rpm on a 
vortexer. Carryover experiments performed by second desorption of the same fiber in new 
solution, showed no detectable amount of any of the analytes after LC-MS/MS analyses. A 
total of 3 replicates were obtained for each time point. The equilibration time for each analyte 
was estimated from plots of the area ratio of the analyte to internal standard (diazepam) versus 
time. 
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As shown in Figure 5.3, the equilibrium time for all analytes was reached within 20 
min of extraction under static conditions (without agitation). This simply that implied that in 
the absence of any solid matrix component that could affect the diffusion kinetics of the 
analyte, a maximum of 20 min extraction was required by each analyte to equilibrate with the 
extraction phase. In an independent equilibration time, determined under agitation mode, a 
much shorter time of approximately 3 min was observed when the sample matrix was agitated 
at 250 rpm. The much shorter equilibrium time under agitated conditions showed that mass 
transport of analytes within the extracellular space could be significantly improved with fluid 
movement.    
 
Figure 5.4 Equilibrium-time profiles for neurotransmitters in 1.5 % gel-aCSF mixture. The 
results are expressed as the mean ± standard errors for 3 extractions. 
To investigate the possible effect of tortuosity of the brain tissue on the diffusion rates 
of the analytes to the extraction phase and subsequently, equilibrium time, equilibration time 
profiles were generated with different percent (1% and 1.5%) agar gel matrices prepared by 
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mixing aCSF with varying amount of agar gel. Gel composition ≥ 1 % was also chosen because 
1 % gel composition was commonly used to model brain tissue and therefore the higher gel 
percentage the greater the tortuosity. The time required for the analytes to reach equilibrium 
were similar both 1 % and 1.5 % (Figure 5.4) gel composition and also for extractions from 
aCSF only. On the basis of this data, it was concluded that tortuosity of the brain tissue may 
not be the rate limiting step for the analytes to reach equilibrium within the brain extracellular 
space provided there is minimal or no depletion at the extraction site. Secondly, the amount 
extracted at equilibrium was so small and therefore was independent of the volume of fluid 
within the extracellular space. This was verified by investigating the effect of the sample 
volume on the extracted amount at equilibrium. Extractions were carried out thus carried using 
different sample volumes (100 µL, 500 µL and 1000 µL). Each extraction was done in 
triplicates. All fibers were initially pre-conditioned in 50% methanolic solution overnight with 
agitation at 250 rpm. As shown in Figure 5.5, there were no significant differences in the 
amounts of each analyte from the 100 µL, 500 µL and 1000 µL sample volumes. The 
implication of this result is that the analyte-fiber partition coefficient is very small and 
therefore the amount of each neurotransmitter extracted from the extracellular space by the 
extraction phase will not lead to depletion of any of the analytes. 
 143 
 
  
Figure 5.5 Comparison of the extracted amount of neurotransmitters from different volume 
of samples. The results are expressed as the mean ± standard errors for 3 extractions. 
5.3.3 In vivo SPME analysis of neurotransmitters 
The optimized in vitro method was used to monitor changes in the neurotransmitters 
brain extracellular space prior and during deep brain stimulation of the pre-frontal cortex (infra 
limbic region). Calibration curves used to calculate the amount of each analyte extracted for in 
vivo extractions were also obtained from aCSF. With this method, it implies that the calculated 
amounts will be the free analyte concentration within the extracellular space of the brain tissue. 
Limits of detection for all analytes ranged from 0.009 to 0.024 ng/mL whereas limit of 
quantitation was computed based on 3x signal-noise ratio (0.030 to 0.08 ng/mL) with GABA 
having the highest LOD value. The percentage relative standard deviation (RSD %) obtained 
for the basal levels ranged from 3–20 % for both left and right brain hemispheres for all 
neurotransmitters in all 4 rats (Figure 5.6).  
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Figure 5.6 Basal concentrations of selected amino acid and monoamine transmitters in rat 
brain 
Figure 5.6 shows the bilateral agreement of the concentrations of all the analytes 
between the left and right brain hemispheres. This is indicative of the fact that the multiple 
introductions of the solid phase microextraction sampler in the brain do not have any possible 
influence on the concentrations of the analytes in the extracellular space. Secondly, the 4-mm 
mixed mode fiber with the biocompatible material did not produce any fouling effect during 
the extraction process, which often characterized by very poor data. This observation has been 
confirmed elsewhere in an independent study, in which the same neurotransmitters were 
monitored over a 3.5 hours using both microdialysis and solid phase microextraction 
simultaneously248.  
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With the exception of 5-HT which showed an increase of about 300% higher than the 
basal concentration, there were no observable induced increases in any of the amino acid 
transmitters and dopamine (Table 5.1).  
Table 5.1 Monitoring changes in concentrations of glutamic acid, -aminobutyric acid and 
dopamine in both left and right brain hemispheres of rat 4 
 
LB represents left brain hemisphere  RB represents right brain hemisphere 
 
This implies that vmPFC deep brain stimulation effects possibly do not have any effect 
on the selected amino acid transmitters and dopamine. However, the increased amount of 5-
HT in the extracellular space of the infra limbic region could be attributed to the deep brain 
stimulation (Figure 5.7).  
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Figure 5.7 Monitoring changes in concentration levels of 5-HT in left and right hemispheres 
of the rat brain before and during deep brain stimulation 
Increase in serotonin after DBS in the present study was similar in magnitude compared 
to previous results obtained by Hamani et al. using microdialysis.248 This suggests that SPME 
as a tissue sampling tool may be a valid alternative approach to measure neurotransmitter 
changes after the application of an external stimulus. 
In separate studies, portions of the in vivo samples were subjected to global untargeted 
chemical profiling. Samples were treated the same way as described in previous chapter. A 
quality control sample was generated from a pool of the samples and desorption solution was 
used as the blank. Details of the sample treatment, LC-MS and data analysis were well 
described in Chapter 4. The rational of the studies was to establish whether there are other 
compounds that might be affected by the DBS in addition to the neurotransmitters. 
Table 5.2 shows some of the identified compounds from the analysis of the data when 
compared to the HMDB database. Subsequently, the peak intensities of the identified 
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compounds prior to and during DBS were compared. It was observed that compounds labeled 
as M1 to M8 (Refer to Table 5.2) seems to show changes in peak intensities before and during 
DBS. Most of these compounds were identified to be fatty acids.   
Table 5.2 Some identified compounds from the analysis of in vivo SPME samples collected 
prior to and during deep brain stimulation of the rat brain 
ID Qualitative identification m/z LogP 
M1 Triglyceride 529.41022 9.34 
M2 Lysophosphatidylcholine 551.39227 - 
M3 Arachinonyl carnitine 546.43671 3.47 
M4 Ganglioside 530.41370 2.99 
M5 Lysophosphatidylcholine 552.39575 3.14 
M6 Eicosanoid acid 311.29465 8.4 
M7 nonadeca-10(2)-enoic acid 329.30530 8.06 
M8 diglyceride  547.44000 9.25 
M9 estradiol derivative 363.25357 3.9 
M10 
N-acetyl-D-mannosamine-6-phosphate/dimethyl 
heptanoyl carnitine 
116.14370 -3.6 
M11 Unknown 153.13900 - 
M12 glutamine 147.07677 -3.6 
M13 leukotriene/phytyl diphosphate 913.47864 4.8 
M14 palmitaldehyde 132.07704 5.1 
M15 Phosphate 158.96431 -3.6 
M16 leucine/aminobutyric acid 164.12859 -2.5 
M17 methylglutaconic acid 223.06416 0.29 
# identification based on the comparison of the experimental data against Human metabolome 
database 
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Figure 5.8 and 
 
Figure 5.9 show the trend of the peak intensities for each of the identified compound 
prior to and during deep brain stimulation.  
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Figure 5.8 Effect of deep brain stimulation on intensity of peak areas of selected compounds 
in both right (top) and left (bottom) hemispheres of the frontal cortex of freely moving rats 
From both figures, preliminary results showed that both the left and right hemispheres 
of the rat brain showed similar patterns of higher peak intensities during DBS whereas the 
peaks areas were very lower prior to the stimulation. Generally, the remaining compounds did 
not show changes in their peak areas during DBS with the exception of M15, M16 and M17. 
In addition, the peak areas of these compounds in both left and right hemispheres were not 
comparable. 
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Figure 5.9 Effect of deep brain stimulation on the intensity of the peak areas of selected 
compounds in both right (top) and left (bottom) hemispheres of the frontal cortex of freely 
moving rats 
Although, this study is in its preliminary stage, some of the metabolites identified such 
as the fatty acids and carnitines are known to be involved in multifactorial functions in brain 
metabolism and their neuromodulatory, neuroprotective and neurotropic properties have 
various medical implications. From the results it is obvious that a better alternative that can be 
used to gain insight into the therapeutic mechanism of DBS treatment is by global untargeted 
metabolomics studies. By this approach and with the appropriate statistical tool, the effects of 
DBS on the chemical activity of the brain can be better understood. That said, there is no doubt 
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that neurotransmitters may be significantly involved in the deep brain stimulation treatments 
for various neurological disorders. 
5.4 Summary 
In this study an equilibrium quantitative SPME method for in vivo monitoring of 
changes in neurotransmitters in the extracellular space of the pre-frontal cortex of the rat brain 
without prior derivatization. The excellent clean-up method of SPME also ensured that the 
huge signal suppression caused by the presence of matrix components in the sample extract, 
as observed for microdialysis when coupled with LC-MS/MS, was absent. This added 
advantage of solid phase microextraction, and also its analyte-enrichment (pre-concentration) 
characteristics enhanced the detection of analytes with improved sensitivity.  
Analytes used in this study were serotonin, dopamine, gamma-aminobutyric acid and 
glutamic acid. A 4 mm long solid phase extraction mixed mode coating immobilized on a 
stainless steel wire with a biocompatible material was successfully used for the extraction of 
analytes from both hemispheres of the rat brain. The possible influence of brain tissue 
tortuosity and fluid volume in the extracellular space were investigated through in vitro 
experiments, and used to estimate the time required for analytes to reach equilibrium with the 
SPME fiber in the rat brain. A 30 min extraction time was found to be adequate to ensure 
equilibration of the analytes in the sample matrix with the fiber. Chromatographic separation 
without prior derivatization was achieved within 5 min run time using a pentafluorophenyl 
core shell column for separation and a triple quadrupole mass spectrometer was used for 
detection of analytes. To be able to effectively monitor changes in neurotransmitters, for the 
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first time, SPME extractions were carried out prior to and during deep brain stimulation (DBS) 
at the ventromedial pre-frontal cortex. Results show that SPME has the potential to detect 
changes in the neurotransmitters in the brain of freely moving rats. No significant changes 
were observed for all the analytes except for serotonin, which showed about 2 - 3x (~ 50 pg/mL 
- 400 pg/mL) increase during DBS. Results corroborate similar studies carried out 
independently using microdialysis elsewhere. The increased serotonin amounts obtained by 
SPME corroborated independent study using microdialysis. Relative standard deviation for 
serotonin at basal concentrations ranged from 3 % to 20 %.  
A global untargeted chemical profiling of the brain showed that DBS of the frontal 
cortex of the brain could affect the levels of certain fatty acids and carnitines. Thus, in vivo 
SPME could be utilized as a potential tool that for various medical/clinical applications of such 
nature.  
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Chapter 6  
     Conclusions and Future Directions 
6.1 Conclusions 
Solid tissue bioanalysis is one of the most challenging, time-consuming and laborious 
bioanalytical tasks compared to the analysis of other biological samples such as blood, plasma, 
urine, etc. Despite its importance to clinical, medical, toxicological, toxicity applications, etc., 
there are currently no existing guidelines for sampling solid biological tissues. Nonetheless, 
the significance of quantitative analytical methods for measurements of exogenous and/or 
endogenous compounds in solid biological tissue cannot be over-emphasized. For sure, the 
development of simple, robust, reliable and appropriate bioanalytical methods for brain tissue 
analysis for endogenous and exogenous chemical substances, will contribute immensely to 
understanding various health related diseases affecting humans, physiological processes and 
metabolisms within a living system, to mention a few. Without doubt, in vivo research is more 
appropriate to monitor the overall effect in a living biological system than in vitro research by 
providing a better indication of the effect in real time. For this reason among others, there is 
rising interest in in vivo methods and techniques for bioanalysis, tissue bioanalysis for that 
matter.  
SPME methods have been broadly applied for invasive and non-invasive in 
vivo studies. The development of biocompatible extraction phases has overall improved the 
sensitivity, selectivity and compatibility of SPME to in vivo applications. The continuous 
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advancement in SPME calibration methods in recent years has also facilitated accurate 
quantitation, especially for in vivo applications even involving pre-equilibrium extractions, 
which significantly improves throughput. However, pre-equilibrium SPME extractions are 
characterized by lower analytes extraction amounts and thus translate into generally lower 
analytical sensitivity. Despite this seemingly limitation, the easy coupling of the method to 
LC-MS/MS has proven its robustness as a quantitative analytical technique since the results 
obtained by SPME are comparable to conventional methods like MD as shown in this thesis.  
Undoubtedly, results shown in this thesis demonstrate the ability of using in vivo SPME 
for brain tissue sampling when coupled to LC-MS/MS. The introduction of new the 
biocompatible mixed-mode SPME coatings showed the potential of the technique for 
simultaneous monitoring of changes in the concentrations of multiple neurotransmitters within 
the brain ECF. The results obviously provide the opportunity to measure and monitor 
interactions among endogenous chemical substances such as neurotransmitters and also 
interactions with drugs within the brain ECF. A critical factor to monitoring neurotransmitters 
within the brain ECF is the ability of the method to measure basal concentrations of the analyte. 
From the results obtained, in vivo SPME clearly has the potential of determining the basal 
concentrations of brain extracellular neurotransmitters. The quantitative determination of 
drugs within the brain as shown in Chapter 4, clearly demonstrates the potential of using in 
vivo SPME for monitoring and measuring neuroactive drugs in toxicity studies from specific 
regions of the brain. Currently, the initial results obtained from simultaneous monitoring of 
different brain regions (cortex and striatum) is a proof of concept for space-resolved SPME 
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with the advantage of using a single fibre compared to in vivo MD where multiple probes will 
be required.264 
In general, untargeted tissue metabolomics is particularly interesting for the study of 
damaged tissues in search of novel biomarkers since the concentration of such biomarkers is 
often expected to be higher in such tissue. A fundamental concept of untargeted metabolomics 
is to develop a method that is capable to provide larger metabolites coverage in addition to 
been able to capture the true metabolome during the sampling process. This thesis has clearly 
demonstrated that a good sampling approach to untargeted brain tissue metabolomics analyses 
is through the simultaneous use of multiple analytical sampling methods. Preliminary results 
obtained in Chapter 4 for untargeted metabolomics studies demonstrate this phenomenon by 
combining in vivo SPME and MD for brain tissue sampling. 
Despite the success of in vivo SPME for brain tissue sampling, there are inherent 
challenges especially if the method is intended for monitoring very fast changes in 
neurotransmission. The current sampling time of 30 min, though synonymous to conventional 
in vivo MD, it may not be an appropriate tool for monitoring rapid changes extracellular 
changes in the concentration of neurotransmitters. This will require further studies in order to 
improve the method. A possible approach will be exploring new mixed-mode coatings, include 
more neurochemicals and to use pre-equilibrium extraction approach for improved time 
resolution. Another challenge will be the extent of tissue damage due to multiple 
microextractions from the same site.  
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6.2 Future directions 
Brain tissue metabolomics study offers exciting prospects for in-depth study of brain. 
Currently, there are very few brain tissue analyses that explore more simultaneous use of 
multiple bioanalytical methods. Owing to the fact that in vivo SPME and MD preferably extract 
non-polar and polar analytes, the combination of these methods will certainly advance the 
quest for biomarker discovery in a global metabolomics study. This thesis has clearly laid the 
foundation for further development of appropriate workflows for the two methods while 
capturing the sensitivity and selectivity of electrospray LC-MS/MS.  
The issue of tissue damage and subsequent rupture of the blood brain barrier during in 
vivo brain tissue sampling has been of primary concern in brain research. This calls for 
minimizing the size of existing in vivo SPME probes used for brain sampling. Ultra small in 
vivo SPME probes can be developed using smaller particle sizes (nanoparticles). The 
advantage of such approach will be overall improvement in sensitivity due to the increased 
surface area to volume ratio. Though invasive, the method will provide an opportunity to carry 
out in vivo brain tissue sampling while the blood brain barrier remains intact. This obviously 
will improve pharmacokinetic and pharmacodynamics of exogenous drugs and their 
xenobiotics in the brain extracellular fluid. 
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